

CITATION REPORT

List of articles citing

A computational procedure for determining energetically favorable binding sites on biologically important macromolecules

DOI: 10.1021/jm00145a002

Journal of Medicinal Chemistry, 1985, 28, 849-57.

Source: <https://exaly.com/paper-pdf/18029658/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2353	Replacement of Protein Binding-Site Waters Contributes to Favorable Halogen Bond Interactions.		
2352	ChemInform Abstract: A COMPUTATIONAL PROCEDURE FOR DETERMINING ENERGETICALLY FAVORABLE BINDING SITES ON BIOLOGICALLY IMPORTANT MACROMOLECULES. 1985 , 16, no		1
2351	The modelling of electrostatic interactions in the function of globular proteins. 1986 , 48, 37-66		77
2350	Research topics in the medicinal chemistry and molecular pharmacology of opioid peptides--present and future. 1986 , 39, 1825-43		20
2349	Chapter 28. X-Ray Crystallography of Drug Molecule-Macromolecule Interactions as an Aid to Drug Design. 1986 , 293-302		2
2348	Chapter 27 Molecular Modeling as an Aid to Drug Design and Discovery. 1987 , 22, 269-279		14
2347	Numerical Calculations of Electrostatic Potentials of Protein-Solvent Systems by the Self Consistent Boundary Method. 1987 , 56, 1609-1622		62
2346	A method for fast energy estimation and visualization of protein-ligand interaction. 1987 , 1, 197-210		29
2345	Distance geometry analysis of ligand binding to drug receptor sites. 1987 , 1, 257-64		6
2344	PEPCRE: an interactive program to create, manipulate and display oligopeptides. 1987 , 5, 119-125		6
2343	Electrostatic potential and binding of drugs to the minor groove of DNA. 1987 , 5, 165-166		16
2342	Conformational analysis and computer graphics in drug research. 1988 , 8, 1-25		16
2341	Engineering antibody affinity and specificity. 1988 , 3, 13-6		2
2340	Symposium overview. The Shell Conference on Computer-Aided Molecular Modelling. 1988 , 2, 165-78		0
2339	Molecular modelling in design of crop protection chemicals. 1988 , 2, 191-216		7
2338	COMMUNICATIONS. 1988 , 95, 475P-589P		5
2337	On the dissection of binding epitopes on carbohydrate receptors for microbes using molecular modelling. 1988 , 70, 1673-82		8

2336	Preliminary Analysis of Water Molecule Distributions in Proteins. 1989 , 3, 167-182	4
2335	Molecular applications of volume rendering and 3-D texture maps. 1989 ,	5
2334	ALADDIN: an integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric, and substructure searching of three-dimensional molecular structures. 1989 , 3, 225-51	162
2333	Theoretical studies of the mechanism of the action of the neurohypophyseal hormones. I. Molecular electrostatic potential (MEP) and molecular electrostatic field (MEF) maps of some vasopressin analogues. 1989 , 3, 261-84	6
2332	Conformational analysis of blood group A-active glycosphingolipids using HSEA-calculations. The possible significance of the core oligosaccharide chain for the presentation and recognition of the A-determinant. 1989 , 2, 103-13	44
2331	Identifying targets for bioreductive agents: using GRID to predict selective binding regions of proteins. 1989 , 7, 103-8, 100	30
2330	Automated site-directed drug design: a general algorithm for knowledge acquisition about hydrogen-bonding regions at protein surfaces. 1989 , 236, 101-13	73
2329	Expression, purification, and crystallization of the HIV-1 reverse transcriptase (RT). 1990 , 6, 1297-303	37
2328	Correlation Analysis and Molecular Modeling of Cholecystokinin Inhibitors. 1990 , 9, 94-101	3
2327	Testing of insulin hexamer-stabilizing ligands using theoretical binding, microcalorimetry, and nuclear magnetic resonance (NMR) line broadening techniques. 1990 , 7, 600-5	1
2326	Use of molecular fields to compare series of potentially bioactive molecules designed by scientists or by computer. 1990 , 3, 723-738	15
2325	Automated docking of substrates to proteins by simulated annealing. 1990 , 8, 195-202	943
2324	Use of crystallographic data in searching for isosteric replacements: Composite crystal-field environments of nitro and carbonyl groups. 1990 , 29, 197-213	31
2323	Solvation of the active site of cytochrome P450-cam. 1990 , 4, 199-204	29
2322	Use of parallel processing in the study of protein. Ligand binding. 1990 , 11, 314-325	6
2321	Aspartate aminotransferase: investigation of the active sites. 1990 , 8, 111-5, 92-3	3
2320	Computer design of potentially bioactive molecules by geometric searching with ALADDIN. 1990 , 3, 15-25	20
2319	3D database searching and de novo construction methods in molecular design. 1990 , 3, 697-711	33

2318	Hydrophilicity of proteins and DNA. <i>Journal of Molecular Structure</i> , 1990 , 237, 63-73	3-4	5
2317	Comparison of the binding of glucose and glucose 1-phosphate derivatives to T-state glycogen phosphorylase b. 1990 , 29, 10745-57		116
2316	Computerized Probe Analysis of the Energetically Favored Binding Sites of an Aspartyl Protease. 1990 , 616, 611-612		
2315	Protein-water interaction energies as predictor for antigenic determinants. 1990 , 27, 1057-60		1
2314	Glucose analogue inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes. 1991 , 30, 10101-16		118
2313	Predicting receptor-ligand interactions. 1991 , 1, 213-218		7
2312	Structure-Activity Relationships Using Multivariate Analysis Techniques: Application to Topical Corticosteroids. 1992 , 93-127		
2311	Computer modeling of combining site structure of anti-hapten monoclonal antibodies. 1991 , 203, 21-45		7
2310	Structure and ligand binding in membrane-bound proteins and immunoglobulins. 1991 , 1071, 393-406		1
2309	Theoretical Prediction of Antigenic Determinants Based on Protein-Water Interaction Energies. 1991 , 10, 300-305		1
2308	Three-dimensional structure of fatty-acid-binding protein from bovine heart. 1991 , 199, 271-6		52
2307	A general approach for atom-type assignment and the interconversion of molecular structure files. 1991 , 12, 209-214		5
2306	A molecular dynamics study of thermodynamic and structural aspects of the hydration of cavities in proteins. 1991 , 31, 919-31		67
2305	Functionality maps of binding sites: a multiple copy simultaneous search method. 1991 , 11, 29-34		455
2304	Computer design of bioactive molecules: a method for receptor-based de novo ligand design. 1991 , 11, 314-28		200
2303	OVID and SUPER: two overlap programs for drug design. 1991 , 5, 511-24		45
2302	Ion channels formed by amphipathic helical peptides. A molecular modelling study. 1991 , 20, 229-40		32
2301	Computer-assisted rational drug design. 1991 , 203, 587-613		33

2300	Comparative modeling of proteins in the design of novel renin inhibitors. 1991 , 26, 77-127		37
2299	Characterization of the interactions of a bifunctional inhibitor with alpha-thrombin by molecular modelling and peptide synthesis. 1992 , 5, 77-85		14
2298	Proline residues in transmembrane helices of channel and transport proteins: a molecular modelling study. 1992 , 5, 53-60		61
2297	Soci�t� Belge de Biochimie Belgische Vereniging voor Biochemie. 1992 , 100, B1-B26		
2296	Molecular surface recognition: determination of geometric fit between proteins and their ligands by correlation techniques. 1992 , 89, 2195-9		844
2295	Chapter 29. Macromolecular X-Ray Crystallography and NMR as Tools for Structure-based Drug Design. 1992 , 27, 271-289		19
2294	3D database searching in drug design. <i>Journal of Medicinal Chemistry</i> , 1992 , 35, 2145-54	8.3	227
2293	Structure-based strategies for drug design and discovery. 1992 , 257, 1078-82		862
2292	Macromolecular graphics. 1992 , 2, 193-201		9
2291	Binding of an antiviral agent to a sensitive and a resistant human rhinovirus. Computer simulation studies with sampling of amino acid side-chain conformation. I. Mapping the rotamers of residue 188 of viral protein 1. 1992 , 225, 679-96		27
2290	Docking by least-squares fitting of molecular surface patterns. 1992 , 225, 849-58		84
2289	Location of potential binding sites on deoxy hemoglobin for the design of antigelling agents. 1992 , 223, 791-800		9
2288	The computer program LUDI: a new method for the de novo design of enzyme inhibitors. 1992 , 6, 61-78		615
2287	Automated site-directed drug design: the generation of a basic set of fragments to be used for automated structure assembly. 1992 , 6, 385-96		20
2286	LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. 1992 , 6, 593-606		335
2285	In search of new lead compounds for trypanosomiasis drug design: a protein structure-based linked-fragment approach. 1992 , 6, 131-47		57
2284	The roles of serine and threonine sidechains in ion channels: a modelling study. 1992 , 21, 281-98		16
2283	CLIX: a search algorithm for finding novel ligands capable of binding proteins of known three-dimensional structure. 1992 , 12, 31-41		134

2282	Substrate-enzyme interactions and catalytic mechanism in phospholipase C: a molecular modeling study using the GRID program. 1992 , 12, 331-8	25
2281	A multiple-start Monte Carlo docking method. 1992 , 13, 206-22	187
2280	Structural biology and diabetes mellitus: molecular pathogenesis and rational drug design. 1992 , 35 Suppl 2, S69-76	3
2279	Prediction of the structure of a receptor-protein complex using a binary docking method. 1992 , 358, 774-6	68
2278	Automated site-directed drug design using molecular lattices. 1992 , 10, 66-78, 106	83
2277	3D-Quantitative Structure-Activity Relationships: Description of Electronic Effects Directly from 3D Structures Using a GRID-Comparative Molecular Field Analysis (CoMFA) Approach. 1992 , 11, 127-134	18
2276	3D-Quantitative Structure-Activity Relationships: Nonlinear Dependence Described Directly from 3D Structures Using a Comparative Molecular Field Analysis (CoMFA) Approach. 1992 , 11, 309-317	12
2275	3D-Quantitative Structure-Activity Relationships: Investigation of Steric Effects with Descriptors Directly from 3D Structures Using a Comparative Molecular Field Analysis (CoMFA) Approach. 1992 , 11, 453-460	11
2274	Computer-aided drug design: getting the best results. 1992 , 10, 357-63	9
2273	A review of three-dimensional chemical structure retrieval systems. 1992 , 6, 289-305	17
2272	Molecular docking using shape descriptors. 1992 , 13, 380-397	348
2271	Automated docking with grid-based energy evaluation. 1992 , 13, 505-524	770
2270	Conformational analysis of flexible ligands in macromolecular receptor sites. 1992 , 13, 730-748	171
2269	Fast generation of molecular surfaces from 3D data fields with an enhanced marching cube algorithm. 1993 , 14, 246-250	83
2268	AQUARIUS2: Knowledge-based modeling of solvent sites around proteins. 1993 , 14, 1007-1018	37
2267	CONCEPTS: New dynamic algorithm for de novo drug suggestion. 1993 , 14, 1184-1193	67
2266	Adenosine A1 receptor and ligand molecular modeling. 1993 , 28, 237-243	20
2265	PLIM: a protein-ligand interaction modeller. 1993 , 6, 111-5	6

2264	A novel computational tool for automated structure-based drug design. 1993 , 6, 131-7	40
2263	Texture mapping in molecular graphics. 1993 , 11, 259-260	
2262	Hydrophobic interactions and CoMFA using hint. 1993 , 11, 260	
2261	Structure design: an artificial intelligence-based method for the design of molecules under geometrical constraints. 1993 , 11, 166-73	4
2260	GenStar: a method for de novo drug design. 1993 , 7, 23-43	103
2259	Hydrophilic surface maps of channel-forming peptides: analysis of amphipathic helices. 1993 , 22, 269-77	15
2258	Ion channel formation by zervamicin-IIB. A molecular modelling study. 1993 , 21, 369-83	22
2257	NMR structure-based drug design. 1993 , 3, 261-9	44
2256	Use of the hydrogen bond potential function in a comparative molecular field analysis (CoMFA) on a set of benzodiazepines. 1993 , 7, 263-80	24
2255	SPROUT: a program for structure generation. 1993 , 7, 127-53	149
2254	Semi-empirical molecular orbital studies of porphine and phthalocyanine derivatives, to simulate their intermolecular interactions. 1993 , 46, 191-210	24
2253	Automated docking in crystallography: analysis of the substrates of aconitase. 1993 , 17, 1-10	71
2252	Toward computational determination of peptide-receptor structure. 1993 , 2, 1827-43	28
2251	Definition of a pharmacophore for the metabotropic glutamate receptors negatively linked to adenylyl cyclase. <i>Bioorganic and Medicinal Chemistry</i> , 1993 , 1, 259-65	3-4 21
2250	Amino Acids Characterization by GRID and Multivariate Data Analysis. 1993 , 12, 1-8	61
2249	Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D-QSAR Problems. 1993 , 12, 9-20	270
2248	3D-Quantitative Structure-Activity Relationships: Describing Hydrophobic Interactions Directly from 3D Structures Using a Comparative Molecular Field Analysis (CoMFA) Approach. 1993 , 12, 232-238	18
2247	Rational design of potent sialidase-based inhibitors of influenza virus replication. 1993 , 363, 418-23	1613

2246	HIV protease: Structure-based design. 1993 , 1, 49-68	18
2245	A good ligand is hard to find: Automated docking methods. 1993 , 1, 301-319	115
2244	Seeing our way to drug design. 1993 , 1, 329-344	5
2243	Structure-based drug design (SBDD): Every structure tells a story.... 1993 , 1, 371-390	18
2242	Modeling and energy minimization studies on the herbicide binding protein (D1) in Photosystem II of plants. 1993 , 1142, 106-114	17
2241	On the specificity of carboxypeptidase N, a comparative study. 1993 , 374, 843-9	3
2240	Molecular recognition analyzed by docking simulations: the aspartate receptor and isocitrate dehydrogenase from Escherichia coli. 1993 , 90, 1146-53	30
2239	Chapter 29. 3D Database Searching and Docking Strategies. 1993 , 28, 275-284	3
2238	Computer-Aided Structure Based Drug Design.. 1993 , 67, 1295-1298	
2237	Oligosaccharides: How can flexible molecules act as signals?. 1993 , 65, 763-770	120
2236	Enzyme crystal structure in a neat organic solvent. 1993 , 90, 8653-7	209
2235	References. 1993 , 183-210	
2234	Fundamentals of drug design from a biophysical viewpoint. 1994 , 27, 435-81	20
2233	Molecular Docking: A Tool for Ligand Discovery and Design. 1994 , 28, 735-749	1
2232	Discovery of new anticancer drugs by computer-aided drug design. 1994 , 5 Suppl 4, 51-4	2
2231	A proposal for the catalytic mechanism in phospholipase C based on interaction energy and distance geometry calculations. 1994 , 7, 571-7	25
2230	Favoured carbonyl binding regions around the QA and Q B sites of Rps. viridis. 1994 , 39, 51-6	3
2229	FLOG: a system to select 'quasi-flexible' ligands complementary to a receptor of known three-dimensional structure. 1994 , 8, 153-74	217

2228	On the use of LUDI to search the Fine Chemicals Directory for ligands of proteins of known three-dimensional structure. 1994 , 8, 623-32	102
2227	Prediction of the binding sites of huperzine A in acetylcholinesterase by docking studies. 1994 , 8, 669-81	73
2226	The effect of physical organic properties on hydrophobic fields. 1994 , 8, 41-9	31
2225	GREEN: a program package for docking studies in rational drug design. 1994 , 8, 347-66	32
2224	Nucleotide-binding properties of adenylate kinase from Escherichia coli: a molecular dynamics study in aqueous and vacuum environments. 1994 , 8, 367-88	17
2223	Current methods for site-directed structure generation. 1994 , 8, 467-75	48
2222	A shape- and chemistry-based docking method and its use in the design of HIV-1 protease inhibitors. 1994 , 8, 231-42	39
2221	The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. 1994 , 8, 243-56	75 ¹
2220	Automated molecular design: a new fragment-joining algorithm. 1994 , 8, 283-98	26
2219	Conformational analysis of the carbohydrate portion of T and TN haptens by NMR spectroscopy and molecular modeling. 1994 , 50, 77-92	5
2218	A role for surface hydrophobicity in protein-protein recognition. 1994 , 3, 717-29	290
2217	Structural similarity between binding sites in influenza sialidase and isocitrate dehydrogenase: implications for an alternative approach to rational drug design. 1994 , 3, 1128-30	9
2216	Computer modeling of substrate binding to lipases from Rhizomucor miehei, Humicola lanuginosa, and Candida rugosa. 1994 , 3, 1493-503	58
2215	Influenza virus neuraminidase: structure, antibodies, and inhibitors. 1994 , 3, 1687-96	288
2214	[The key to the castle. II. Hansch analysis, 3d-QSAR and de novo design]. 1994 , 23, 281-90	10
2213	Molecular dynamics simulation of the docking of substrates to proteins. 1994 , 19, 174-82	86
2212	HOOK: a program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site. 1994 , 19, 199-221	182
2211	Hydrophobic docking: a proposed enhancement to molecular recognition techniques. 1994 , 20, 320-9	164

2210	A ring-bracing approach to computer-assisted ligand design. 1994 , 15, 233-240		15
2209	Implementation of artificial intelligence for automatic drug design. I. Stepwise computation of the interactive drug-design sequence. 1994 , 15, 1393-1402		4
2208	A search for specificity in DNA-drug interactions. 1994 , 12, 116-29		22
2207	Three-dimensional modeling and drug development. Has "rational" drug design arrived?. 1994 , 12, 147-50		1
2206	Analogous inhibitors of elastase do not always bind analogously. 1994 , 1, 55-8		80
2205	Prediction of new serine proteinase inhibitors. 1994 , 1, 735-43		62
2204	Structure-based drug design: progress, results and challenges. 1994 , 2, 577-87		204
2203	Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. <i>Journal of Medicinal Chemistry</i> , 1994 , 37, 616-24	8.3	194
2202	Software for structure-based drug design. 1994 , 4, 777-781		22
2201	SPROUT: recent developments in the de novo design of molecules. 1994 , 34, 207-17		126
2200	Structure-based drug design. 1994 , 4, 868-74		71
2199	Molecular Similarity Determination of Heteroaromatics Using CoMFA and Multivariate Data Analysis. 1994 , 13, 402-405		
2198	Theory of macromolecule-ligand interactions. 1994 , 4, 240-245		49
2197	. 1994 ,		
2196	. 1994 ,		
2195	Genetically evolved receptor models: a computational approach to construction of receptor models. <i>Journal of Medicinal Chemistry</i> , 1994 , 37, 2527-36	8.3	93
2194	The use of the GRID program in the 3-D QSAR analysis of a series of calcium-channel agonists. <i>Journal of Medicinal Chemistry</i> , 1994 , 37, 963-72	8.3	32
2193	Structure Correlation and Ligand/Receptor Interactions. 1994 , 543-603		10

2192	Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigen. 1995 , 92, 753-7	60
2191	Multivariate Data Analysis of Chemical and Biological Data. 1995 , 113-308	30
2190	Rational approaches to computer drug design based on drug-receptor interactions. 1995 , 3-48	1
2189	Identifying small-molecule lead compounds: the screening approach to drug discovery. 1995 , 13, 115-21	72
2188	Glucose analogue inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID force-field and GOLPE variable selection. 1995 , 51, 458-72	46
2187	Structure-based analysis of inhibitor binding to Ht-d. 1995 , 51, 597-604	3
2186	Molecular dynamics and structure-based drug design for predicting non-natural nonapeptide binding to a class I MHC protein. 1995 , 51, 541-9	3
2185	Inhibitoren von Disulfid-Reduktasen als Chemotherapeutica □Design von Wirkstoffen gegen die Chagas-Krankheit und gegen die Malaria. 1995 , 107, 153-166	17
2184	Kinetic analysis of the interaction between protein A domain variants and human Fc using plasmon resonance detection. 1995 , 8, 270-8	73
2183	Interactive variable selection (IVS) for PLS. Part II: Chemical applications. 1995 , 9, 331-342	67
2182	Disulfide-Reductase Inhibitors as Chemotherapeutic Agents: The Design of Drugs for Trypanosomiasis and Malaria. 1995 , 34, 141-154	196
2181	A molecular mechanics/grid method for evaluation of ligand-receptor interactions. 1995 , 16, 454-464	158
2180	Flexible ligand docking without parameter adjustment across four ligand-receptor complexes. 1995 , 16, 1210-1226	85
2179	Localization and quantitative evaluation of potent local binding sites on the accessible Lennard-Jones surface. 1995 , 16, 1459-1467	1
2178	Site-directed structure generation by fragment-joining. 1995 , 3, 21-33	21
2177	SPROUT, HIPPO and CAESA: Tools for de novo structure generation and estimation of synthetic accessibility. 1995 , 3, 34-50	95
2176	Computational combinatorial chemistry for de novo ligand design: Review and assessment. 1995 , 3, 51-84	35
2175	Accomplishments and challenges in integrating software for computer-aided ligand design in drug discovery. 1995 , 3, 139-150	4

2174	Hydration in drug design. 1. Multiple hydrogen-bonding features of water molecules in mediating protein-ligand interactions. 1995 , 9, 500-12	135
2173	A genetic algorithm for the automated generation of molecules within constraints. 1995 , 9, 181-202	91
2172	BUILDER v.2: improving the chemistry of a de novo design strategy. 1995 , 9, 269-82	70
2171	The atom assignment problem in automated de novo drug design. 1. Transferability of molecular fragment properties. 1995 , 9, 341-50	14
2170	A strategy for theoretical binding constant, K_i , calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase. 1995 , 23, 264-77	37
2169	Metal ion binding affinities of gastrin and CCK in membrane mimetic environments. 1995 , 1, 360-70	4
2168	Description of hydrophobicity parameters of a mixed set from their three-dimensional structures. <i>Bioorganic and Medicinal Chemistry</i> , 1995 , 3, 1389-96	3-4 5
2167	Flexible docking of peptides to class I major-histocompatibility-complex receptors. 1995 , 12, 1-21	31
2166	A CoMFA Analysis of Selected Physical Properties of Amino Acids in Water. 1995 , 14, 19-23	5
2165	Comparative Molecular Field Analysis of Hydrophobicity Descriptors of Cytosine Nucleosides. 1995 , 14, 335-343	4
2164	Use of Predictive Toxicology in the Design of New Chemicals. 1995 , 236-249	
2163	The structure of chitinases and prospects for structure-based drug design. 1995 , 73, 1142-1146	7
2162	The use of graph theoretical methods for the comparison of the structures of biological macromolecules. 1995 , 73-103	6
2161	Similarity Searching in Files of Three-Dimensional Structures: Evaluation of Similarity Coefficients and Standardisation Methods for Field-Based Similarity Searching. 1995 , 3, 101-130	14
2160	Flexible docking and design. 1995 , 24, 677-700	116
2159	Neuraminidase inhibitors as potential anti-influenza drugs. 1996 , 10, 1-16	17
2158	Molecular Similarity in Drug Design. 1995 ,	52
2157	Free energy simulations of the HyHEL-10/HEL antibody-antigen complex. 1995 , 8, 663-75	8

2156 Drug design: the present and the future. **1995**, 26, 45-142

2155 .

2154 A molecular dynamics approach to receptor mapping: application to the 5HT3 and beta 2-adrenergic receptors. *Journal of Medicinal Chemistry*, **1995**, 38, 4080-6 8.3 14

2153 What makes a binding site a binding site?. **1995**, 5, 825-9 119

2152 Modelling of the interaction of verotoxin-1 (VT1) with its glycolipid receptor, globotriaosylceramide (Gb3). **1995**, 17, 199-204 29

2151 Thermodynamics of water mediating protein-ligand interactions in cytochrome P450cam: a molecular dynamics study. **1995**, 69, 810-24 88

2150 Crystallographic and molecular-modeling studies of lipase B from *Candida antarctica* reveal a stereospecificity pocket for secondary alcohols. **1995**, 34, 16838-51 418

2149 Statistical Validation of QSAR Results. **1995**, 309-338 175

2148 3D-QSAR: a current perspective. **1995**, 16, 285-91 61

2147 Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. *Journal of Medicinal Chemistry*, **1996**, 39, 5064-71 8.3 87

2146 RASSE: a new method for structure-based drug design. **1996**, 36, 1187-94 33

2145 Rational design of specific high-affinity peptide ligands for the Abl-SH3 domain. **1996**, 35, 10634-40 115

2144 Neural network studies. 2. Variable selection. **1996**, 36, 794-803 122

2143 Improved binding of cytochrome P450cam substrate analogues designed to fill extra space in the substrate binding pocket. **1996**, 35, 1485-99 53

2142 VR techniques for the investigation of molecule data. **1996**, 20, 207-217 12

2141 Empirical free energy as a target function in docking and design: application to HIV-1 protease inhibitors. **1996**, 384, 87-91 18

2140 X-SITE: use of empirically derived atomic packing preferences to identify favourable interaction regions in the binding sites of proteins. **1996**, 259, 175-201 80

2139 High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. *Journal of Medicinal Chemistry*, **1996**, 39, 892-903 8.3 81

2138	Structural analysis of ricin and implications for inhibitor design. 1996 , 34, 1325-34		18
2137	A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. <i>Journal of Medicinal Chemistry</i> , 1996 , 39, 388-91	8.3	104
2136	Principal components describing biological activities and molecular diversity of heterocyclic aromatic ring fragments. <i>Journal of Medicinal Chemistry</i> , 1996 , 39, 4065-72	8.3	36
2135	SMoG: a de Novo Design Method Based on Simple, Fast, and Accurate Free Energy Estimates. 1. Methodology and Supporting Evidence. 1996 , 118, 11733-11744		239
2134	. 1996 ,		79
2133	. 1996 ,		29
2132	Computer Assisted Molecular Design: Overview of cModern Techniques in Quantitative Structure Activity Relationships (QSAR). 1996 , 44, 718-733		5
2131	Batimastat, a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding. 1996 , 93, 2749-54		122
2130	Partition-based selection. 1996 , 7-8, 85-114		29
2129	Simulations on the activation of the bradykinin B2 receptor. 1996 , 24, 259-63		2
2128	Intermediate trapping and laue X-ray diffraction: potential for enzyme mechanism, dynamics, and inhibitor screening. 1996 , 70, 215-56		13
2127	Computer-based screening of compound databases for the identification of novel leads. 1996 , 1, 363-370		21
2126	Computational tools for structure-based ligand design. 1996 , 66, 197-210		28
2125	Just add water! The effect of water on the specificity of protein-ligand binding sites and its potential application to drug design. 1996 , 3, 973-80		391
2124	Was lß sich aus der molekularen Erkennung in Protein-Ligand-Komplexen ff. das Design neuer Wirkstoffe lernen?. 1996 , 108, 2750-2778		35
2123	Design of Inhibitors of Photosystem II using a Model of the D1 Protein. 1996 , 47, 145-158		17
2122	Peptide docking using dynamic programming. 1996 , 17, 418-428		18
2121	Fitting an inhibitor into the active site of thermolysin: a molecular dynamics case study. 1996 , 24, 227-37		46

2120	Hydrophilicity of cavities in proteins. 1996 , 24, 433-8	306
2119	Molecular docking using surface complementarity. 1996 , 25, 120-9	61
2118	Docking enzyme-inhibitor complexes using a preference-based free-energy surface. 1996 , 25, 403-419	46
2117	Automated docking of flexible ligands: applications of AutoDock. 1996 , 9, 1-5	1057
2116	Experimental results from host-guest complexes for the design of effectors in biological systems and of enzyme analogous catalysts. 1996 , 9, 123-32	5
2115	Computational screening of combinatorial libraries. <i>Bioorganic and Medicinal Chemistry</i> , 1996 , 4, 631-8	3.4 22
2114	Current computational tools for de novo ligand design. 1996 , 7, 433-6	39
2113	The World Wide Web as a graphical user interface to program macros for molecular graphics, molecular modeling, and structure-based drug design. 1996 , 14, 291-6, 280-2	9
2112	Knowledge-based modeling of a legume lectin and docking of the carbohydrate ligand: the Ulex europaeus lectin I and its interaction with fucose. 1996 , 14, 322-7, 363-4	17
2111	Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. 1996 , 10, 293-304	796
2110	Three-dimensional hydrogen-bond geometry and probability information from a crystal survey. 1996 , 10, 607-22	191
2109	AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. 1996 , 14, 295-303	49
2108	A New Set of Principal Properties for Heteroaromatics Obtained by GRID. 1996 , 15, 108-120	28
2107	3D-Quantitative Structure-Activity Relationships for Hydrophobic Interactions: Comparative Molecular Field Analysis (CoMFA) including Molecular Lipophilicity Potentials as Applied to the Glycine Conjugation of Aromatic as well as Aliphatic Carboxylic Acids. 1996 , 15, 194-200	2
2106	Molecular Similarity Determination of Heteroaromatic Ring Fragments Using GRID and Multivariate Data Analysis. 1996 , 15, 469-474	3
2105	Locating and characterizing binding sites on proteins. 1996 , 14, 595-9	221
2104	Crystal structure of a PDZ domain. 1996 , 382, 649-52	298
2103	Predicting the structure of protein complexes: a step in the right direction. 1996 , 3, 151-6	45

2102	Drug receptor interactions. 1996 , 363-404		1
2101	An Experimental Approach to Mapping the Binding Surfaces of Crystalline Proteins 1996 , 100, 2605-2611		167
2100	Multiple human taste receptor sites: a molecular modeling approach. 1996 , 21, 425-45		13
2099	Experimental Techniques and Data Banks. 1996 , 139-217		
2098	Modeling Drug Receptor Interactions. 1996 , 235-336		10
2097	Comparison of experimental and computational functional group mapping of an RNase A structure: implications for computer-aided drug design. 1996 , 9, 773-80		15
2096	Generalization of the Molecular Electrostatic Potential for the Study of Noncovalent interactions. 1996 , 3, 181-218		37
2095	The Role of Geometric Fit Between Protein Molecules and their Ligands in Determining Biological Specificity. 1996 , 623-637		
2094	Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 4347-59 ^{8.3}		133
2093	Chapter 17 Rational methods for site-directed drug design. 1997 , 8, 323-343		
2092	Protein Crystallography in Medicine. 1997 , 1-50		
2091	Characterization of the interaction of Ca ²⁺ with hydroxy and non-hydroxy fatty acid species of cerebroside sulfate by Fourier transform infrared spectroscopy and molecular modeling. 1997 , 36, 3438-47		33
2090	Exceptionally stable salt bridges in cytochrome P450cam have functional roles. 1997 , 36, 5402-17		91
2089	Reliability of comparative molecular field analysis models: effects of data scaling and variable selection using a set of human synovial fluid phospholipase A2 inhibitors. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 1136-48	8.3	61
2088	Assessment of solvation effects on calculated binding affinity differences: trypsin inhibition by flavonoids as a model system for congeneric series. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 4136-45	8.3	35
2087	Simulated Annealing on Coupled Free Energy Surfaces: Relative Solvation Energies of Small Molecules. 1997 , 101, 9362-9374		7
2086	Nonpolar interactions of thrombin S' subsites with its bivalent inhibitor: methyl scan of the inhibitor linker. 1997 , 36, 13494-502		14
2085	Explanation of Where and How Enantioselective Binding Takes Place on Permethylated β -Cyclodextrin, a Chiral Stationary Phase Used in Gas Chromatography. 1997 , 119, 600-610		75

2084	A new approach to docking in the beta 2-adrenergic receptor that exploits the domain structure of G-protein-coupled receptors. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 3871-86	8.3	68
2083	A strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantitative structure-activity relationship analysis. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 4089-102	8.3	91
2082	Structure-based drug design: computational advances. 1997 , 37, 71-90		117
2081	Molecular Recognition of Proteinminus signLigand Complexes: Applications to Drug Design. 1997 , 97, 1359-1472		853
2080	[21] Stereoselectivity of lipase from <i>Rhizopus oryzae</i> toward triacylglycerols and analogs: Computer-aided modeling and experimental validation. 1997 , 353-376		11
2079	[18] Kinetics, molecular modeling, and synthetic applications with microbial lipases. 1997 , 386-405		11
2078	Structure-based identification of a ricin inhibitor. 1997 , 266, 1043-9		86
2077	Molecular Simulation of Peptide Interactions with an RP-HPLC Sorbent. 1997 , 101, 10962-10970		38
2076	Transcription Factor-Based Drug Design in Anticancer Drug Development. 1997 , 3, 799-810		7
2075	Computer-aided modelling of stereoselective triglyceride hydrolysis catalyzed by <i>Rhizopus oryzae</i> lipase. 1997 , 3, 73-82		24
2074	'Flu' and structure-based drug design. 1997 , 5, 1139-45		72
2073	Computational screening of combinatorial libraries via multicopy sampling. 1997 , 2, 229-234		7
2072	Site-directed mutagenesis and halophilicity of dihydrolipoamide dehydrogenase from the halophilic archaeon, <i>Haloferax volcanii</i> . 1997 , 248, 362-8		27
2071	Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 4360-71	8.3	77
2070	Heuristic lipophilicity potential for computer-aided rational drug design. 1997 , 11, 503-15		20
2069	A Monte Carlo method for finding important ligand fragments from receptor data. 1997 , 11, 243-55		1
2068	Alignment of flexible molecules at their receptor site using 3D descriptors and Hi-PCA. 1997 , 11, 601-12		16
2067	Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design. 1997 , 11, 175-92		66

2066	PRO_SELECT: combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology. 1997 , 11, 193-207	62
2065	Automatic identification and representation of protein binding sites for molecular docking. 1997 , 6, 524-33	166
2064	A Pharmacophore Model for PDE IV Inhibitors. 1997 , 16, 231-234	10
2063	Applications of nuclear magnetic resonance spectroscopy and molecular modeling to the study of protein-carbohydrate interactions. 1997 , 15, 9-17, 53	15
2062	Modeling and prediction of molecular properties. Theory of grid-weighted holistic invariant molecular (G-WHIM) descriptors. 1997 , 36, 65-73	21
2061	Flexible protein-ligand docking by global energy optimization in internal coordinates. 1997 , 29, 215-220	304
2060	Automated docking of monosaccharide substrates and analogues and methyl alpha-acarviosinide in the glucoamylase active site. 1997 , 27, 235-48	28
2059	High resolution fast quantitative docking using fourier domain correlation techniques. 1997 , 27, 493-506	28
2058	Automated docking of glucosyl disaccharides in the glucoamylase active site. 1997 , 28, 162-173	20
2057	Substrate binding and catalytic mechanism in phospholipase C from Bacillus cereus: a molecular mechanics and molecular dynamics study. 1997 , 42, 319-36	14
2056	Anatomy of lipase binding sites: the scissile fatty acid binding site. 1998 , 93, 67-80	362
2055	Molecular similarity characterization using CoMFA. 1998 , 12/14, 215-231	4
2054	Comparative molecular similarity indices analysis: CoMSIA. 1998 , 12/14, 87-104	79
2053	3D QSAR: current state, scope, and limitations. 1998 , 12/14, 3-23	42
2052	Recent progress in CoMFA methodology and related techniques. 1998 , 12/14, 25-39	26
2051	Receptor surface models. 1998 , 12/14, 117-133	8
2050	3D QSAR of flexible molecules using tensor representation. 1998 , 12/14, 167-182	4
2049	Lipase-catalyzed esterification of unusual substrates: Synthesis of glucuronic acid and ascorbic acid (vitamin C) esters. 1998 , 20, 1091-1094	25

2048	Ligand binding affinity prediction by linear interaction energy methods. 1998 , 12, 27-35	355
2047	Classification of auxin plant hormones by interaction property similarity indices. 1998 , 12, 63-79	19
2046	Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors. <i>Journal of Medicinal Chemistry</i> , 1998 , 41, 4021-35	8.3 36
2045	Rapid estimation of relative binding affinities of enzyme inhibitors. 1998 , 9/11, 85-98	
2044	Progress in force-field calculations of molecular interaction fields and intermolecular interactions. 1998 , 9/11, 3-17	3
2043	Molecular dynamics simulations: a tool for drug design. 1998 , 9/11, 181-209	11
2042	Structure of the key toxin in gas gangrene. 1998 , 5, 738-46	142
2041	Heterocyclic-fused 3(2H)-pyridazinones as potent and selective PDE IV inhibitors: Further structure-activity relationships and molecular modelling studies. 1998 , 33, 789-797	28
2040	Targeted molecular diversity in drug discovery: Integration of structure-based design and combinatorial chemistry. 1998 , 3, 105-112	43
2039	Virtual screening—overview. 1998 , 3, 160-178	769
2038	Mass spectrometric and thermodynamic studies reveal the role of water molecules in complexes formed between SH2 domains and tyrosyl phosphopeptides. 1998 , 6, 1141-51	65
2037	The role of ligand flexibility in predicting biological activity: Structure—activity relationships for aryl hydrocarbon, estrogen, and androgen receptor binding affinity. 1998 , 17, 15-25	22
2036	Low-resolution docking: Prediction of complexes for underdetermined structures. 1998 , 39, 455-464	63
2035	Binding of rationally designed non-natural peptides to the human leukocyte antigen HLA-B*2705. 1998 , 4, 378-88	10
2034	New Principal Components Derived Parameters Describing Molecular Diversity of Heteroaromatic Residues. 1998 , 17, 211-223	5
2033	A Kinetic Analysis of the Conformational Flexibility of Steroid Hormones. 1998 , 17, 437-449	4
2032	B-spline method for energy minimization in grid-based molecular mechanics calculations. 1998 , 19, 71-85	22
2031	Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. 1998 , 19, 1639-1662	754 ⁸

2030	Characterization of receptors with a new negative image: Use in molecular docking and lead optimization. 1998 , 30, 321-336		18
2029	Hydration energy landscape of the active site cavity in cytochrome P450cam. 1998 , 32, 381-396		47
2028	SCORE: A New Empirical Method for Estimating the Binding Affinity of a Protein-Ligand Complex. 1998 , 4, 379-394		248
2027	Structure-based drug design. 1998 , 9, 366-9		65
2026	[Molecular similarity. 2. The structural basis of drug design]. 1998 , 27, 158-72		8
2025	Prediction of liquid chromatographic retention times of steroids by three-dimensional structure descriptors and partial least squares modeling. 1998 , 44, 257-269		29
2024	Orthogonal signal correction of near-infrared spectra. 1998 , 44, 175-185		769
2023	3D QSAR in Drug Design. 1998 ,		19
2022	Visualizing the future of molecular graphics. 1998 , 8, 233-47		5
2021	Structure-based drug design approaches for predicting binding affinities of HIV1 protease inhibitors. 1998 , 14, 1-14		7
2020	Escherichiacoliβ-Galactosidase Recognizes a High-Energy Conformation of C-Lactose, a Nonhydrolyzable Substrate Analogue. NMR and Modeling Studies of the Molecular Complex. 1998 , 120, 1309-1318		88
2019	Three-dimensional models of estrogen receptor ligand binding domain complexes, based on related crystal structures and mutational and structure-activity relationship data. <i>Journal of Medicinal Chemistry</i> , 1998 , 41, 1803-14	8.3	56
2018	On the Use of Chemical Function-Based Alignments as Input for 3D-QSAR. 1998 , 38, 325-330		17
2017	A new method for predicting the alignment of flexible molecules and orienting them in a receptor cleft of known structure. <i>Journal of Medicinal Chemistry</i> , 1998 , 41, 691-8	8.3	6
2016	Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase. <i>Journal of Medicinal Chemistry</i> , 1998 , 41, 4636-47	8.3	22
2015	Oriental Dynamics of β-Cyclodextrin Inclusion Complexes. 1998 , 102, 9617-9624		73
2014	External action of di- and polyamines on maxi calcium-activated potassium channels: an electrophysiological and molecular modeling study. 1998 , 74, 722-30		34
2013	Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. <i>Journal of Medicinal Chemistry</i> , 1998 , 41, 4819-32	8.3	233

2012	Automated Docking of β -(1,4)- and β -(1,6)-Linked Glucosyl Trisaccharides in the Glucoamylase Active Site. 1998 , 37, 2148-2157		13
2011	7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase. <i>Journal of Medicinal Chemistry</i> , 1998 , 41, 2268-77	8,3	28
2010	Comparison of CoMFA models for <i>Salmonella typhimurium</i> TA98, TA100, TA98 + S9 and TA100 + S9 mutagenicity of nitroaromatics. 1998 , 9, 187-215		10
2009	Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues. 1998 , 9, 481-9		200
2008	Glossary of Terms Used in Computational Drug Design (IUPAC Recommendations 1997). 1998 , 33, 397-409		15
2007	A modification of the generalized Born theory for improved estimates of solvation energies and pK shifts. 1998 , 109, 1465-1471		102
2006	3D QSAR in Drug Design. 1998 ,		49
2005	Interdomain binding of NADPH in p-hydroxybenzoate hydroxylase as suggested by kinetic, crystallographic and modeling studies of histidine 162 and arginine 269 variants. 1998 , 273, 21031-9		41
2004	Molecular modeling of ligand-gated ion channels. 1998 , 293, 589-620		15
2003	Three-dimensional models of glutamate receptors. 1998 , 26, 450-8		11
2002	Molecular structure descriptors in the computer-aided design of biologically active compounds. 1999 , 68, 505-524		17
2001	Method for Including the Dynamic Fluctuations of a Protein in Computer-Aided Drug Design. 1999 , 103, 10213-10219		91
2000	A method for computational combinatorial peptide design of inhibitors of Ras protein. 1999 , 12, 457-68		13
1999	Influenza neuraminidase as target for antivirals. 1999 , 54, 375-402		17
1998	Using a galactose library for exploration of a novel hydrophobic pocket in the receptor binding site of the <i>Escherichia coli</i> heat-labile enterotoxin. 1999 , 274, 33469-73		22
1997	Molecular model of the interaction between nimesulide and human cyclooxygenase-2. 1999 , 38 Suppl 1, 14-8		19
1996	"RKKH" peptides from the snake venom metalloproteinase of <i>Bothrops jararaca</i> bind near the metal ion-dependent adhesion site of the human integrin α (2) I-domain. 1999 , 274, 31493-505		30
1995	Three-dimensional models of α (2A)-adrenergic receptor complexes provide a structural explanation for ligand binding. 1999 , 274, 23405-13		25

1994	Overview of Rational Drug Design. 1999 , 1-11		7
1993	Towards an understanding of drug resistance in malaria: three-dimensional structure of Plasmodium falciparum dihydrofolate reductase by homology building. <i>Bioorganic and Medicinal Chemistry</i> , 1999 , 7, 1003-11	3.4	48
1992	Towards molecular dynamics simulation of large proteins with a hydration shell at constant pressure. 1999 , 78, 157-82		52
1991	3D-QSAR study of insecticidal neonicotinoid compounds based on 3-way partial least squares model. 1999 , 47, 33-40		18
1990	Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling. 1999 , 17, 259-64		106
1989	Conformational and configurational features of acidic polysaccharides and their interactions with calcium ions: a molecular modeling investigation. 1999 , 317, 119-30		221
1988	Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4-dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: a molecular modeling study. 1999 , 13, 233-42		19
1987	A comparative study of ligand-receptor complex binding affinity prediction methods based on glycogen phosphorylase inhibitors. 1999 , 13, 243-58		54
1986	The structural and electronical factors that contribute affinity for the time-dependent inhibition of PGHS-1 by indomethacin, diclofenac and fenamates. 1999 , 13, 297-313		15
1985	Functional concerted motions in the bovine serum retinol-binding protein. 1999 , 13, 11-20		17
1984	Probing the nature of interactions in SH2 binding interfaces--evidence from electrospray ionization mass spectrometry. 1999 , 8, 1962-70		32
1983	Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 4071-80	8.3	58
1982	Computational Approaches to Drug Design. 1999 , 25, 347-371		28
1981	Lattice models for QSAR investigations. 1999 , 33, 473-479		
1980	Structure-based Reevaluation of the Mechanism of Class I Fructose-1,6-bisphosphate Aldolase. 1999 , 5, 37-45		4
1979	Computational approaches to structure-based ligand design. 1999 , 84, 179-91		73
1978	Regulation of cyclooxygenase activity by metamizol. 1999 , 378, 339-47		66
1977	Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors. 1999 , 7, 81-9		181

1976	Analysis of the binding surfaces of proteins. 1999 , 19, 321-31		29
1975	Development of neuraminidase inhibitors as anti-influenza virus drugs. 1999 , 46, 176-196		56
1974	Mouse acetylcholinesterase unliganded and in complex with huperzine A: a comparison of molecular dynamics simulations. 1999 , 50, 35-43		25
1973	Docking of 4-oxalocrotonate tautomerase substrates: implications for the catalytic mechanism. 1999 , 50, 319-28		22
1972	Molecular dynamics of mouse acetylcholinesterase complexed with huperzine A. 1999 , 50, 347-59		22
1971	Modelling of factor Xa-inhibitor complexes: a computational flexible docking approach. 1999 , 34, 173-83		41
1970	Docking of flexible ligands to flexible receptors in solution by molecular dynamics simulation. 1999 , 35, 153-62		102
1969	Exhaustive docking of molecular fragments with electrostatic solvation. 1999 , 37, 88-105		148
1968	Computational studies of the domain movement and the catalytic mechanism of thymidine phosphorylase. 1999 , 37, 242-52		22
1967	Locating interaction sites on proteins: The crystal structure of thermolysin soaked in 2% to 100% isopropanol. 1999 , 37, 628-640		79
1966	Die Bedeutung der Balance von Wasserstoffbrückenbindungen und hydrophoben Wechselwirkungen im Wirkstoff-Rezeptor-Komplex. 1999 , 111, 778-792		25
1965	A Peptidic Binding Site Model for PDE 4 Inhibitors. 1999 , 18, 543-547		3
1964	Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 458-77	8.3	407
1963	Computer-assisted comparison of the structural and electronic dispositions of ebastine and terfenadine. 1999 , 21 Suppl 1, 45-61; discussion 81-7		7
1962	6-Substituted benzopyrans as potassium channel activators: synthesis, vasodilator properties, and multivariate analysis. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 981-91	8.3	52
1961	Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 1908-20	8.3	78
1960	Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 2498-503	8.3	124
1959	Docking of Glycosaminoglycans to Heparin-Binding Proteins: Validation for aFGF, bFGF, and Antithrombin and Application to IL-8. 1999 , 121, 3004-3013		80

1958	Internal Dynamics of Green Fluorescent Protein. 1999 , 103, 3263-3269		68
1957	Lead generation using pharmacophore mapping and three-dimensional database searching: application to muscarinic M(3) receptor antagonists. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 3210-6	8.3	107
1956	GA strategy for variable selection in QSAR studies: application of GA-based region selection to a 3D-QSAR study of acetylcholinesterase inhibitors. 1999 , 39, 112-20		69
1955	Structure and conformation of complex carbohydrates of glycoproteins, glycolipids, and bacterial polysaccharides. 1999 , 28, 269-93		135
1954	A general and fast scoring function for protein-ligand interactions: a simplified potential approach. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 791-804	8.3	935
1953	MS-WHIM Scores for Amino Acids: A New 3D-Description for Peptide QSAR and QSPR Studies. 1999 , 39, 525-533		107
1952	Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 4506-23	8.3	64
1951	The role of waters in docking strategies with incremental flexibility for carbohydrate derivatives: heat-labile enterotoxin, a multivalent test case. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 1778-88	8.3	65
1950	Solution Chemistry and Twinning in Saccharin Crystals: A Combined Probe for the Structure and Functionality of the Crystal/Fluid Interface. 1999 , 121, 4563-4567		20
1949	Self-organizing molecular field analysis: a tool for structure-activity studies. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 573-83	8.3	148
1948	Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 67-86	8.3	107
1947	The discovery of steroids and other novel FKBP inhibitors using a molecular docking program. 1999 , 287, 853-8		65
1946	The 2.2 Å structure of the rRNA methyltransferase ErmC' and its complexes with cofactor and cofactor analogs: implications for the reaction mechanism. 1999 , 289, 277-91		85
1945	SuperStar: a knowledge-based approach for identifying interaction sites in proteins. 1999 , 289, 1093-108		187
1944	Sialidase inhibitors as anti-influenza drugs. 1999 , 145-160		
1943	NMR-based screening in drug discovery. 1999 , 32, 211-40		195
1942	Influenza virus sialidase: a target for drug discovery. 1999 , 36, 1-28		15
1941	SmoG: A Ligand Design Method Based on Knowledge-Based Parametrization of a Solvent Reorganization Model. 1999 , 70-86		1

1940	De Novo Molecular Design. 2000 , 49-69		4
1939	Modelling Structure-Activity Relationships. 2000 , 81-116		8
1938	Molecular Modelling of Human DT-Diaphorase For Enzyme-Directed Bioreductive Drug Design. 2000 , 24, 209-214		3
1937	Molecular basis of lipase stereoselectivity. 2000 , 102, 61-77		21
1936	Use of theoretical descriptors to characterize cation-binding sites in (macro)molecules. 2000 , 21, 847-855		16
1935	Macromolecular crystallography as a tool for investigating drug, enzyme and receptor interactions. 2000 , 27, 145-51		7
1934	The three-dimensional structures of the pectic polysaccharides. 2000 , 38, 37-55		150
1933	Synergy between combinatorial chemistry and de novo design. 2000 , 18, 358-67, 526		22
1932	Library design using BCUT chemistry-space descriptors and multiple four-point pharmacophore fingerprints: simultaneous optimization and structure-based diversity. 2000 , 18, 438-51, 538		30
1931	The design, synthesis and biological evaluation of neuraminic acid-based probes of <i>Vibrio cholerae</i> sialidase. 2000 , 11, 53-73		23
1930	Synthesis and biological evaluation of 1,3,4-triaryl-3-pyrrolin-2-ones, a new class of selective cyclooxygenase-2 inhibitors. 2000 , 10, 1745-8		27
1929	Synthesis and biological evaluation of 2,5-dihydropyrazol. 2000 , 10, 2661-4		30
1928	Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets. <i>Bioorganic and Medicinal Chemistry</i> , 2000 , 8, 2385-98	3.4	38
1927	Application of nonlinear and local modeling methods for 3D QSAR study of class I antiarrhythmics. 2000 , 54, 107-122		10
1926	Hydrophobicity: is LogP(o/w) more than the sum of its parts?. 2000 , 35, 651-61		205
1925	Discovering novel ligands for macromolecules using X-ray crystallographic screening. 2000 , 18, 1105-8		302
1924	Substrate specificity of lipase B from <i>Candida antarctica</i> in the synthesis of arylaliphatic glycolipids. 2000 , 8, 201-211		94
1923	Molecules as complex adaptative systems: constrained molecular properties and their biochemical significance. 2000 , 11 Suppl 2, S3-14		10

1922	VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. 2000 , 11 Suppl 2, S29-39	333
1921	A potential target enzyme for trypanocidal drugs revealed by the crystal structure of NAD-dependent glycerol-3-phosphate dehydrogenase from <i>Leishmania mexicana</i> . 2000 , 8, 541-52	45
1920	Progress in predicting human ADME parameters in silico. 2000 , 44, 251-72	198
1919	Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. 2000 , 503, 17-30	429
1918	Structure-based 3D-QSAR—merging the accuracy of structure-based alignments with the computational efficiency of ligand-based methods. 2000 , 503, 31-50	29
1917	Simple knowledge-based descriptors to predict protein-ligand interactions. methodology and validation. 2000 , 14, 787-803	16
1916	Receptor-based 3D QSAR analysis of estrogen receptor ligands—merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods. 2000 , 14, 559-72	89
1915	Computer based screening of compound databases: 1. Preselection of benzamidine-based thrombin inhibitors. 2000 , 14, 411-25	13
1914	Chemometric rationalization of the structural and physicochemical basis for selective cyclooxygenase-2 inhibition: toward more specific ligands. 2000 , 14, 277-91	16
1913	New QSAR Descriptors Calculated from Interatomic Interaction Spectra. 2000 , 34, 646-649	3
1912	New methods in predictive metabolism. 2002 , 5, 277-87	3
1911	Use of alignment-free molecular descriptors in diversity analysis and optimal sampling of molecular libraries. 2003 , 6, 135-47	6
1910	Binding of Zn ²⁺ to a Ca ²⁺ loop allosterically attenuates the activity of factor VIIa and reduces its affinity for tissue factor. 2000 , 9, 859-66	24
1909	Long chain diamines inhibit growth of C6 glioma cells according to their hydrophobicity. An in vitro and molecular modeling study. 2000 , 361, 235-46	8
1908	Recent developments in structure-based drug design. 2000 , 78, 269-81	188
1907	Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. 2000 , 45, 423-7	9
1906	Lattice Model for QSAR Studies. 2000 , 6, 517-526	18
1905	Mini-review: computational structure-based design of inhibitors that target protein surfaces. 2000 , 3, 355-62	27

1904	. 2000,		32
1903	. 2000,		70
1902	. 2000,		1417
1901	Molecular Basis for the Stereospecificity of Candida Rugosa Lipase (Crl) Towards Ibuprofen. 2000, 17, 475-486		5
1900	Convergence of the multipole expansion for electrostatic potentials of finite topological atoms. 2000, 113, 3969-3974		72
1899	MIPSIM: similarity analysis of molecular interaction potentials. 2000, 16, 568-9		11
1898	Deterministic Global Optimization. 2000,		297
1897	Conformational behavior of hyaluronan in relation to its physical properties as probed by molecular modeling. 2000, 10, 587-94		68
1896	How do substrates enter and products exit the buried active site of cytochrome P450cam? 1. Random expulsion molecular dynamics investigation of ligand access channels and mechanisms. 2000, 303, 797-811		279
1895	How do substrates enter and products exit the buried active site of cytochrome P450cam? 2. Steered molecular dynamics and adiabatic mapping of substrate pathways. 2000, 303, 813-30		135
1894	Developing a dynamic pharmacophore model for HIV-1 integrase. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 2100-14	8.3	248
1893	La sélection assistée par marqueurs. 2000, 2000, 16-18		1
1892	Les sciences de la vie à l'honneur. 2000, 2000, 1A-10A		
1891	Development of a unique 3D interaction model of endogenous and synthetic peripheral benzodiazepine receptor ligands. 2000, 14, 753-68		22
1890	Novel potent ligands for the central nicotinic acetylcholine receptor: synthesis, receptor binding, and 3D-QSAR analysis. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 2217-26	8.3	216
1889	Analysis of Binding Affinities for Celecoxib Analogues with COX-1 and COX-2 from Combined Docking and Monte Carlo Simulations and Insight into the COX-2/COX-1 Selectivity. 2000, 122, 9455-9466		123
1888	The characterization of chemical structures using molecular properties. A survey. 2000, 40, 195-209		225
1887	Three-dimensional moments of molecular property fields. 2000, 40, 1470-6		30

1886	Series Design in Synthetic Chemistry. 2000 , 17-37		2
1885	Bibliography. 2000 , 524-667		
1884	Pharmacophore Pattern Application in Virtual Screening. Library Design and QSAR. 2000 , 131-159		10
1883	Understanding Receptor-Ligand Interactions as a Prerequisite for Virtual Screening. 2000 , 207-227		5
1882	A new, electrophoretically silent, fetal hemoglobin variant: Hb F-Calabria [Ggamma118(GH1)Phe-->Leu]. 2000 , 24, 37-44		4
1881	Structural differences of matrix metalloproteinases. Homology modeling and energy minimization of enzyme-substrate complexes. 2000 , 17, 933-46		19
1880	Modeling cyclooxygenase inhibition. Implication of active site hydration on the selectivity of ketoprofen analogues. <i>Journal of Medicinal Chemistry</i> , 2000 , 43, 2280-4	8.3	48
1879	A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors. <i>Journal of Medicinal Chemistry</i> , 2000 , 43, 2300-9	8.3	33
1878	2-amino-2-oxazolines as subtype selective alpha(2) adrenoceptor agonists. <i>Journal of Medicinal Chemistry</i> , 2000 , 43, 1699-704	8.3	18
1877	One Water Molecule Stiffens a Protein. 2000 , 122, 2950-2951		44
1876	GRID/CPCA: a new computational tool to design selective ligands. <i>Journal of Medicinal Chemistry</i> , 2000 , 43, 3033-44	8.3	179
1875	Predicting blood-brain barrier permeation from three-dimensional molecular structure. <i>Journal of Medicinal Chemistry</i> , 2000 , 43, 2204-16	8.3	387
1874	Computer-Assisted Scanning of Ligand Interactions: Analysis of the Fructose 1,6-Bisphosphatase-AMP Complex Using Free Energy Calculations. 2000 , 122, 6114-6115		22
1873	GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. <i>Journal of Medicinal Chemistry</i> , 2000 , 43, 3233-43	8.3	419
1872	Computer simulations of enantioselective ester hydrolyses catalyzed by Pseudomonas cepacia lipase. 2000 , 65, 3659-65		35
1871	Use of an additional hydrophobic binding site, the Z site, in the rational drug design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines. <i>Journal of Medicinal Chemistry</i> , 2000 , 43, 3148-56	8.3	97
1870	QSAR study of steroid benchmark and dipeptides based on MEDV-13. 2001 , 41, 321-9		58
1869	A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities. <i>Journal of Medicinal Chemistry</i> , 2001 , 44, 2333-43	8.3	102

1868	Protein-Ligand Docking in Drug Design. 2001 , 315-360		5
1867	Chemography: the art of navigating in chemical space. 2001 , 3, 157-66		282
1866	Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold. <i>Journal of Medicinal Chemistry</i> , 2001 , 44, 1158-76	8.3	63
1865	Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. <i>Journal of Medicinal Chemistry</i> , 2001 , 44, 4072-81	8.3	79
1864	Inhibitors to the Src SH2 domain: a lesson in structure--thermodynamic correlation in drug design. 2001 , 390, 158-68		32
1863	SuperStar: improved knowledge-based interaction fields for protein binding sites. 2001 , 307, 841-59		96
1862	SuperStar: comparison of CSD and PDB-based interaction fields as a basis for the prediction of protein-ligand interactions. 2001 , 312, 275-87		34
1861	A fragment library based on Gaussian mixtures predicting favorable molecular interactions. 2001 , 313, 197-214		26
1860	Exploration of novel aryl binding sites of Farnesyltransferase using molecular modeling and benzophenone-based farnesyltransferase inhibitors. <i>Journal of Medicinal Chemistry</i> , 2001 , 44, 3117-24	8.3	26
1859	Molecular dynamics simulations of the rehydration of folded and unfolded cytochrome C ions in the vapor phase. 2001 , 123, 6503-7		19
1858	Identification of active molecular sites using quantum-self-similarity measures. 2001 , 41, 978-91		35
1857	Three-dimensional quantitative structure-permeability relationship analysis for a series of inhibitors of rhinovirus replication. 2001 , 41, 1578-86		41
1856	Identification of a putative binding site for [2',5'-bis-O-(tert-butyl dimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. <i>Journal of Medicinal Chemistry</i> , 2001 , 44, 1853-65	8.3	64
1855	Volume learning algorithm artificial neural networks for 3D QSAR studies. <i>Journal of Medicinal Chemistry</i> , 2001 , 44, 2411-20	8.3	43
1854	Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes. <i>Journal of Medicinal Chemistry</i> , 2001 , 44, 961-71	8.3	86
1853	Identification of amino acid residues in GluR1 responsible for ligand binding and desensitization. 2001 , 21, 3052-62		52
1852	Determination, prediction, and understanding of structures, using the energy landscapes of chemical systems [Part II. 2001 , 216, 361-383		50
1851	Modelling G-protein coupled receptors. 2001 , 341-376		1

1850	MODELLING ENZYME - LIGAND INTERACTIONS. 2001 , 539-595		1
1849	Binding interactions between barley thaumatin-like proteins and (1,3)-beta-D-glucans. Kinetics, specificity, structural analysis and biological implications. 2001 , 268, 4190-9		92
1848	Design, modeling and synthesis of functionalized paromamine analogs. 2001 , 57, 3255-3265		36
1847	Design and synthesis of MMP inhibitors using N -arylsulfonylaziridine hydroxamic acids as constrained scaffolds. 2001 , 57, 6885-6900		19
1846	Where to attach dye molecules to a protein: lessons from the computer program what if. <i>Journal of Molecular Structure</i> , 2001 , 598, 1-8	3-4	4
1845	Collagen-ligand interaction in dentinal adhesion: computer visualization and analysis. 2001 , 22, 2911-20		27
1844	Modelling studies of the active site of human sorbitol dehydrogenase: an approach to structure-based inhibitor design of the enzyme. 2001 , 11, 3133-6		24
1843	Structure-based design of inhibitors of the rice blast fungal enzyme trihydroxynaphthalene reductase. 2001 , 19, 434-47, 470-1		35
1842	Development of molecular hydrogen-bonding potentials (MHBPs) and their application to structure-permeation relations. 2001 , 19, 521-35, 594-7		28
1841	Protein interaction property similarity analysis. 2001 , 83, 122-127		64
1840	Theoretical evidence of a salt bridge disruption as the initiating process for the β 1d-adrenergic receptor activation: A molecular dynamics and docking study. 2001 , 43, 382-394		17
1839	Classical molecular interaction potentials: improved setup procedure in molecular dynamics simulations of proteins. 2001 , 45, 428-37		79
1838	Use of Relibase for retrieving complex three-dimensional interaction patterns including crystallographic packing effects. 2001 , 61, 99-110		53
1837	Computationally accessible method for estimating free energy changes resulting from site-specific mutations of biomolecules: systematic model building and structural/hydropathic analysis of deoxy and oxy hemoglobins. 2001 , 42, 355-77		43
1836	Solvation energy density occlusion approximation for evaluation of desolvation penalties in biomolecular interactions. 2001 , 43, 12-27		17
1835	High throughput docking for library design and library prioritization. 2001 , 43, 113-24		231
1834	Improved enantioselectivity of a lipase by rational protein engineering. 2001 , 2, 766-70		93
1833	Subnanomolar wirksame Inhibitoren aus dem Computerscreening: eine Modellstudie an der humanen Carboanhydrase II. 2001 , 113, 404-408		4

1832	Rechnergestützte Methoden erleichtern die Aufklärung von Proteinfunktionen. 2001 , 113, 4303-4305	2
1831	Subnanomolar Inhibitors from Computer Screening: A Model Study Using Human Carbonic Anhydrase II. 2001 , 40, 389-393	56
1830	Computational Methods Facilitate the Assignment of Protein Functions. 2001 , 40, 4175-4177	3
1829	Molecular basis of C(2+)-induced gelation in alginates and pectins: the egg-box model revisited. 2001 , 2, 1089-96	766
1828	Functional group placement in protein binding sites: a comparison of GRID and MCSS. 2001 , 15, 935-60	17
1827	A comparative docking study and the design of potentially selective MMP inhibitors. 2001 , 15, 873-81	26
1826	A genetic algorithm for structure-based de novo design. 2001 , 15, 911-33	85
1825	Synthesis, in vitro skin permeation studies, and PLS-analysis of new naproxen derivatives. 2001 , 18, 600-7	4
1824	Very empirical treatment of solvation and entropy: a force field derived from log Po/w. 2001 , 15, 381-93	48
1823	Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors. 2001 , 15, 395-410	60
1822	FILo (field interaction ligand optimization): a simplex strategy for searching the optimal ligand interaction field in drug design. 2001 , 15, 57-66	2
1821	Selective inhibition of 6-phosphogluconate dehydrogenase from <i>Trypanosoma brucei</i> . 2001 , 15, 465-75	12
1820	Neuronal nicotinic receptor agonists: a multi-approach development of the pharmacophore. 2001 , 15, 859-72	15
1819	Predicting plasticization efficiency from three-dimensional molecular structure of a polymer plasticizer. 2001 , 18, 1760-6	46
1818	Molecular mimicry of substrate oxygen atoms by water molecules in the beta-amylase active site. 2001 , 10, 1645-57	12
1817	Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. 2001 , 9, 389-97	122
1816	The design of combinatorial libraries using properties and 3D pharmacophore fingerprints. 2001 , 6, 251-258	44
1815	The changes in surface energetics with relative humidity of carbamazepine and paracetamol as measured by inverse gas chromatography. 2001 , 13, 219-25	33

1814	Structure and mechanism of the epoxide hydrolase from <i>Agrobacterium radiobacter</i> AD1. 2001 , 11, 1035-1042	19
1813	Molecular mechanism for agonist-promoted alpha(2A)-adrenoceptor activation by norepinephrine and epinephrine. 2001 , 59, 1343-54	54
1812	Experimental and computational mapping of the binding surface of a crystalline protein. 2001 , 14, 47-59	88
1811	Characterization of the stromal cell-derived factor-1alpha-heparin complex. 2001 , 276, 8288-96	173
1810	Structural basis for pterin antagonism in nitric-oxide synthase. Development of novel 4-oxo-pteridine antagonists of (6R)-5,6,7,8-tetrahydrobiopterin. 2001 , 276, 49133-41	24
1809	Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. 2001 , 59, 909-19	111
1808	Computational Chemistry in Lead Identification, Library Design and Lead Optimisation. 2001 , 26, 33-49	
1807	Deterministic Global Optimization and Ab Initio Approaches for the Structure Prediction of Polypeptides, Dynamics of Protein Folding, and Protein-Protein Interactions. 2002 , 265-457	4
1806	Pharmacophore definition and three-dimensional quantitative structure-activity relationship study on structurally diverse prostacyclin receptor agonists. 2002 , 62, 1103-11	17
1805	Computational mapping identifies the binding sites of organic solvents on proteins. 2002 , 99, 4290-5	105
1804	Computational Approaches to Biochemical Reactivity. 2002 ,	10
1803	Molecular Similarity Characterization Using CoMFA. 1998 , 215-231	
1802	Concept and prototype of protein-ligand docking simulator with force feedback technology. 2002 , 18, 140-6	41
1801	Structural diversity of heparan sulfate binding domains in chemokines. 2002 , 99, 1229-34	214
1800	Structure-based inhibitor design targeting HIV-1 integrase. 2002 , 2, 217-34	27
1799	Glycogen phosphorylase as a molecular target for type 2 diabetes therapy. 2002 , 3, 561-86	139
1798	Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. 2002 , 15, 727-37	69
1797	In Silico and Ex silico ADME approaches for drug discovery. 2002 , 2, 1287-304	70

1796	Neuraminic acid Structure, Chemistry, Biological Activity. 2002 , 103-154		2
1795	Receptor Surface Models. 1998 , 117-133		1
1794	Molecular docking of competitive phosphodiesterase inhibitors. 2002 , 61, 20-5		52
1793	STRUCTURE-BASED DRUG DESIGN AND ITS CONTRIBUTIONS TO CANCER CHEMOTHERAPY. 2002 , 171-cp1		
1792	Discrimination between agonists and antagonists by the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-selective glutamate receptor. A mutation analysis of the ligand-binding domain of GluR-D subunit. 2002 , 277, 41940-7		9
1791	Small molecule ligands define a binding site on the immune regulatory protein B7.1. 2002 , 277, 7363-8		40
1790	A dissimilarity matrix between protein atom classes based on Gaussian mixtures. 2002 , 18, 1257-63		4
1789	Combining pharmacophore and protein modeling to predict CYP450 inhibitors and substrates. 2002 , 357, 133-44		11
1788	A Brassinosteroid Derivative Useful to Provide More Information About the Importance of the C2 Group in the Brassinosteroid-Receptor Interaction. 2002 , 67, 19-29		0
1787	Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 2366-78	8.3	99
1786	Hydrophobicity maps of the N-peptide coiled coil of HIV-1 gp41. 2002 , 41, 2956-61		24
1785	Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 541-58	8.3	193
1784	TreeDock: a tool for protein docking based on minimizing van der Waals energies. 2002 , 124, 1241-50		58
1783	Pharmacokinetically based mapping device for chemical space navigation. 2002 , 4, 258-66		69
1782	Combined MEDV-GA-MLR method for QSAR of three panels of steroids, dipeptides, and COX-2 inhibitors. 2002 , 42, 749-56		42
1781	Development of new hydrogen-bond descriptors and their application to comparative molecular field analyses. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 1585-97	8.3	34
1780	A kinetics and modeling study of RANTES(9-68) binding to heparin reveals a mechanism of cooperative oligomerization. 2002 , 41, 14779-89		67
1779	Structural requirements for inhibition of the neuronal nitric oxide synthase (NOS-I): 3D-QSAR analysis of 4-oxo- and 4-amino-pteridine-based inhibitors. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 2923-41	8.3	27

1778	Structure-based approach for binding site identification on AmpC beta-lactamase. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 3222-34	8.3	115
1777	A View of the Hydrophobic Effect. 2002 , 106, 521-533		696
1776	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 3381-93	8.3	84
1775	Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 5410-3	8.3	143
1774	Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 2675-84	8.3	86
1773	Selective agonists at group II metabotropic glutamate receptors: synthesis, stereochemistry, and molecular pharmacology of (S)- and (R)-2-amino-4-(4-hydroxy[1,2,5]thiadiazol-3-yl)butyric acid. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 4240-5	8.3	15
1772	New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 54-71	8.3	49
1771	Molecular mapping in the CNS. 2002 , 8, 1547-70		9
1770	Preliminary mutational analysis of the human kinin B2 receptor for nonpeptide antagonist ligands recognition. 2002 , 80, 303-9		12
1769	Structure of tagatose-1,6-bisphosphate aldolase. Insight into chiral discrimination, mechanism, and specificity of class II aldolases. 2002 , 277, 22018-24		47
1768	Comparative Molecular Similarity Indices Analysis: CoMSIA. 1998 , 87-104		18
1767	Recent Progress in CoMFA Methodology and Related Techniques. 1998 , 25-39		5
1766	Transient exposure of hydrophobic surface in the photoactive yellow protein monitored with Nile Red. 2002 , 82, 1632-43		86
1765	Properties of water molecules in the active site gorge of acetylcholinesterase from computer simulation. 2002 , 82, 2671-82		42
1764	Novel tricyclic-alpha-alkoxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 789-804	8.3	136
1763	A simple model to predict blood-brain barrier permeation from 3D molecular fields. 2002 , 1587, 118-25		56
1762	Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 3588-602	8.3	159
1761	Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 1633-43	8.3	76

1760	GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND). <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 1577-84	8.3	17
1759	. 2002 ,		8
1758	Identification and mapping of small-molecule binding sites in proteins: computational tools for structure-based drug design. 2002 , 57, 243-51		77
1757	The effect of anions on azide binding to myoglobin: an unusual functional modulation. 2002 , 1594, 341-52		5
1756	Computational analysis of the aminic subsite of PGA explains the influence of amine structure on enantioselectivity. 2002 , 19-20, 423-430		9
1755	De novo chemical ligand design. 2002 , 7, 802-3		1
1754	Structure-based virtual screening: an overview. 2002 , 7, 1047-55		469
1753	Ansätze zur Beschreibung und Vorhersage der Bindungsaffinität niedermolekularer Liganden an makromolekulare Rezeptoren. 2002 , 114, 2764-2798		34
1752	Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. 2002 , 41, 2644-76		595
1751	CoMFA, CoMSIA and GRID/GOLPE studies on calcium entry blocking 1,4-dihydropyridines. 2002 , 21, 239-248		9
1750	Mapping of stereoselective recognition sites on human serum transferrin by capillary electrophoresis and molecular modelling. 2002 , 23, 964-71		14
1749	Extracting hydration sites around proteins from explicit water simulations. 2002 , 23, 861-9		74
1748	Pattern recognition strategies for molecular surfaces. I. Pattern generation using fuzzy set theory. 2002 , 23, 1176-87		34
1747	Structure-based design of cyclooxygenase-2 selectivity into ketoprofen. 2002 , 12, 533-7		54
1746	Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship. <i>Bioorganic and Medicinal Chemistry</i> , 2002 , 10, 3529-44	3-4	51
1745	Combining molecular modeling with experimental methodologies: mechanism of membrane permeation and accumulation of ofloxacin. <i>Bioorganic and Medicinal Chemistry</i> , 2002 , 10, 3871-89	3-4	66
1744	Binding affinity prediction of novel estrogen receptor ligands using receptor-based 3-D QSAR methods. <i>Bioorganic and Medicinal Chemistry</i> , 2002 , 10, 3741-55	3-4	44
1743	Chemical space navigation in lead discovery. 2002 , 6, 384-9		78

1742	GRID/tetrahedral intermediate computational approach to the study of selectivity of penicillin G acylase in amide bond synthesis. 2002 , 1601, 85-92	12
1741	Differential binding mode of diverse cyclooxygenase inhibitors. 2002 , 20, 359-71	67
1740	A simple method for visualizing the differences between related receptor sites. 2002 , 21, 217-225	7
1739	Local intersection volume: a new 3D descriptor applied to develop a 3D-QSAR pharmacophore model for benzodiazepine receptor ligands. 2002 , 37, 219-29	26
1738	Theoretical Prediction of the Phenoxy Radical Formation Capacity and Cyclooxygenase Inhibition Relationships by Phenolic Compounds. 2002 , 21, 605-612	7
1737	Principles of docking: An overview of search algorithms and a guide to scoring functions. 2002 , 47, 409-43	954
1736	Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6. 2002 , 49, 216-31	62
1735	Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme. 2003 , 50, 230-8	20
1734	Insights into the bile acid transportation system: the human ileal lipid-binding protein-cholyltaurine complex and its comparison with homologous structures. 2003 , 50, 312-28	36
1733	High-throughput crystallography for lead discovery in drug design. 2002 , 1, 45-54	432
1732	Virtual screening using grid computing: the screensaver project. 2002 , 1, 551-5	64
1731	Structural approach of the mechanism of inhibition of alpha-chymotrypsin by coumarins. 2002 , 12, 1109-12	9
1730	Molecular modelling in structural biology. 2002 , 33, 365-84	55
1729	Molecular modelling of the differential interaction between several non-steroidal anti-inflammatory drugs and human prostaglandin endoperoxide H synthase-2 (h-PGHS-2). 2002 , 20, 329-43	30
1728	A simple method for visualizing the differences between related receptor sites. 2002 , 21, 71-9	7
1727	The application of molecular modelling to the interpretation of inverse gas chromatography data. 2002 , 969, 49-57	17
1726	Computer-aided molecular modeling techniques for predicting the stability of drug-cyclodextrin inclusion complexes in aqueous solutions. 2002 , 358, 383-390	52
1725	Crystal engineering nucleation, the key step. 2002 , 4, 257-264	163

1724	Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 2749-69	8.3	72
1723	Synthesis, biological evaluation, and binding mode of novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles targeted at the HIV-1 reverse transcriptase. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 1567-76	8.3	59
1722	Modes of action in ecotoxicology: their role in body burdens, species sensitivity, QSARs, and mixture effects. 2002 , 36, 4201-17		399
1721	3D QSAR: Current State, Scope, and Limitations. 1998 , 3-23		8
1720	Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. 2002 , 41, 15625-34		139
1719	Q-fit: a probabilistic method for docking molecular fragments by sampling low energy conformational space. 2002 , 16, 43-57		29
1718	Further development and validation of empirical scoring functions for structure-based binding affinity prediction. 2002 , 16, 11-26		842
1717	3D hydrogen bond thermodynamics (HYBOT) potentials in molecular modelling. 2002 , 16, 1-10		19
1716	Flexible docking under pharmacophore type constraints. 2002 , 16, 129-49		139
1715	A review of protein-small molecule docking methods. 2002 , 16, 151-66		463
1714	New methods in predictive metabolism. 2002 , 16, 403-13		50
1713	De novo ligand design with explicit water molecules: an application to bacterial neuraminidase. 2002 , 16, 479-99		35
1712	Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors. 2002 , 16, 443-58		39
1711	Structure-based QSAR study on differential inhibition of human prostaglandin endoperoxide H synthase-2 (COX-2) by nonsteroidal anti-inflammatory drugs. 2002 , 16, 683-709		14
1710	Binding models of reversible inhibitors to type-B monoamine oxidase. 2002 , 16, 769-78		21
1709	A model of the human M2 muscarinic acetylcholine receptor. 2002 , 16, 795-801		27
1708	Structure of a functional IGF2R fragment determined from the anomalous scattering of sulfur. 2002 , 21, 1054-62		61
1707	A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation. 2002 , 21, 5396-407		209

1706	Improved mapping of protein binding sites. 2003 , 17, 173-86		22
1705	Evaluation of extended parameter sets for the 3D-QSAR technique MaP: implications for interpretability and model quality exemplified by antimalarially active naphthylisoquinoline alkaloids. 2003 , 17, 347-65		20
1704	Binding of alpha-hydroxy-beta-amino acid inhibitors to methionine aminopeptidase. The performance of two types of scoring functions. 2003 , 17, 383-97		1
1703	3D QSAR studies on binding affinities of coumarin natural products for glycosomal GAPDH of <i>Trypanosoma cruzi</i> . 2003 , 17, 277-90		24
1702	A new method for estimating the importance of hydrogen-bonding groups in the binding site of a protein. 2003 , 17, 401-14		7
1701	A Bayesian molecular interaction library. 2003 , 17, 435-61		12
1700	Comparative study of several algorithms for flexible ligand docking. 2003 , 17, 755-63		245
1699	Peroxisome proliferator-activated receptors target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. 2003 , 17, 785-96		19
1698	A structure-activity relationship study of catechol-O-methyltransferase inhibitors combining molecular docking and 3D QSAR methods. 2003 , 17, 797-810		28
1697	Competitive binding of fatty acids and the fluorescent probe 1-8-anilinonaphthalene sulfonate to bovine beta-lactoglobulin. 2003 , 12, 1596-603		92
1696	Metabolism and functions of phosphatidylserine in mammalian brain. 2003 , 28, 195-214		67
1695	Field interaction and geometrical overlap: a new simplex and experimental design based computational procedure for superposing small ligand molecules. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 1359-71	8.3	32
1694	Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 2313-24	8.3	145
1693	Polymorph Selection: Challenges for the Future? 2003 , 3, 873-885		185
1692	A rapid method for quantitative prediction of high affinity CTL epitopes: QSAR studies on peptides having affinity with the class I MHC molecular HLA-A*0201. 2003 , 10, 15-23		
1691	Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin. 2003 , 11, 557-67		88
1690	Selective agonist binding of (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) and 2S-(2alpha,3beta,4beta)-2-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid (kainate) receptors: a molecular modeling study. 2003 , 66, 2413-25		25
1689	Small molecule antagonists of proteins. 2003 , 65, 1-8		100

1688	Anti-HIV agents: design and discovery of new potent RT inhibitors. 2003 , 58, 259-63		48
1687	Anwendung und Grenzen kristallographischer Daten im strukturbezogenen Liganden- und Wirkstoff-Design. 2003 , 115, 2822-2841		16
1686	A homology model of penicillin acylase from <i>Alcaligenes faecalis</i> and in silico evaluation of its selectivity. 2003 , 4, 615-22		6
1685	On the generation of catalytic antibodies by transition state analogues. 2003 , 4, 277-85		27
1684	Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. 2003 , 42, 2718-36		285
1683	Conformational behavior of chondroitin and chondroitin sulfate in relation to their physical properties as inferred by molecular modeling. 2003 , 69, 15-28		31
1682	The process of structure-based drug design. 2003 , 10, 787-97		455
1681	2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductase. <i>Bioorganic and Medicinal Chemistry</i> , 2003 , 11, 4693-711	3-4	50
1680	Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. 2003 , 21, 273-87		87
1679	Alpha(1) adrenoceptor subtype selectivity. 3D-QSAR models for a new class of alpha(1) adrenoceptor antagonists derived from the novel antipsychotic sertindole. 2003 , 21, 523-34		10
1678	Investigation of platelet aggregation inhibitory activity by phenyl amides and esters of piperidinecarboxylic acids. <i>Bioorganic and Medicinal Chemistry</i> , 2003 , 11, 1439-50	3-4	13
1677	Algorithms for computational solvent mapping of proteins. 2003 , 51, 340-51		48
1676	Automated generation of MCSS-derived pharmacophoric DOCK site points for searching multiconformation databases. 2003 , 51, 189-202		35
1675	ICM-DISCO docking by global energy optimization with fully flexible side-chains. 2003 , 52, 113-7		159
1674	Computational detection of the binding-site hot spot at the remodeled human growth hormone-receptor interface. 2003 , 53, 201-19		25
1673	Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the alpha2A-adrenoceptor. 2003 , 140, 347-58		23
1672	Structure-based design of inhibitors of human L-xylulose reductase modelled into the active site of the enzyme. 2003 , 13, 1469-74		3
1671	Molecular recognition and docking algorithms. 2003 , 32, 335-73		543

1670	PHARMACOPHORE IDENTIFICATION AND RECEPTOR MAPPING. 2003 , 387-403		1
1669	Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. 2003 , 22, 1666-79		211
1668	The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. 2003 , 22, 5757-68		181
1667	Molecular parameters responsible for the melting point of 1,2,3-diazaborine compounds. 2003 , 43, 1513-9		15
1666	Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of ATPO bound to the GluR2 ligand-binding core, in comparison with DNQX. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 214-21	8.3	97
1665	A new approach to predict the biological activity of molecules based on similarity of their interaction fields and the logP and logD values: application to auxins. 2003 , 43, 1532-41		11
1664	Quantum mechanical models correlating structure with selectivity: predicting the enantioselectivity of beta-amino alcohol catalysts in aldehyde alkylation. 2003 , 125, 6614-5		88
1663	QSAR and proteo-chemometric analysis of the interaction of a series of organic compounds with melanocortin receptor subtypes. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 2572-9	8.3	46
1662	Molecular determinants of steroid inhibition for the mouse constitutive androstane receptor. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 4687-95	8.3	29
1661	Surface descriptors for protein-ligand affinity prediction. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 25-338,3		57
1660	Effects of multiple ligand binding on kinetic isotope effects in PQQ-dependent methanol dehydrogenase. 2003 , 42, 3966-78		16
1659	Chemometrical classification of ephrin ligands and Eph kinases using GRID/CPCA approach. 2003 , 43, 1004-10		24
1658	Identification of substrate binding sites in enzymes by computational solvent mapping. 2003 , 332, 1095-113		65
1657	3D QSAR in modern drug design. 2003 , 223-41		12
1656	Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 1306-17	8.3	104
1655	Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. 2003 , 310, 78-83		74
1654	Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 2. Computational titration and pH effects in molecular models of neuraminidase-inhibitor complexes. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 4487-500	8.3	69
1653	NMR studies of protein hydration and TEMPOL accessibility. 2003 , 332, 437-47		35

1652	Solution structure and p43 binding of the p38 leucine zipper motif: coiled-coil interactions mediate the association between p38 and p43. 2003 , 542, 119-24		27
1651	Computer simulation of water in cytochrome c oxidase. 2003 , 1557, 99-107		86
1650	Asymmetric structural motions of the homomeric alpha7 nicotinic receptor ligand binding domain revealed by molecular dynamics simulation. 2003 , 85, 3007-18		68
1649	A molecular basis for the endo-beta 1,3-glucanase activity of the thaumatin-like proteins from edible fruits. 2003 , 85, 123-31		86
1648	Inhibition of T-cell activation with HLA-DR1/DR4 restricted Non-T-cell stimulating peptides. 2003 , 64, 857-65		26
1647	Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 5184-95	8.3	42
1646	QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 3210-20	8.3	56
1645	FLUFF-BALL, a template-based grid-independent superposition and QSAR technique: validation using a benchmark steroid data set. 2003 , 43, 1780-93		20
1644	Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 1390-407 ^{8.3}		55
1643	A three-dimensional model of Suppressor Of Cytokine Signalling 1 (SOCS-1). 2003 , 16, 115-24		52
1642	EF loop conformational change triggers ligand binding in beta-lactoglobulins. 2003 , 278, 38840-6		62
1641	Molecular evaluation using in silico protein interaction profiles. 2003 , 19, 1514-23		11
1640	Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. 2003 , 23, 644-9		61
1639	Interaction of T4 endonuclease V with DNA: importance of the flexible loop regions in protein-DNA interaction. 2003 , 278, 30985-92		1
1638	Theoretical comparison between structural and dynamical features of Dolastatins 11 and 12 antineoplastic depsipeptides. 2003 , 14, 475-84		2
1637	A Novel Quantitative Structure-Biodegradability Relationship (QSBR) of Substituted Benzenes Based on MHDV Descriptor. 2003 , 50, 319-324		3
1636	3D QSAR Modeling in Drug Design. 2003 ,		1
1635	Twists and turns: a tale of two shikimate-pathway enzymes. 2003 , 31, 543-7		14

1634	Molecular Docking in Structure-Based Design. 2003 , 417-452	
1633	Influenza Virus Neuraminidase Inhibitors. 2003 , 105-113	0
1632	The FlexX database docking environment--rational extraction of receptor based pharmacophores. 2004 , 1, 49-60	22
1631	STRUCTURAL ANALYSIS OF CYP2C9 AND CYP2C5 AND AN EVALUATION OF COMMONLY USED MOLECULAR MODELING TECHNIQUES. 2004 , 32, 1218-1229	24
1630	Predicting synthetic accessibility: application in drug discovery and development. 2004 , 4, 681-92	42
1629	Recent advances in the investigation of the bioactive conformation of peptides active at the micro-opioid receptor. conformational analysis of endomorphins. 2004 , 4, 105-21	48
1628	Free energy of ligand binding to protein: evaluation of the contribution of water molecules by computational methods. 2004 , 11, 3093-118	82
1627	In silico methods for predicting ligand binding determinants of cytochromes P450. 2004 , 4, 1803-24	60
1626	Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design. 2004 , 11, 71-90	114
1625	Mutation-induced quisqualic acid and ibotenic acid affinity at the metabotropic glutamate receptor subtype 4: ligand selectivity results from a synergy of several amino acid residues. 2004 , 279, 34811-7	14
1624	Recent development and application of virtual screening in drug discovery: an overview. 2004 , 10, 1011-33	158
1623	Enzyme-catalyzed mechanism of isoniazid activation in class I and class III peroxidases. 2004 , 279, 39000-9	45
1622	Crystal structure of Mycobacterium tuberculosis catalase-peroxidase. 2004 , 279, 38991-9	151
1621	Jararhagin-derived RKKH peptides induce structural changes in alpha1I domain of human integrin alpha1beta1. 2004 , 279, 7962-70	33
1620	Docking and scoring in virtual screening for drug discovery: methods and applications. 2004 , 3, 935-49	2083
1619	AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis. 2004 , 23, 1514-21	220
1618	Complementarity of structure ensembles in protein-protein binding. 2004 , 12, 2125-36	160
1617	Novel technologies for virtual screening. 2004 , 9, 27-34	153

1616	Ibotenic acid and thioibotenic acid: a remarkable difference in activity at group III metabotropic glutamate receptors. 2004 , 486, 241-50		45
1615	Drug permeation in biomembranes: in vitro and in silico prediction and influence of physicochemical properties. 2004 , 23, 13-47		142
1614	Site-directed mutagenesis at the human B2 receptor and molecular modelling to define the pharmacophore of non-peptide bradykinin receptor antagonists. 2004 , 67, 601-9		29
1613	Scaffold hopping. 2004 , 1, 217-24		239
1612	Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. 2004 , 13, 1031-42		68
1611	Gaussian mapping of chemical fragments in ligand binding sites. 2004 , 18, 101-18		5
1610	Model based on GRID-derived descriptors for estimating CYP3A4 enzyme stability of potential drug candidates. 2004 , 18, 155-66		36
1609	Docking and scoring of metallo-beta-lactamases inhibitors. 2004 , 18, 287-302		26
1608	New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 6195-206	8.3	96
1607	Structure-based method for analyzing protein-protein interfaces. 2004 , 10, 44-54		84
1606	BODIL: a molecular modeling environment for structure-function analysis and drug design. 2004 , 18, 401-19		185
1605	An automated PLS search for biologically relevant QSAR descriptors. 2004 , 18, 437-49		69
1604	Aldose reductase structures: implications for mechanism and inhibition. 2004 , 61, 750-62		84
1603	Towards a MIP-based alignment and docking in computer-aided drug design. 2004 , 56, 585-94		4
1602	A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors. 2004 , 57, 36-50		21
1601	FlexX-Scan: fast, structure-based virtual screening. 2004 , 57, 504-17		55
1600	Novel approaches for modeling of the A1 adenosine receptor and its agonist binding site. 2004 , 54, 705-15		19
1599	Developments in the CCP4 molecular-graphics project. 2004 , 60, 2288-94		484

1598	Pattern recognition strategies for molecular surfaces: III. Binding site prediction with a neural network. 2004 , 25, 779-89		52
1597	Biology and chemistry of the inhibition of nitric oxide synthases by pteridine-derivatives as therapeutic agents. 2004 , 24, 662-84		19
1596	An unprecedented catalytic motif revealed in the model structure of amide hydrolyzing antibody 312d6. 2004 , 5, 129-31		4
1595	Comparative analysis of putative agonist-binding modes in the human A1 adenosine receptor. 2004 , 5, 841-9		9
1594	Peptide studies by means of principal properties of amino acids derived from MIF descriptors. 2004 , 18, 146-155		30
1593	Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability. <i>Bioorganic and Medicinal Chemistry</i> , 2004 , 12, 257-64	3-4	59
1592	2,6-Bis(3,4,5-trihydroxybenzylidene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays. <i>Bioorganic and Medicinal Chemistry</i> , 2004 , 12, 199-215	3-4	71
1591	Combining NMR and molecular modelling in a drug delivery context: investigation of the multi-mode inclusion of a new NPY-5 antagonist bromobenzenesulfonamide into beta-cyclodextrin. <i>Bioorganic and Medicinal Chemistry</i> , 2004 , 12, 447-58	3-4	38
1590	Design, synthesis and in vitro antitumor activity of new trans 2-[2-(heteroaryl)vinyl]-1,3-dimethylimidazolium iodides. <i>Bioorganic and Medicinal Chemistry</i> , 2004 , 12, 1689-95	3-4	31
1589	Probing the ultra-high resolution structure of aldose reductase with molecular modelling and noncovalent mass spectrometry. <i>Bioorganic and Medicinal Chemistry</i> , 2004 , 12, 3797-806	3-4	17
1588	Molecular electronegativity-distance vector (MEDV-4): a two-dimensional QSAR method for the estimation and prediction of biological activities of estradiol derivatives. 2004 , 679, 107-113		4
1587	In silico tools to aid risk assessment of endocrine disrupting chemicals. 2004 , 205, 43-53		66
1586	Calorimetry and structure-activity relationships for a series of antimicrobial hydrazides. 2004 , 417, 283-294		16
1585	Getting it right: modeling of pH, solvent and "nearly" everything else in virtual screening of biological targets. 2004 , 22, 479-86		25
1584	Modelling in vitro hepatotoxicity using molecular interaction fields and SIMCA. 2004 , 22, 487-97		27
1583	Structure-based rationalization of antitumor drugs mechanism of action by a MIF approach. 2004 , 39, 281-9		16
1582	LIV-3D-QSAR models for PGI2 receptor ligands using multiple conformations. 2004 , 39, 359-67		
1581	Design, synthesis and biological evaluation of new potent 5-nitrofuryl derivatives as anti-Trypanosoma cruzi agents. Studies of trypanothione binding site of trypanothione reductase as target for rational design. 2004 , 39, 421-31		52

1580	Piezoelectric sensors for dioxins: a biomimetic approach. 2004 , 20, 1203-10		50
1579	Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates. 2004 , 14, 881-5		35
1578	The heparin-Ca(2+) interaction: the influence of the O-sulfation pattern on binding. 2004 , 339, 975-83		34
1577	Optimising the EVA descriptor for prediction of biological activity. 2004 , 2, 3301-11		8
1576	Combined use of physicochemical data and small-molecule crystallographic contact propensities to predict interactions in protein binding sites. 2004 , 2, 3238-49		12
1575	Theoretical analysis of peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase: Insight into the mechanism of inhibition and the application of QM/MM calculations in structure-based drug design. 2004 , 2, 2275-80		18
1574	Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo-[1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 4517-29	8.3	52
1573	Isolation of a library of aromadendranes from <i>Landolphia dulcis</i> and its characterization using the VolSurf approach. 2004 , 67, 799-805		14
1572	Molecular basis for the binding of competitive inhibitors of maize polyamine oxidase. 2004 , 43, 3426-35		42
1571	Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1. 2004 , 65, 558-70		67
1570	A computational model for anthracycline binding to DNA: tuning groove-binding intercalators for specific sequences. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 1360-74	8.3	44
1569	Molecular motions in chitosan studied by dielectric relaxation spectroscopy. 2004 , 5, 2073-8		41
1568	From the Arctic to fetal life: physiological importance and structural basis of an 'additional' chloride-binding site in haemoglobin. 2004 , 380, 889-96		27
1567	Molecular surface point environments for virtual screening and the elucidation of binding patterns (MOLPRINT 3D). <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 6569-83	8.3	46
1566	Crystal structure of chicken liver basic fatty acid-binding protein complexed with cholic acid. 2004 , 43, 14072-9		52
1565	Incorporating molecular shape into the alignment-free Grid-Independent Descriptors. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 2805-15	8.3	69
1564	Tetrahydrobiopterin binding to aromatic amino acid hydroxylases. Ligand recognition and specificity. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 5962-71	8.3	18
1563	Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 907-14	8.3	61

1562	Broad-based quantitative structure-activity relationship modeling of potency and selectivity of farnesyltransferase inhibitors using a Bayesian regularized neural network. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 6230-8	8.3	30
1561	SitePrint: three-dimensional pharmacophore descriptors derived from protein binding sites for family based active site analysis, classification, and drug design. 2004 , 44, 2190-8		10
1560	Chemometrical identification of mutations in HIV-1 reverse transcriptase conferring resistance or enhanced sensitivity to arylsulfonylbenzotrioles. 2004 , 126, 2718-9		20
1559	An in silico approach to discovering novel inhibitors of human sirtuin type 2. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 6292-8	8.3	96
1558	An innovative application of the "flexible" GRID/PCA computational method: study of differences in selectivity between PGAs from Escherichia coli and a Providentia rettgeri mutant. 2004 , 20, 1025-31		10
1557	Using 3D protein structures to derive 3D-QSARs. 2004 , 1, 241-6		7
1556	Characterization of a ligand-receptor binding event using receptor-dependent four-dimensional quantitative structure-activity relationship analysis. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 3075-88	8.3	24
1555	Comparative molecular active site analysis (CoMASA). 1. An approach to rapid evaluation of 3D QSAR. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 2732-42	8.3	10
1554	Synthesis and quantitative structure-activity relationship of hydrazones of N-amino-N'-hydroxyguanidine as electron acceptors for xanthine oxidase. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 3105-10	8.3	20
1553	Combining pharmacophore search, automated docking, and molecular dynamics simulations as a novel strategy for flexible docking. Proof of concept: docking of arginine-glycine-aspartic acid-like compounds into the alphavbeta3 binding site. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 4178-87	8.3	50
1552	Hydration free energies and entropies for water in protein interiors. 2004 , 126, 7991-8000		94
1551	A quantum mechanics-based scoring function: study of zinc ion-mediated ligand binding. 2004 , 126, 1020-1		142
1550	Structural mining: self-consistent design on flexible protein-peptide docking and transferable binding affinity potential. 2004 , 126, 8515-28		50
1549	Toward the quantitative prediction of T-cell epitopes: QSAR studies on peptides having affinity with the class I MHC molecular HLA-A*0201. 2004 , 11, 683-94		20
1548	Structural basis for the binding of didemnins to human elongation factor eEF1A and rationale for the potent antitumor activity of these marine natural products. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 4439-52	8.3	36
1547	Drug Discovery, Design, and Development. 2004 , 7-120		4
1546	Identification of protein-protein interaction sites from docking energy landscapes. 2004 , 335, 843-65		231
1545	Comparative structural and energetic analysis of WW domain-peptide interactions. 2004 , 344, 865-81		34

1544	Analysis of void volumes in proteins and application to stability of the p53 tumour suppressor protein. 2004 , 344, 1199-209		48
1543	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 5912-22	8.3	79
1542	Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 5114-25	8.3	193
1541	Research applications of the Cambridge Structural Database (CSD). 2004 , 33, 463-75		126
1540	Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 3. The free energy contribution of structural water molecules in HIV-1 protease complexes. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 4507-16	8.3	107
1539	Revisiting free energy calculations: a theoretical connection to MM/PBSA and direct calculation of the association free energy. 2004 , 86, 67-74		408
1538	Successful Application of the Derived Crystal Packing (DCP) Model in Resolving the Crystal Structure of a Metastable Polymorph of (-) Modafinil 2004 , 4, 1143-1151		21
1537	The Role of Virtual Screening in Computer Aided Structure-Based Drug Design. 2004 , 57, 1029		12
1536	Dynamic water networks in cytochrome C oxidase from <i>Paracoccus denitrificans</i> investigated by molecular dynamics simulations. 2004 , 86, 1873-89		89
1535	Applications of Small Molecule Crystallography and the Cambridge Structural Database in Drug Design. 2004 , 1, 595-606		
1534	Integrative bioinformatics for functional genome annotation: trawling for G protein-coupled receptors. 2004 , 15, 693-701		10
1533	Efficient Strategies for Lead Optimization by Simultaneously Addressing Affinity, Selectivity and Pharmacokinetic Parameters. 2005 , 333-379		2
1532	Chapter 12 Structure-Based Lead Optimization. 2005 , 169-183		2
1531	Structure, function and molecular adaptations of haemoglobins of the polar cartilaginous fish <i>Bathyraja eatonii</i> and <i>Raja hyperborea</i> . 2005 , 389, 297-306		37
1530	Expression, purification, characterization and structure of <i>Pseudomonas aeruginosa</i> arylamine N-acetyltransferase. 2005 , 385, 605-12		62
1529	GRID-Derived Molecular Interaction Fields for Predicting the Site of Metabolism in Human Cytochromes. 2005 , 273-290		1
1528	Problems in Computational Structural Genomics. 2005 , 223-250		
1527	Algorithmic Engines in Virtual Screening. 2005 , 59-115		0

1526	Inhibitor-based validation of a homology model of the active-site of tripeptidyl peptidase II. 2005 , 23, 409-18		5
1525	Structure-based discovery of human L-xylulose reductase inhibitors from database screening and molecular docking. <i>Bioorganic and Medicinal Chemistry</i> , 2005 , 13, 301-12	3-4	18
1524	Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase. <i>Bioorganic and Medicinal Chemistry</i> , 2005 , 13, 2637-49	3-4	51
1523	Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: application to prediction of Caco-2 cell permeability. <i>Bioorganic and Medicinal Chemistry</i> , 2005 , 13, 4721-32	3-4	87
1522	Insight into 2-phenylpyrazolo[1,5-a]pyrimidin-3-yl acetamides as peripheral benzodiazepine receptor ligands: synthesis, biological evaluation and 3D-QSAR investigation. <i>Bioorganic and Medicinal Chemistry</i> , 2005 , 13, 4821-34	3-4	60
1521	Binding studies and GRIND/ALMOND-based 3D QSAR analysis of benzothiazine type K(ATP)-channel openers. <i>Bioorganic and Medicinal Chemistry</i> , 2005 , 13, 5581-91	3-4	19
1520	Identification and characterization of small molecule modulators of KChIP/Kv4 function. <i>Bioorganic and Medicinal Chemistry</i> , 2005 , 13, 6112-9	3-4	12
1519	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). 2005 , 15, 1101-6		79
1518	Molecular modeling and chemical modification for finding peptide inhibitor against severe acute respiratory syndrome coronavirus main proteinase. 2005 , 337, 262-70		88
1517	Identification of chiral selectors for improved enantioseparation based on molecular interaction fields. 2005 , 545, 33-45		11
1516	Exploiting structural principles to design cyclin-dependent kinase inhibitors. 2005 , 1754, 58-64		24
1515	alpha-Aminoalkylphosphonates as a tool in experimental optimisation of P1 side chain shape of potential inhibitors in S1 pocket of leucine- and neutral aminopeptidases. 2005 , 40, 764-71		38
1514	AMBER force field implementation of the boronate function to simulate the inhibition of beta-lactamases by alkyl and aryl boronic acids. 2005 , 40, 1134-42		29
1513	In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 1984-2008	8.3	50
1512	Computer-based de novo design of drug-like molecules. 2005 , 4, 649-63		583
1511	Mechanism of Lys48-linked polyubiquitin chain recognition by the Mud1 UBA domain. 2005 , 24, 3178-89		79
1510	Do mammalian cytochrome P450s show multiple ligand access pathways and ligand channelling?. 2005 , 6, 584-9		114
1509	Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity. 2005 , 60, 409-17		30

1508	Predicting protein druggability. 2005 , 10, 1675-82	226
1507	An inflammatory role for the mammalian carboxypeptidase inhibitor latexin: relationship to cystatins and the tumor suppressor TIG1. 2005 , 13, 309-17	64
1506	Visual methods from atoms to cells. 2005 , 13, 347-54	40
1505	VSMP for Modeling the Biodegradability of Substituted Benzenes Based on Electrotopological State Indices for Atom Types. 2005 , 23, 622-626	7
1504	Structure-Based Drug Discovery. 2005 , 295-321	1
1503	Prediction of contact angle for pharmaceutical solids from their molecular structure. 2005 , 94, 745-58	9
1502	QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. 2005 , 25, 133-66	226
1501	Target-family-oriented focused libraries for kinases--conceptual design aspects and commercial availability. 2005 , 6, 500-5	35
1500	A theoretical study on the activation of Ser70 in the acylation mechanism of cephalosporin antibiotics. 2005 , 114, 103-13	8
1499	A three-dimensional model of the human immunodeficiency virus type 1 integration complex. 2005 , 19, 301-17	45
1498	The 3D structure of the binding pocket of the human oxytocin receptor for benzoxazine antagonists, determined by molecular docking, scoring functions and 3D-QSAR methods. 2005 , 19, 341-56	9
1497	VolSurf analysis of pharmacokinetic properties for several antifungal sesquiterpene lactones isolated from Greek Centaurea sp. 2005 , 19, 617-23	26
1496	Structure of human semicarbazide-sensitive amine oxidase/vascular adhesion protein-1. 2005 , 61, 1550-62	60
1495	Principal component analysis of the effects of wavefunction modification on the electrostatic potential of indole. 2005 , 102, 379-386	1
1494	Improving CAPRI predictions: optimized desolvation for rigid-body docking. 2005 , 60, 308-13	41
1493	Kinetic and crystallographic studies of glucopyranose spirohydantoin and glucopyranosylamine analogs inhibitors of glycogen phosphorylase. 2005 , 61, 966-83	21
1492	Rapid ADME Filters for Lead Discovery. 2005 , 249-272	1
1491	Molecular Basis of Specificity and Stereoselectivity of Microbial Lipases toward Triacylglycerols. 2005 , 85-99	1

1490	A novel statistical ligand-binding site predictor: application to ATP-binding sites. 2005 , 18, 65-70	9
1489	Knowledge-driven lead discovery. 2005 , 5, 1045-52	4
1488	Computer-aided drug design strategies used in the discovery of fructose 1, 6-bisphosphatase inhibitors. 2005 , 11, 283-94	18
1487	The Design and Docking of Virtual Compound Libraries to Structures of Drug Targets. 2005 , 1, 103-127	15
1486	Viral Membrane Proteins: Structure, Function, and Drug Design. 2005 ,	6
1485	Molecular Interaction Fields in ADME and Safety. 2005 , 197-218	1
1484	Protein Selectivity Studies Using GRID-MIFs. 2005 , 43-82	1
1483	A priori contact preferences in molecular recognition. 2005 , 3, 861-90	3
1482	3D-QSAR Using the GRID/GOLPE Approach. 2005 , 145-170	3
1481	Principles and Methods of Docking and Ligand Design. 2005 , 441-476	2
1480	Progress in ADME Prediction Using GRID-Molecular Interaction Fields. 2005 , 219-247	
1479	The Basic Principles of GRID. 2005 , 1-25	5
1478	Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates. 2005 , 21, 2145-60	78
1477	The cAMP binding domain: an ancient signaling module. 2005 , 102, 45-50	164
1476	Calculation and Application of Molecular Interaction Fields. 2005 , 27-42	4
1475	Delineating a Ca ²⁺ binding pocket within the venus flytrap module of the human calcium-sensing receptor. 2005 , 280, 37917-23	115
1474	N-myristoylation determines dual targeting of mammalian NADH-cytochrome b5 reductase to ER and mitochondrial outer membranes by a mechanism of kinetic partitioning. 2005 , 168, 735-45	66
1473	Receptor-Based 3D QSAR Analysis of Serotonin 5-HT _{1D} Receptor Agonists. 2005 , 70, 1482-1492	1

1472	Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)- pyrazole derivatives. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 7113-22	8.3	98
1471	MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 6970-9	8.3	413
1470	Binding mode prediction of cytochrome p450 and thymidine kinase protein-ligand complexes by consideration of water and rescoring in automated docking. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 2308-18	8.3	110
1469	Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 3290-312	8.3	61
1468	Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters $\Delta \log P(N)(\text{oct-alk})$ and $\log D(\text{pH})(\text{alk})$. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 3269-79	8.3	47
1467	Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 4511-25	8.3	90
1466	Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. 2005 , 21, 1908-16		796
1465	3D structure and the drug-discovery process. 2005 ,		
1464	Improving the performance of SOMFA by use of standard multivariate methods. 2005 , 16, 567-79		5
1463	Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 2469-79	8.3	30
1462	Structural analysis of isoform-specific inhibitors targeting the tetrahydrobiopterin binding site of human nitric oxide synthases. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 4783-92	8.3	29
1461	Binding of 5'-GMP to the GluR2 AMPA receptor: insight from targeted molecular dynamics simulations. 2005 , 44, 14470-6		26
1460	Theoretical prediction of the enantiomeric excess in asymmetric catalysis. An alignment-independent molecular interaction field based approach. 2005 , 70, 9025-7		26
1459	Metabolic regio- and stereoselectivity of cytochrome P450 2D6 towards 3,4-methylenedioxy-N-alkylamphetamines: in silico predictions and experimental validation. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 6117-27	8.3	56
1458	Molecular modeling, synthesis, and preliminary biological evaluation of glutathione-S-transferase inhibitors as potential therapeutic agents. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 6084-9	8.3	10
1457	Chain-chain interactions for methyl polygalacturonate: models for high methyl-esterified pectin junction zones. 2005 , 6, 1322-8		18
1456	Comparison of ligand-based and structure-based 3D-QSAR approaches: a case study on (aryl)-bridged 2-aminobenzonitriles inhibiting HIV-1 reverse transcriptase. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 3756-67	8.3	41
1455	Processing multimode binding situations in simulation-based prediction of ligand-macromolecule affinities. 2005 , 109, 6387-91		5

1454	Comparing the performance of FLUFF-BALL to SEAL-CoMFA with a large diverse estrogen data set: from relevant superpositions to solid predictions. 2005 , 45, 1874-83		13
1453	Geminate rebinding in R-state hemoglobin: kinetic and computational evidence for multiple hydrophobic pockets. 2005 , 127, 17427-32		28
1452	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 4312-31	8.3	112
1451	The role of the peripheral anionic site and cation-pi interactions in the ligand penetration of the human AChE gorge. 2005 , 127, 9147-55		87
1450	Cytochrome p450 in silico: an integrative modeling approach. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 2725-55	8.3	187
1449	Modeling water molecules in protein-ligand docking using GOLD. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 6504-15	8.3	327
1448	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 2113-23	8.3	73
1447	Searching for a reliable orientation of ligands in their binding site: comparison between a structure-based (Glide) and a ligand-based (FIGO) approach in the case study of PDE4 inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 1657-65	8.3	9
1446	Induced fit in mouse acetylcholinesterase upon binding a femtomolar inhibitor: a molecular dynamics study. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 8155-62	8.3	21
1445	N-Acetylneuraminic Acid Derivatives and Mimetics as Anti-Influenza Agents. 2005 , 831-861		1
1444	Ligand-induced conformational change in the alpha7 nicotinic receptor ligand binding domain. 2005 , 88, 2564-76		62
1443	Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. 2005 , 280, 21353-7		98
1442	A new method for estimating the importance of hydrophobic groups in the binding site of a protein. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 1069-78	8.3	18
1441	The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations. 2005 , 127, 7570-8		47
1440	Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sulfide. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 8087-97	8.3	80
1439	Total synthesis of two novel subpicomolar sarco/endoplasmatic reticulum Ca ²⁺ -ATPase inhibitors designed by an analysis of the binding site of thapsigargin. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 7005-11	8.3	24
1438	Virtual screening and scaffold hopping based on GRID molecular interaction fields. 2005 , 45, 1313-23		53
1437	A new class of selective myocardial calcium channel modulators. 2. Role of the acetal chain in oxadiazol-3-one derivatives. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 2445-56	8.3	36

1436	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 4389-99	8.3	52
1435	Structural bioinformatics in drug discovery. 2003 , 44, 477-97		8
1434	Anchor-GRIND: filling the gap between standard 3D QSAR and the GRIND-INdependent descriptors. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 2687-94	8.3	75
1433	Chemical Genomics. 2005 ,		2
1432	Synthesis and in vitro characterization of organometallic rhenium and technetium glucose complexes against Glut 1 and hexokinase. 2005 , 16, 105-12		76
1431	Synthesis, biological evaluation, and three-dimensional quantitative structure-activity relationship study of small-molecule positive modulators of adrenomedullin. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 4068-75	8.3	13
1430	Computational Life Sciences. 2005 ,		3
1429	A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 2927-35	8.3	84
1428	Ligand-based prediction of active conformation by 3D-QSAR flexibility descriptors and their application in 3+3D-QSAR models. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 3239-50	8.3	21
1427	Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 6790-802	8.3	43
1426	Bioinformatics and Drug Discovery. 2006 ,		1
1425	Blot Spot Analysis of Protein-binding Sites as a Prerequisite for Structure-based Virtual Screening and Lead Optimization. 2006 , 171-192		6
1424	QSAR and Molecular Modeling Studies of HIV Protease Inhibitors. 181-271		5
1423	Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1 H-pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 inhibitor. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 7549-53	8.3	26
1422	Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 4912-25	8.3	92
1421	Structural e-bioinformatics and drug design. 2006 , 17, 1-10		6
1420	Pharmacophore modelling: applications in drug discovery. 2006 , 1, 261-7		40
1419	Pocket v.2: further developments on receptor-based pharmacophore modeling. 2006 , 46, 2684-91		95

1418	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 3172-84	8.3	135
1417	Chapter 9 Molecular Similarity: Advances in Methods, Applications and Validations in Virtual Screening and QSAR. 2006 , 2, 141-168		10
1416	Computational models for identifying potential P-glycoprotein substrates and inhibitors. 2006 , 3, 33-44		97
1415	Combinatorial Chemistry in the Drug Discovery Process. 2006 , 129-167		2
1414	Design and biological evaluation of novel tubulin inhibitors as antimetabolic agents using a pharmacophore binding model with tubulin. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 5664-70	8.3	68
1413	Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 2417-30	8.3	124
1412	Development of a chirality-sensitive flexibility descriptor for 3+3D-QSAR. 2006 , 46, 1431-8		20
1411	Structural insights into human 5-lipoxygenase inhibition: combined ligand-based and target-based approach. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 186-95	8.3	40
1410	Modeling the structural basis of human CCR5 chemokine receptor function: from homology model building and molecular dynamics validation to agonist and antagonist docking. 2006 , 46, 1223-35		32
1409	Activity of B-nor analogues of neurosteroids on the GABA(A) receptor in primary neuronal cultures. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 3225-34	8.3	24
1408	Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: potential for development of tumor-selective N-oxides. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 7013-23	8.3	41
1407	Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 51-69	8.3	53
1406	A theoretical study to investigate D2DAR/D4DAR selectivity: receptor modeling and molecular docking of dopaminergic ligands. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 1397-407	8.3	15
1405	N,N'-Bisbenzylidenebenzene-1,4-diamines and N,N'-Bisbenzylidenenaphthalene-1,4-diamines as Sirtuin Type 2 (SIRT2) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 7907-11	8.3	42
1404	3-D QSAR studies on histone deacetylase inhibitors. A GOLPE/GRID approach on different series of compounds. 2006 , 46, 1420-30		36
1403	Comparison of the binding and reactivity of plant and mammalian peroxidases to indole derivatives by computational docking. 2006 , 45, 2940-50		28
1402	Computational analysis of aza analogues of [2',5'-bis-O-(tert-butylidimethylsilyl)-beta-D-ribofuranose]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) as HIV-1 reverse transcriptase inhibitors: relevance of conformational properties on the inhibitory activity. 2006 , 46, 1666-77		8
1401	Calcium channel antagonists discovered by a multidisciplinary approach. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 5206-16	8.3	58

1400	Receptor-ligand binding sites and virtual screening. 2006 , 13, 1283-304	18
1399	Resolution of the structure of the allergenic and antifungal banana fruit thaumatin-like protein at 1.7-A. 2006 , 88, 45-52	61
1398	Molecular field extrema as descriptors of biological activity: definition and validation. 2006 , 46, 665-76	243
1397	Multiple solvent crystal structures: probing binding sites, plasticity and hydration. 2006 , 357, 1471-82	129
1396	Mapping the energetics of water-protein and water-ligand interactions with the "natural" HINT forcefield: predictive tools for characterizing the roles of water in biomolecules. 2006 , 358, 289-309	75
1395	Three-dimensional models of non-steroidal ligands: a comparative molecular field analysis. 2006 , 71, 417-28	8
1394	Around O. 2006 , 353-356	49
1393	. 2006 ,	56
1392	. 2006 ,	6
1391	Molecular graphics and animation. 2006 , 357-368	1
1390	The Drug Discovery Process. 2006 ,	1
1389	GRID-based Pharmacophore Models: Concept and Application Examples. 2006 , 151-170	3
1388	The relevance of the Cambridge Structural Database in protein crystallography. 2006 , 558-574	
1387	Success Stories of Computer-Aided Design. 2006 , 377-424	41
1386	Pharmacophore Model Generation Software Tools. 2006 , 15-47	12
1385	Concept and Applications of Pseudoreceptors. 2006 , 117-130	2
1384	Structures of the Dsk2 UBL and UBA domains and their complex. 2006 , 62, 177-88	62
1383	Similarity Metrics and Descriptor Spaces [Which Combinations to Choose?]. 2006 , 25, 1133-1142	37

1382	Water: How to evaluate its contribution in protein-ligand interactions. 2006 , 106, 647-651		11
1381	Ab initio prediction of peptide-MHC binding geometry for diverse class I MHC allotypes. 2006 , 63, 512-26		61
1380	Crystal structure of axolotl (<i>Ambystoma mexicanum</i>) liver bile acid-binding protein bound to cholic and oleic acid. 2006 , 64, 79-88		12
1379	Virtual and biomolecular screening converge on a selective agonist for GPR30. 2006 , 2, 207-12		644
1378	A novel missense mutation in ACTG1 causes dominant deafness in a Norwegian DFNA20/26 family, but ACTG1 mutations are not frequent among families with hereditary hearing impairment. 2006 , 14, 1097-105		48
1377	Action mechanisms and structure-activity relationships of PI3Kgamma inhibitors on the enzyme: a molecular modeling study. 2006 , 41, 558-65		8
1376	Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series. 2006 , 16, 2095-100		42
1375	Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. 2006 , 16, 6281-7		51
1374	Chemical space of orally active compounds. 2006 , 84, 134-141		7
1373	The role of molecular interaction fields on enantioselective and nonselective separation of chiral sulfoxides. 2006 , 1121, 64-75		15
1372	Evaluation of aldose reductase inhibition and docking studies of some secondary metabolites, isolated from <i>Origanum vulgare</i> L. ssp. <i>hirtum</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2006 , 14, 1653-9	3-4	25
1371	A simplified model to predict P-glycoprotein interacting drugs from 3D molecular interaction field. 2006 , 309, 109-14		6
1370	Tools for building a comprehensive modeling system for virtual screening under real biological conditions: The Computational Titration algorithm. 2006 , 24, 434-9		16
1369	A neural networks-based drug discovery approach and its application for designing aldose reductase inhibitors. 2006 , 24, 244-53		24
1368	A combined in silico strategy to describe the variation of some 3D molecular properties of beta-cyclodextrin due to the formation of inclusion complexes. 2006 , 25, 296-303		9
1367	Adenosine mimetics as inhibitors of NAD ⁺ -dependent histone deacetylases, from kinase to sirtuin inhibition. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 7307-16	8,3	140
1366	Molecular modelling. 2006 , 2, 660-81		8
1365	Localization of binding sites in protein structures by optimization of a composite scoring function. 2006 , 15, 2366-80		19

1364	Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 2804-11 ^{8.3}	55
1363	Lactandrate: a D-homo-aza-androsterone alkylator in the treatment of breast cancer. 2006 , 97, 17-31	30
1362	Mechanism of enhanced conversion of 1,2,3-trichloropropane by mutant haloalkane dehalogenase revealed by molecular modeling. 2006 , 20, 375-83	25
1361	Successful computer guided planned synthesis of (4R)-thiazolidine carboxylic acid and its 2-substituted analogues as urease inhibitors. 2006 , 10, 223-31	16
1360	Study on improving the selectivity of compounds that inhibit two PI3Ks (gamma and delta). 2006 , 12, 445-52	10
1359	The role of the anticancer drug vinorelbine in lipid bilayers using differential scanning calorimetry and molecular modeling. 2006 , 144, 85-95	20
1358	A new descriptor of amino acids based on the three-dimensional vector of atomic interaction field. 2006 , 51, 524-529	15
1357	Structure-permeation relationships for the non-invasive transdermal delivery of cationic peptides by iontophoresis. 2006 , 29, 53-9	24
1356	Virtual ligand screening: strategies, perspectives and limitations. 2006 , 11, 580-94	543
1355	Recognition forces in ligand-protein complexes: blending information from different sources. 2006 , 72, 1633-45	14
1354	Computational methods to rationalize experimental strategies in biocatalysis. 2006 , 24, 419-25	31
1353	Structure of the virus capsid protein VP1 of enterovirus 71 predicted by some homology modeling and molecular docking studies. 2006 , 27, 1556-70	12
1352	Design, synthesis, biological evaluation, and molecular modeling studies of TIBO-like cyclic sulfones as non-nucleoside HIV-1 reverse transcriptase inhibitors. 2006 , 1, 82-95	18
1351	Integrated approach using protein and ligand information to analyze selectivity- and affinity-determining features of carbonic anhydrase isozymes. 2006 , 1, 839-53	16
1350	Combining docking and molecular dynamic simulations in drug design. 2006 , 26, 531-68	453
1349	Location of Binding Sites on Proteins by the Multiple Solvent Crystal Structure Method. 2006 , 67-88	3
1348	Fragment Docking to Proteins with the Multi-copy Simultaneous Search Methodology. 2006 , 125-146	2
1347	3D-QSAR Applied to the Quantitative Prediction of Penicillin G Amidase Selectivity. 2006 , 348, 773-780	10

1346	Steroid-binding G-protein-coupled receptors: new drug discovery targets for old ligands. 2006 , 1, 137-50	6
1345	Ligand Docking and Virtual Screening in Structure-based Drug Discovery. 2006 ,	3
1344	Methods for the prediction of protein-ligand binding sites for structure-based drug design and virtual ligand screening. 2006 , 7, 395-406	130
1343	Insights into drug metabolism from modelling studies of cytochrome P450-drug interactions. 2006 , 6, 1619-26	5
1342	Computational models for predicting interactions with cytochrome p450 enzyme. 2006 , 6, 1609-18	56
1341	Molecular descriptors and methods for ligand based virtual high throughput screening in drug discovery. 2006 , 12, 2099-110	45
1340	Recent developments in focused library design: targeting gene-families. 2006 , 6, 19-29	42
1339	Pharmacophore models for metabotropic 5-HT receptor ligands. 2006 , 6, 2005-26	37
1338	Multiconformation continuum electrostatics analysis of the NhaA Na ⁺ /H ⁺ antiporter of Escherichia coli with functional implications. 2006 , 103, 2629-34	51
1337	Predicting protein interaction sites: binding hot-spots in protein-protein and protein-ligand interfaces. 2006 , 22, 1335-42	143
1336	Modeling the structure of the StART domains of MLN64 and StAR proteins in complex with cholesterol. 2006 , 47, 2614-30	87
1335	Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions. 2006 , 34, 976-83	73
1334	Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. 2006 , 70, 181-93	52
1333	Chemometric Characterization of Chromatographic Retention Parameters of Mesoionic 1,3,4-Thiadiazolium-3-Aminides by Molecular Interaction Fields. 2006 , 29, 307-327	1
1332	Epac1 and cAMP-dependent protein kinase holoenzyme have similar cAMP affinity, but their cAMP domains have distinct structural features and cyclic nucleotide recognition. 2006 , 281, 21500-21511	113
1331	GBPM: GRID-based pharmacophore model: concept and application studies to protein-protein recognition. 2006 , 22, 1449-55	93
1330	Receptor-binding sites: bioinformatic approaches. 2006 , 316, 291-358	1
1329	Structure-Based Drug Discovery. 2007 ,	23

1328	Searching Databases of Three-Dimensional Structures. 2007 , 213-263	27
1327	Computational Chemistry in the Undergraduate Curriculum. 2007 , 149-228	1
1326	Selectivity and affinity determinants for ligand binding to the aromatic amino acid hydroxylases. 2007 , 14, 455-67	41
1325	Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6. 2007 , 8, 59-77	39
1324	Computational identification of inhibitors of protein-protein interactions. 2007 , 7, 63-82	77
1323	Ab Initio potential grid based docking: From High Performance Computing to In Silico Screening. 2007 ,	2
1322	LFM-Pro: a tool for detecting significant local structural sites in proteins. 2007 , 23, 709-16	18
1321	Ligand docking and structure-based virtual screening in drug discovery. 2007 , 7, 1006-14	203
1320	ParDOCK: an all atom energy based Monte Carlo docking protocol for protein-ligand complexes. 2007 , 14, 632-46	103
1319	Structure-based drug design: docking and scoring. 2007 , 8, 312-28	228
1318	The in silico insights of alpha-adrenergic receptors over the last decade: methodological approaches and structural features of the 3D models. 2007 , 7, 195-205	3
1317	The Cambridge Crystallographic Database. 2007 , 389-410	2
1316	Computer-Aided Drug Design: Integration of Structure-Based and Ligand-Based Approaches in Drug Design. 2007 , 3, 133-148	29
1315	Anti-influenza drug discovery: are we ready for the next pandemic?. 2007 , 61, 293-352	10
1314	Scaffold-Based Drug Discovery. 2007 , 129-153	6
1313	An optimal alignment of proteins energy characteristics with crisp and fuzzy similarity awards. 2007 ,	16
1312	Indolyl aryl sulphones as HIV-1 reverse transcriptase inhibitors: docking and 3D QSAR studies. 2007 , 2, 87-114	5
1311	Structure-Based Drug Design The Use of Protein Structure in Drug Discovery. 2007 , 597-650	

1310	Chapter 5 Linear Quantitative Structure-Activity Relationships for the Interaction of Small Molecules with Human Cytochrome P450 Isoenzymes. 2007 , 63-81	2
1309	New Applications for Structure-Based Drug Design. 2007 , 775-806	0
1308	Similarity Searching in Databases of Chemical Structures. 2007 , 1-66	13
1307	Sugar-derived Heterocycles and Their Precursors as Inhibitors Against Glycogen Phosphorylases (GP). 2007 , 33-52	6
1306	A Perspective of Modern Methods in Computer-Aided Drug design. 2007 , 337-379	8
1305	Three-Dimensional Structure Database Searches. 2007 , 67-117	14
1304	Molecular Recognition in Biology: Models for Analysis of Protein-Ligand Interactions. 2007 , 25-71	1
1303	Efficient Strategies for Lead Optimization by Simultaneously Addressing Affinity, Selectivity and Pharmacokinetic Parameters. 705-754	1
1302	H-Bonding Parameterization in Quantitative Structure-Activity Relationships and Drug Design. 2007 , 127-154	5
1301	Molecular Modeling Software in Use: Publication Trends. 2007 , 317-354	2
1300	Current Issues in De Novo Molecular Design. 2007 , 67-125	13
1299	Approaches to Three-Dimensional Quantitative Structure-Activity Relationships. 2007 , 183-240	11
1298	Mapping selectivity and specificity of active site of plasmeppsins from Plasmodium falciparum using molecular interaction field approach. 2007 , 14, 569-74	6
1297	Free Energy Calculations: Use and Limitations in Predicting Ligand Binding Affinities. 2007 , 217-304	20
1296	Ligand design: Identification of interaction sites. 2007 , 57, 291-293	
1295	Brassinolide activities of 2alpha,3alpha-diols versus 3alpha,4alpha-diols in the bean second internode bioassay: explanation by molecular modeling methods. 2007 , 72, 740-50	6
1294	Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 1241-53	88
1293	Binding modes of L35 to alpha- and beta-semihemoglobins: structural insights into the inequivalence of alpha- and beta-subunits of hemoglobin. 2007 , 354, 720-6	4

1292	Crystallographic and in silico analysis of the sialoside-binding characteristics of the Siglec sialoadhesin. 2007 , 365, 1469-79		27
1291	Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution. 2007 , 368, 618-38		64
1290	An approach to address <i>Candida rugosa</i> lipase regioselectivity in the acylation reactions of trytilated glucosides. 2007 , 128, 908-18		17
1289	CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 5382-91	8.3	32
1288	Modeling and Informatics in Drug Design. 2007 , 1-45		7
1287	The reactivity with CO of AHb1 and AHb2 from <i>Arabidopsis thaliana</i> is controlled by the distal HisE7 and internal hydrophobic cavities. 2007 , 129, 2880-9		49
1286	Target-based approach to inhibitors of histone arginine methyltransferases. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 2319-25	8.3	124
1285	Thermodynamics of Phases having Constant Composition. 2007 , 1-62		
1284	ConCEPT: de novo design of synthetic receptors for targeted ligands. 2007 , 47, 425-34		14
1283	Ligand recognition by chloroperoxidase using molecular interaction fields and quantum chemistry calculations. 2007 , 33, 649-654		14
1282	Inhibitory effect on soybean lipoxygenase and docking studies of some secondary metabolites, isolated from <i>Origanum vulgare</i> L. ssp. <i>hirtum</i> . 2007 , 22, 99-104		12
1281	In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 742-8	8.3	30
1280	Virtual screening for novel openers of pancreatic K(ATP) channels. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 2117-26	8.3	44
1279	Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 1231-40	8.3	118
1278	Water at biomolecular binding interfaces. 2007 , 9, 573-81		157
1277	Lennard-Jones potential and dummy atom settings to overcome the AUTODOCK limitation in treating flexible ring systems. 2007 , 47, 1481-92		35
1276	SHOP: scaffold HOPping by GRID-based similarity searches. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 2708-17	8.3	69
1275	New and original pKa prediction method using grid molecular interaction fields. 2007 , 47, 2172-81		238

1274	Prediction of the Structure of Complexes Comprised of Proteins and Glycosaminoglycans Using Docking Simulation and Cluster Analysis. 2007 , 3, 2347-56		12
1273	Exploration of enzyme-ligand interactions in CYP2D6 & 3A4 homology models and crystal structures using a novel computational approach. 2007 , 47, 1234-47		27
1272	An Introduction To Chemoinformatics. 2007 ,		191
1271	The influence of protonation states on the dynamics of the NhaA antiporter from Escherichia coli. 2007 , 92, 3784-91		42
1270	Docking and Scoring for Structure-based Drug Design. 541-599		5
1269	Pharmacophoric fingerprint method (TOPP) for 3D-QSAR modeling: application to CYP2D6 metabolic stability. 2007 , 47, 76-84		27
1268	Use of Molecular Descriptors for Absorption, Distribution, Metabolism, and Excretion Predictions. 2007 , 531-554		8
1267	Molecular Fields to Assess Recognition Forces and Property Spaces. 2007 , 577-602		3
1266	State-of-the-art tools for computational site of metabolism predictions: comparative analysis, mechanistical insights, and future applications. 2007 , 39, 61-86		114
1265	Three-Dimensional Quantitative Structure-Activity Relationship: The State of the Art. 2007 , 575-595		4
1264	CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 4444-52	8.3	89
1263	Classification of water molecules in protein binding sites. 2007 , 129, 2577-87		225
1262	Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 2981-9	8.3	81
1261	TMACC: interpretable correlation descriptors for quantitative structure-activity relationships. 2007 , 47, 626-34		24
1260	A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. 2007 , 47, 279-94		342
1259	Characterization of Protein-Binding Sites and Ligands Using Molecular Interaction Fields. 2007 , 237-253		1
1258	Docking and Scoring. 2007 , 255-281		
1257	Structural, Energetic, and Dynamic Aspects of Ligand-Receptor Interactions. 2007 , 193-213		5

1256	Design and Synthesis of Sialidase Inhibitors for Influenza Virus Infections. 2007 , 885-922	5
1255	Introduction to Computer-Assisted Drug Design [Overview and Perspective for the Future. 2007 , 13-41	
1254	Library Design: Reactant and Product-Based Approaches. 2007 , 337-378	
1253	Structure-Based Drug Design [A Historical Perspective and the Future. 2007 , 65-86	2
1252	De Novo Design. 2007 , 283-305	6
1251	Cheminformatics. 2007 , 235-264	1
1250	Molecular Modeling in Glycoscience. 2007 , 347-388	6
1249	Estudos de QSAR-3D em derivados 5-nitro-2-tiofilidílicos com atividade frente a Staphylococcus aureus multi-resistente. 2007 , 43, 281-294	
1248	. 2007 ,	6
1247	An alignment-free methodology for modelling field-based 3D-structure activity relationships using inductive logic programming. 2007 , 21, 509-519	5
1246	Complexity in modeling and understanding protonation states: computational titration of HIV-1-protease-inhibitor complexes. 2007 , 4, 2564-77	9
1245	Computer-Aided Drug Design. 89-107	3
1244	In Silico Analysis of Enzyme Surface and Glycosylation Effect as a Tool for Efficient Covalent Immobilisation of CalB and PGA on Sepabeads[. 2007 , 349, 877-886	41
1243	Effect of different treatments of long-range interactions and sampling conditions in molecular dynamic simulations of rhodopsin embedded in a dipalmitoyl phosphatidylcholine bilayer. 2007 , 28, 1017-30	27
1242	A semiempirical free energy force field with charge-based desolvation. 2007 , 28, 1145-52	1602
1241	WATGEN: an algorithm for modeling water networks at protein-protein interfaces. 2007 , 28, 2241-51	21
1240	Structure-activity studies on suramin analogues as inhibitors of NAD ⁺ -dependent histone deacetylases (sirtuins). 2007 , 2, 1419-31	163
1239	Functional classification of protein kinase binding sites using Cavbase. 2007 , 2, 1432-47	57

1238	Overcoming the inadequacies or limitations of experimental structures as drug targets by using computational modeling tools and molecular dynamics simulations. 2007 , 2, 1388-401		32
1237	Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols. 2007 , 2, 1750-62		28
1236	Protein dynamics tightly connected to the dynamics of surrounding and internal water molecules. 2007 , 8, 23-33		85
1235	Dioxane and oxathiane nuclei: suitable substructures for muscarinic agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2007 , 15, 886-96	3-4	29
1234	Benzoic acid and pyridine derivatives as inhibitors of <i>Trypanosoma cruzi</i> trans-sialidase. <i>Bioorganic and Medicinal Chemistry</i> , 2007 , 15, 2106-19	3-4	38
1233	Explaining cyclodextrin-mycotoxin interactions using a 'natural' force field. <i>Bioorganic and Medicinal Chemistry</i> , 2007 , 15, 4585-94	3-4	29
1232	Novel TOPP descriptors in 3D-QSAR analysis of apoptosis inducing 4-aryl-4H-chromenes: comparison versus other 2D- and 3D-descriptors. <i>Bioorganic and Medicinal Chemistry</i> , 2007 , 15, 6450-62	3-4	23
1231	SAR of the arylpiperazine moiety of obeline somatostatin sst1 receptor antagonists. 2007 , 17, 3988-91		8
1230	The consequences of scoring docked ligand conformations using free energy correlations. 2007 , 42, 921-33		52
1229	Three dimensional holographic vector of atomic interaction field (3D-HoVAIF). 2007 , 87, 88-94		17
1228	Synthesis and evaluation of 4-O-alkylated 2-deoxy-2,3-didehydro-N-acetylneuraminic acid derivatives as inhibitors of human parainfluenza virus type-3 sialidase activity. 2007 , 17, 1655-8		21
1227	Receptor-based QSAR studies of non-peptide human oxytocin receptor antagonists. 2007 , 25, 711-20		7
1226	CoMFA based de novo design of pyridazine analogs as PTP1B inhibitors. 2007 , 26, 117-23		18
1225	A simple method to calculate the accessible volume of protein-bound ligands: application for ligand selectivity. 2007 , 26, 429-33		1
1224	Computational analyses of the surface properties of protein-protein interfaces. 2007 , 63, 50-7		22
1223	Energetics of the protein-DNA-water interaction. 2007 , 7, 4		48
1222	Conformational behavior of antineoplastic peptides Dolastatin 10 and Dolastatin 15 from Monte Carlo and molecular dynamics simulations. 2007 , 107, 318-325		1
1221	X-ray absorption and molecular dynamics study of cation binding sites in the purple membrane. 2007 , 67, 360-74		11

1220	Accuracy of binding mode prediction with a cascadic stochastic tunneling method. 2007 , 68, 195-204	13
1219	Efficient comprehensive scoring of docked protein complexes using probabilistic support vector machines. 2008 , 70, 1367-78	16
1218	Receptor-specific scoring functions derived from quantum chemical models improve affinity estimates for in-silico drug discovery. 2008 , 70, 1264-73	33
1217	Automated prediction of ligand-binding sites in proteins. 2008 , 70, 1506-17	94
1216	Three-dimensional holograph vector of atomic interaction field (3D-HoVAIF): a novel rotation-translation invariant 3D structure descriptor and its applications to peptides. 2007 , 13, 549-66	21
1215	ATP as effector of inorganic pyrophosphatase of Escherichia coli. Identification of the binding site for ATP. 2007 , 72, 93-9	4
1214	The war against influenza: discovery and development of sialidase inhibitors. 2007 , 6, 967-74	532
1213	Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. 2008 , 6, 166-73	40
1212	qPIPSA: relating enzymatic kinetic parameters and interaction fields. 2007 , 8, 373	36
1211	Insight into the structural determinants for selective inhibition of matrix metalloproteinases. 2007 , 12, 640-6	98
1210	Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems. 2007 , 32, 169-81	5
1209	Volsurf computational method applied to the prediction of stability of thermostable enzymes. 2007 , 2, 214-20	12
1208	Molecular field technology applied to virtual screening and finding the bioactive conformation. 2007 , 2, 131-44	58
1207	Chapter 2:The Changing Landscape in Drug Discovery. 2007 , 24-45	3
1206	Computational and Structural Approaches to Drug Discovery. 2007 ,	2
1205	Molecular Modelling. 2007 , 54-96	
1204	Anti-Influenza Drugs from Neuraminidase Inhibitors. 2007 , 193-218	
1203	3D Structure and the Drug Discovery Process. 2007 , 1-31	1

1202	Structure of the fungal beta-glucan-binding immune receptor dectin-1: implications for function. 2007 , 16, 1042-52	118
1201	The Role of Small Molecule-Small Molecule Interactions in Overcoming Biological Barriers for Antibacterial Drug Action. 2007 , 117, 231-238	11
1200	Predicting the oxidative metabolism of statins: an application of the MetaSite algorithm. 2007 , 24, 480-501	35
1199	Caco-2 cell permeability modelling: a neural network coupled genetic algorithm approach. 2007 , 21, 207-21	20
1198	In silico strategies to describe the formation of the inclusion complex between β -cyclodextrin and β -naphthoxyacetic acid: a preliminary step towards prediction of log K. 2007 , 57, 355-361	2
1197	Identification of a putative binding site for 5-alkyl-benzothiadiazides in the AMPA receptor dimer interface. 2007 , 26, 213-25	11
1196	Comparing the electronic properties and docking calculations of heme derivatives on CYP2B4. 2008 , 14, 537-45	4
1195	Three-Dimensional Holographic Vector of Atomic Interaction Field Applied in QSAR of Anti-HIV HEPT Analogues. 2008 , 27, 330-337	8
1194	Characterizing the microenvironment surrounding protein sites. 1995 , 4, 622-35	85
1193	Second step of hydrolytic dehalogenation in haloalkane dehalogenase investigated by QM/MM methods. 2008 , 70, 707-17	24
1192	The role of Li ⁺ , Na ⁺ , and K ⁺ in the ligand binding inside the human acetylcholinesterase gorge. 2008 , 70, 779-85	13
1191	Dopamine transporter comparative molecular modeling and binding site prediction using the LeuT(Aa) leucine transporter as a template. 2008 , 70, 1033-46	69
1190	Highly accurate method for ligand-binding site prediction in unbound state (apo) protein structures. 2008 , 73, 468-79	33
1189	Small molecule inhibitors targeting HIV-1 reverse transcriptase dimerization. 2008 , 9, 916-22	25
1188	Small-molecule negative modulators of adrenomedullin: design, synthesis, and 3D-QSAR study. 2008 , 3, 1345-55	6
1187	Thiobarbiturates as sirtuin inhibitors: virtual screening, free-energy calculations, and biological testing. 2008 , 3, 1965-76	56
1186	A Gibbs free energy correlation for automated docking of carbohydrates. 2008 , 29, 1131-41	23
1185	Prediction of the binding mode of biarylpropylsulfonamide allosteric AMPA receptor modulators based on docking, GRID molecular interaction fields and 3D-QSAR analysis. 2008 , 26, 874-83	12

1184	Prediction of the receptor conformation for iGluR2 agonist binding: QM/MM docking to an extensive conformational ensemble generated using normal mode analysis. 2008 , 26, 1259-68		15
1183	Three-dimensional holographic vector of atomic interaction field for quantitative structure-activity relationship of Aza-bioisosteres of anthrapyrazoles (Aza-APs). 2008 , 26, 1252-8		4
1182	Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies. 2008 , 43, 621-32		36
1181	GRIND-based 3D-QSAR to predict inhibitory activity for similar enzymes, OSC and SHC. 2008 , 43, 1462-8		11
1180	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. 2008 , 43, 2853-60		19
1179	A novel sesquiterpene lactone from <i>Centaurea pullata</i> : structure elucidation, antimicrobial activity, and prediction of pharmacokinetic properties. <i>Bioorganic and Medicinal Chemistry</i> , 2008 , 16, 3725-31	3-4	25
1178	Comparative docking studies of labdane-type diterpenes with forskolin at the active site of adenylyl cyclase. <i>Bioorganic and Medicinal Chemistry</i> , 2008 , 16, 8237-43	3-4	5
1177	CYP19 (aromatase): exploring the scaffold flexibility for novel selective inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2008 , 16, 8349-58	3-4	23
1176	1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: design, synthesis, structure-affinity and structure-selectivity relationships. <i>Bioorganic and Medicinal Chemistry</i> , 2008 , 16, 9780-9	3-4	21
1175	Isolation and quantification by high-performance liquid chromatography-ion-trap mass spectrometry of androgen sulfoconjugates in human urine. 2008 , 1196-1197, 153-60		41
1174	Role of complexes formation between drugs and penetration enhancers in transdermal delivery. 2008 , 363, 40-9		26
1173	Stereoselectivity of Mucorales lipases toward triacylglycerols--a simple solution to a complex problem. 1999 , 8, 215-21		24
1172	Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble. 2008 , 71, 106-16		88
1171	The structure of glycosaminoglycans and their interactions with proteins. 2008 , 72, 455-82		678
1170	Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions. 2008 , 153 Suppl 1, S82-9		34
1169	Structure and functional analysis of the IGF-II/IGF2R interaction. 2008 , 27, 265-76		69
1168	Discovery of substituted sulfonamides and thiazolidin-4-one derivatives as agonists of human constitutive androstane receptor. 2008 , 76, 1288-97		28
1167	An early history of the molecular modeling industry. 2008 , 13, 659-64		12

1166	Limitations and lessons in the use of X-ray structural information in drug design. 2008 , 13, 831-41		133
1165	Hot-spots-guided receptor-based pharmacophores (HS-Pharm): a knowledge-based approach to identify ligand-anchoring atoms in protein cavities and prioritize structure-based pharmacophores. 2008 , 48, 1396-410		78
1164	Solution structure of a 2:1 C2-(2-naphthyl) pyrrolo[2,1-c][1,4]benzodiazepine DNA adduct: molecular basis for unexpectedly high DNA helix stabilization. 2008 , 47, 11818-29		23
1163	Targets looking for drugs: a multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery. 2008 , 48, 2166-79		55
1162	Synthesis and biological activity of fluorinated combretastatin analogues. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 2708-21	8.3	54
1161	Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 5552-65	8.3	26
1160	Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 7396-404	8.3	36
1159	Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 3878-94	8.3	190
1158	Structure of daidzin, a naturally occurring anti-alcohol-addiction agent, in complex with human mitochondrial aldehyde dehydrogenase. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 4482-7	8.3	57
1157	PocketDepth: a new depth based algorithm for identification of ligand binding sites in proteins. 2008 , 161, 31-42		82
1156	Structure of the PPX/GPPA phosphatase from <i>Aquifex aeolicus</i> in complex with the alarmone ppGpp. 2008 , 375, 1469-76		27
1155	Conformer selection and induced fit in flexible backbone protein-protein docking using computational and NMR ensembles. 2008 , 381, 1068-87		128
1154	Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease. 2008 , 383, 347-57		17
1153	Molecular basis of kainate receptor modulation by sodium. 2008 , 58, 720-35		73
1152	Interaction of DDSDEEN peptide with N-CAM protein. Possible mechanism enhancing neuronal differentiation. 2008 , 29, 2232-42		
1151	Small Molecules. 2008 , 9-63		1
1150	Robust classification of "relevant" water molecules in putative protein binding sites. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 1063-7	8.3	81
1149	Novel separation of bioactive catechin derivatives from complex plant mixtures by anion-exchange chromatography. 2008 , 62, 317-322		7

1148	Structure-based approach for the study of estrogen receptor binding affinity and subtype selectivity. 2008 , 48, 2243-53	37
1147	Development and validation of AMANDA, a new algorithm for selecting highly relevant regions in Molecular Interaction Fields. 2008 , 48, 1813-23	80
1146	3D Quantitative StructureProperty Relationships. 2008 , 587-604	9
1145	Protein Crystallography and Drug Discovery. 2008 , 605-634	1
1144	An integrated approach to ligand- and structure-based drug design: development and application to a series of serine protease inhibitors. 2008 , 48, 1211-26	43
1143	Characterization of type II ligands in CYP2C9 and CYP3A4. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 1755-63	24
1142	Origins of Resistance Conferred by the R292K Neuraminidase Mutation via Molecular Dynamics and Free Energy Calculations. 2008 , 4, 1526-40	62
1141	AutoShim: empirically corrected scoring functions for quantitative docking with a crystal structure and IC50 training data. 2008 , 48, 861-72	35
1140	Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. 2008 , 130, 3900-14	88
1139	An anchor-dependent molecular docking process for docking small flexible molecules into rigid protein receptors. 2008 , 48, 1638-55	6
1138	Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 7181-92	8.3 32
1137	Flexophore, a new versatile 3D pharmacophore descriptor that considers molecular flexibility. 2008 , 48, 797-810	25
1136	Structural glycobiology: a game of snakes and ladders. 2008 , 18, 426-40	124
1135	Effect of sulphation on the oestrogen agonist activity of the phytoestrogens genistein and daidzein in MCF-7 human breast cancer cells. 2008 , 197, 503-15	54
1134	Introduction to Protein Modeling. 2008 , 77-132	
1133	The molecular basis of CYP2D6-mediated N-dealkylation: balance between metabolic clearance routes and enzyme inhibition. 2008 , 36, 2199-210	15
1132	In Silico Screening. 2008 , 210-227	1
1131	Conformation, dynamics and ion-binding properties of single-chain polyuronates: a molecular dynamics study. 2008 , 34, 421-446	29

1130	Virtual screening and its integration with modern drug design technologies. 2008 , 15, 37-46	152
1129	Ligand structural aspects of hERG channel blockade. 2008 , 8, 1113-27	37
1128	New inhibitors of glycogen phosphorylase as potential antidiabetic agents. 2008 , 15, 2933-83	123
1127	Determination of ligand-binding sites on proteins using long-range hydrophobic potential. 2008 , 31, 1552-8	15
1126	Rational Approaches to Anticancer Drug Design/in silico Drug Development. 29-46	1
1125	Databases of Chemical Structures. 2008 , 523-555	1
1124	Hydrophobic Fields in Quantitative Structure-Activity Relationships. 2008 , 219-232	
1123	. 2008 ,	18
1122	Site of Metabolism Predictions: Facts and Experiences. 2008 , 247-265	1
1121	Computer applications for prediction of protein–protein interactions and rational drug design. 2009 , 101	1
1120	. 2009 ,	32
1119	Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. 2009 , 4, e4124	45
1118	Molecular Dynamics Computations for Proteins: A Case Study in Membrane Ion Permeation. 2009 ,	
1117	Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. 2009 , 25, 621-7	338
1116	Alignment of protein structure energy patterns represented as sequences of Fuzzy Numbers. 2009 ,	10
1115	Volumetric Visualization and Analysis of Molecular Interaction Field. 2009 ,	
1114	Rational design of alpha-conotoxin analogues targeting alpha7 nicotinic acetylcholine receptors: improved antagonistic activity by incorporation of proline derivatives. 2009 , 284, 9498-512	38
1113	Explicit Treatment of Water Molecules in Protein-Ligand Docking. 2009 , 5, 145-154	16

1112	Modeling Reality for Optimal Docking of Small Molecules to Biological Targets. 2009 , 5, 241-263	12
1111	Structure-based drug design strategies in medicinal chemistry. 2009 , 9, 771-90	105
1110	Fragment-based cocktail crystallography by the medical structural genomics of pathogenic protozoa consortium. 2009 , 9, 1678-87	33
1109	Molecular Mechanics Force Fields and their Applications in Drug Design. 2009 , 8, 128-150	10
1108	Drug Discovery. 2009 , 475-560	5
1107	3D-QSAR Study of 7,8-Dialkyl-1,3-diaminopyrrolo-[3,2-f] Quinazolines with Anticancer Activity as DHFR Inhibitors. 2009 , 22, 285-289	3
1106	Rubisco in complex with Rubisco large subunit methyltransferase. 2009 , 106, 3160-5	23
1105	From fragment to clinical candidate—a historical perspective. 2009 , 14, 668-75	186
1104	Ca(2+) binding to c-state of adenine nucleotide translocase (ANT)-surrounding cardiolipins enhances (ANT)-Cys(56) relative mobility: a computational-based mitochondrial permeability transition study. 2009 , 1787, 176-82	20
1103	Flaviviral methyltransferase/RNA interaction: structural basis for enzyme inhibition. 2009 , 83, 28-34	57
1102	Supervised Learning. 2009 , 187-218	
1101	A Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Model for Predicting the Enantioselectivity of <i>Candida antarctica</i> Lipase B. 2009 , 351, 1293-1302	21
1100	Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy. 2009 , 65, 209-17	71
1099	SHOP: a method for structure-based fragment and scaffold hopping. 2009 , 4, 427-39	14
1098	C3 halogen and c8'' substituents on stilbene arotinoids modulate retinoic Acid receptor subtype function. 2009 , 4, 1630-40	24
1097	2D depiction of nonbonding interactions for protein complexes. 2009 , 30, 940-51	55
1096	Blind docking method combining search of low-resolution binding sites with ligand pose refinement by molecular dynamics-based global optimization. 2010 , 31, 1080-92	12
1095	Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction. 2010 , 23, 283-300	28

1094	Computational approaches to identifying and characterizing protein binding sites for ligand design. 2010 , 23, 209-19	130
1093	Endo- and exo-inulinases: enzyme-substrate interaction and rational immobilization. 2010 , 26, 397-405	28
1092	A new method for in-silico drug screening and similarity search using molecular dynamics maximum volume overlap (MD-MVO) method. 2009 , 27, 628-36	9
1091	2D- and 3D-QSAR of tocainide and mexiletine analogues acting as Na(v)1.4 channel blockers. 2009 , 44, 1477-85	18
1090	Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist. 2009 , 44, 2840-6	17
1089	Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands. 2009 , 23, 747-54	23
1088	What induces pocket openings on protein surface patches involved in protein-protein interactions?. 2009 , 23, 73-86	49
1087	Side-chain conformational space analysis (SCSA): a multi conformation-based QSAR approach for modeling and prediction of protein-peptide binding affinities. 2009 , 23, 129-41	7
1086	Comparison of structure fingerprint and molecular interaction field based methods in explaining biological similarity of small molecules in cell-based screens. 2009 , 23, 227-39	9
1085	Design of compound libraries for fragment screening. 2009 , 23, 513-25	61
1084	Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase. 2009 , 23, 491-500	73
1083	The multi-copy simultaneous search methodology: a fundamental tool for structure-based drug design. 2009 , 23, 475-89	19
1082	Challenges of fragment screening. 2009 , 23, 449-51	13
1081	Quantitative structure-retention relationship for polychlorinated dibenzofurans based on molecular interaction field analysis. 2009 , 54, 4644-4650	
1080	Predicting protein pK(a) by environment similarity. 2009 , 76, 484-95	16
1079	Combined computational and biochemical study reveals the importance of electrostatic interactions between the "pH sensor" and the cation binding site of the sodium/proton antiporter NhaA of Escherichia coli. 2009 , 76, 548-59	20
1078	Chemogenomics: Looking at biology through the lens of chemistry. 2009 , 2, 149-160	10
1077	Acute Toxicity of Substituted 2-(1H-pyrazol-1-yl)acetanilides and Related Commercially Available Local Anesthetics Toward Mice. A GRIND/ALMOND-Based 3-D QSAR Study. 2009 , 28, 206-217	1

1076	Generation and Analysis of Interaction Energy Maps of p-Substituted Benzoic Acid [(5-Nitro-thiophen-2-yl)-methylene]- Hydrazides Active against MRSA. 2009 , 28, 1546-1550		1
1075	PLS Analysis for Antibacterial Activity of Natural Coumarins Using VolSurf Descriptors. 2009 , 28, 785-789		6
1074	Comparative Investigation of the ATP-Binding Site of Human and Plasmodial Glycogen Synthase Kinase-3. 2009 , 28, 885-890		7
1073	Optimal assignment methods for ligand-based virtual screening. 2009 , 1, 14		71
1072	A validation study of molecular descriptors for the rational design of peptide libraries. 1998 , 52, 305-14		7
1071	Structural characterization of a zinc high-affinity binding site in rhodopsin. 2009 , 85, 479-84		7
1070	Crystal structure of the OXA-48 beta-lactamase reveals mechanistic diversity among class D carbapenemases. 2009 , 16, 540-7		115
1069	Synthesis and biological evaluation of a new family of anti-benzylanilinosulfonamides as CA IX inhibitors. 2009 , 44, 511-8		11
1068	Highly twisted adamantyl arotinoids: synthesis, antiproliferative effects and RXR transactivation profiles. 2009 , 44, 2434-46		10
1067	1,3-dialkyl-8-N-substituted benzyloxycarbonylamino-9-deazaxanthines as potent adenosine receptor ligands: Design, synthesis, structure-affinity and structure-selectivity relationships. <i>Bioorganic and Medicinal Chemistry</i> , 2009 , 17, 3618-29	3,4	11
1066	2D-QSAR and 3D-QSAR/CoMFA analyses of the N-terminal substituted anthranilic acid based CCK(1) receptor antagonists: 'Hic Rhodus, hic saltus'. <i>Bioorganic and Medicinal Chemistry</i> , 2009 , 17, 5198-206	3,4	2
1065	Selective, potent PPARgamma agonists with cyclopentenone core structure. 2009 , 19, 1883-6		8
1064	Predictive models of Cannabinoid-1 receptor antagonists derived from diverse classes. 2009 , 19, 2990-6		4
1063	Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors. 2009 , 19, 4034-41		14
1062	Soft protein-protein docking in internal coordinates. 2002 , 11, 280-91		150
1061	Inhibition of carnitine acetyltransferase by mildronate, a regulator of energy metabolism. 2009 , 24, 1269-75		17
1060	New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. 2009 , 41, 573-643		115
1059	Understanding enzyme immobilisation. 2009 , 38, 453-68		999

1058	Making sense of a missense mutation: characterization of MutT2, a Nudix hydrolase from <i>Mycobacterium tuberculosis</i> , and the G58R mutant encoded in W-Beijing strains of <i>M. tuberculosis</i> . 2009 , 48, 699-708		21
1057	SHOP: receptor-based scaffold HOPping by GRID-based similarity searches. 2009 , 49, 658-69		18
1056	In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 4488-95	8.3	60
1055	Improving quantitative structure-activity relationships through multiobjective optimization. 2009 , 49, 2290-302		44
1054	Charting the chemical space of target sites: insights into the binding modes of amine and amidine groups. 2009 , 49, 900-12		9
1053	Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20 α -hydroxysteroid dehydrogenase (AKR1C1). <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 3259-64	8.3	34
1052	Quantitative structure-mobility relationship studies of dipeptides in capillary zone electrophoresis using three-dimensional holographic vector of atomic interaction field. 2009 , 35, 263-269		10
1051	Atomic local neighborhood flexibility incorporation into a structured similarity measure for QSAR. 2009 , 49, 549-60		19
1050	Bioisosteric similarity of molecules based on structural alignment and observed chemical replacements in drugs. 2009 , 49, 1280-97		12
1049	Ligand mapping on protein surfaces by the 3D-RISM theory: toward computational fragment-based drug design. 2009 , 131, 12430-40		101
1048	Stereoselective behavior of the functional diltiazem analogue 1-[(4-chlorophenyl)sulfonyl]-2-(2-thienyl)pyrrolidine, a new L-type calcium channel blocker. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 6637-48	8.3	9
1047	L-Type calcium channel blockers: from diltiazem to 1,2,4-oxadiazol-5-ones via thiazinooxadiazol-3-one derivatives. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 2352-62	8.3	24
1046	In silico analysis of antibody-carbohydrate interactions and its application to xenoreactive antibodies. 2009 , 47, 233-46		28
1045	Small-molecule interferon inducers. Toward the comprehension of the molecular determinants through ligand-based approaches. 2009 , 49, 1777-86		8
1044	Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 6637-48	8.3	83
1043	Novel cyano- and amidinobenzothiazole derivatives: synthesis, antitumor evaluation, and X-ray and quantitative structure-activity relationship (QSAR) analysis. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 1744-56	8.3	114
1042	Computational fragment-based approach at PDB scale by protein local similarity. 2009 , 49, 280-94		38
1041	Anti-influenza drugs: the development of sialidase inhibitors. 2009 , 111-54		41

1040	Structural and dynamic properties of water around acetylcholinesterase. 2002 , 11, 2080-90	89
1039	Functionally relevant motions of haloalkane dehalogenases occur in the specificity-modulating cap domains. 2002 , 11, 1206-17	14
1038	A docking study using atomistic conformers generated via elastic network model for cyclosporin A/cyclophilin A complex. 2009 , 27, 13-26	40
1037	Ionic hydrogen-bond networks and ion solvation. 1. An efficient Monte Carlo/quantum mechanical method for structural search and energy computations: ammonium/water. 2009 , 113, 2967-74	18
1036	From Protein Structure to Function with Bioinformatics. 2009 ,	19
1035	Prediction of the water content in protein binding sites. 2009 , 113, 13337-46	153
1034	Computer-aided drug design of novel PLA2 inhibitor candidates for treatment of snakebite. 2009 , 27, 27-36	34
1033	Chemometrics in QSAR. 2009 , 129-172	27
1032	Man-Machine Interactions. 2009 ,	0
1031	Antiviral Strategies. 2009 ,	2
1030	Bibliography. 2009 , 1-241	1
1029	Computational approaches to predict drug metabolism. 2009 , 5, 15-27	36
1028	Identifying and characterizing binding sites and assessing druggability. 2009 , 49, 377-89	897
1027	Modeling kinetics of subcellular disposition of chemicals. 2009 , 109, 1793-899	59
1026	Machine learning in virtual screening. 2009 , 12, 332-43	131
1025	Bayesian modeling in virtual high throughput screening. 2009 , 12, 469-83	16
1024	A multi-scale parameterization approach of peptides for quantitative sequence-activity models. 2010 , 17, 591-8	1
1023	Use of Biological Fingerprints Versus Structure/Chemotypes to Describe Molecules. 2010 , 481-504	1

1022	Fragment-Based Drug Design: Considerations for Good ADME Properties. 2010 , 417-485		
1021	Computational methods and software in computer-aided combinatorial library design. 2010 , 80, 2541-2571		0
1020	Methods for combinatorial and parallel library design. 2011 , 672, 387-434		4
1019	Pharmacophore-based virtual screening. 2011 , 672, 261-98		43
1018	Peptides as Molecular Receptors. 2010 , 249-274		8
1017	Tautomer preference in PDB complexes and its impact on structure-based drug discovery. 2010 , 50, 1062-74		51
1016	From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of <i>Staphylococcus aureus</i> multidrug efflux pumps. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 4466-80	8.3	36
1015	2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage <i>Plasmodium</i> infections. <i>Bioorganic and Medicinal Chemistry</i> , 2010 , 18, 7475-85	3.4	26
1014	The phosphorylation specificity of B-RAF WT, B-RAF D594V, B-RAF V600E and B-RAF K601E kinases: an in silico study. 2010 , 28, 598-603		8
1013	Docking to flexible nicotinic acetylcholine receptors: a validation study using the acetylcholine binding protein. 2010 , 29, 415-24		10
1012	Docking studies on a refined human beta(2) adrenoceptor model yield theoretical affinity values in function with experimental values for R-ligands, but not for S-antagonists. 2010 , 16, 401-9		10
1011	Structural bioinformatics: deriving biological insights from protein structures. 2010 , 2, 347-66		8
1010	EfeO-cupredoxins: major new members of the cupredoxin superfamily with roles in bacterial iron transport. 2010 , 23, 1-17		47
1009	Screening of benzamidine-based thrombin inhibitors via a linear interaction energy in continuum electrostatics model. 2010 , 24, 117-29		6
1008	Prediction of protein-ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations. 2010 , 24, 639-58		198
1007	Rationalizing fragment based drug discovery for BACE1: insights from FB-QSAR, FB-QSSR, multi objective (MO-QSPR) and MIF studies. 2010 , 24, 843-64		36
1006	Experimental and theoretical affinity studies of substituted phenols to chlorocatechol 1,2-dioxygenases: A step toward the comprehension of inhibitor/substrate binding to intradiol dioxygenases. 2010 , 64, 53-59		5
1005	Molecular fields in drug discovery: getting old or reaching maturity?. 2010 , 15, 23-32		58

1004	IAP antagonists: promising candidates for cancer therapy. 2010 , 15, 210-9		81
1003	Pharmacophore modeling and applications in drug discovery: challenges and recent advances. 2010 , 15, 444-50		488
1002	Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. 2010 , 15, 656-67		214
1001	3-Heterocycle-phenyl N-alkylcarbamates as FAAH inhibitors: design, synthesis and 3D-QSAR studies. 2010 , 5, 213-31		14
1000	Fragmenting the S100B-p53 interaction: combined virtual/biophysical screening approaches to identify ligands. 2010 , 5, 428-35		19
999	Rational design, synthesis, biophysical and antiproliferative evaluation of fluorenone derivatives with DNA G-quadruplex binding properties. 2010 , 5, 575-83		33
998	Connectivity and binding-site recognition: applications relevant to drug design. 2010 , 31, 2677-88		11
997	Exploration of human serum albumin binding sites by docking and molecular dynamics flexible ligand-protein interactions. 2010 , 93, 161-70		75
996	Pharmacophores in Drug Research. 2010 , 29, 470-5		43
995	Probabilistic Modeling of Conformational Space for 3D Machine Learning Approaches. 2010 , 29, 441-55		8
994	Wavelet Approximation of GRID Fields: Application to Quantitative Structure-Activity Relationships. 2010 , 29, 603-20		4
993	Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy. 2010 , 28, 513-23		24
992	QSAR modeling of peptide biological activity by coupling support vector machine with particle swarm optimization algorithm and genetic algorithm. 2010 , 29, 188-96		27
991	QSAR analysis of antitumor active amides and quinolones from thiophene series. 2010 , 394, 106-14		17
990	4-Aryl-4-oxo-N-phenyl-2-aminybutyramides as acetyl- and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure-activity relationship based on molecular interaction fields. <i>Bioorganic and Medicinal Chemistry</i> , 2010 , 18, 1181-93	3-4	22
989	Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole. <i>Bioorganic and Medicinal Chemistry</i> , 2010 , 18, 2107-2114	3-4	53
988	Pyrazolone-fused combretastatins and their precursors: synthesis, cytotoxicity, antitubulin activity and molecular modeling studies. <i>Bioorganic and Medicinal Chemistry</i> , 2010 , 18, 2375-87	3-4	34
987	Design, synthesis and in vitro evaluation of (R)-4-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenyl hydrogen phenylboronate: a novel salbutamol derivative with high intrinsic efficacy on the β_2 adrenoceptor. 2010 , 20, 5623-9		11

986	gCOMBINE: A graphical user interface to perform structure-based comparative binding energy (COMBINE) analysis on a set of ligand-receptor complexes. 2010 , 78, 162-72	18
985	A novel and efficient tool for locating and characterizing protein cavities and binding sites. 2010 , 78, 825-42	43
984	On the diversity of physicochemical environments experienced by identical ligands in binding pockets of unrelated proteins. 2010 , 78, 1120-36	51
983	Detection of multiscale pockets on protein surfaces using mathematical morphology. 2010 , 78, 1195-211	136
982	Combined use of computational chemistry, NMR screening, and X-ray crystallography for identification and characterization of fluorophilic protein environments. 2010 , 78, 3281-91	25
981	Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach. 2010 , 76, 201-17	91
980	Visualization of macromolecular structures. 2010 , 7, S42-55	107
979	Biochemical profiling of histone binding selectivity of the yeast bromodomain family. 2010 , 5, e8903	26
978	Generation and Analysis of Interaction Energy Maps of p-Substituted Benzoic Acid N'-(5-Nitrothiophen-2-yl)Methylenehydrazides Active Against Multidrug-Resistant Staphylococcus aureus. 2010 , 9, 1-8	2
977	Synthesis of non-cytotoxic poly(ester-amine) dendrimers as potential solubility enhancers for drugs: methotrexate as a case study. 2010 , 15, 8082-97	9
976	Computational prediction of binding affinity for CYP1A2-ligand complexes using empirical free energy calculations. 2010 , 38, 1347-54	31
975	In Silico Design and Evaluation of Carboxylesterase Inhibitors. 2010 , 35, 240-249	7
974	Influenza Virus Neuraminidase Inhibitors. 2010 , 103-110	1
973	Virtual Screening. 2010 , 1-46	1
972	Evaluation of Some Synthetic Oligolignols as Adhesives: A Molecular Docking Study. 2010 , 24, 1739-1751	5
971	Computer tools in the discovery of HIV-1 integrase inhibitors. 2010 , 2, 1123-40	13
970	Roll: a new algorithm for the detection of protein pockets and cavities with a rolling probe sphere. 2010 , 26, 46-52	202
969	Using sequence-specific chemical and structural properties of DNA to predict transcription factor binding sites. 2010 , 6, e1001007	21

968	Identification of protein binding surfaces using surface triplet propensities. 2010 , 26, 2549-55	15
967	Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients. 2010 , 17, 290-308	25
966	In silico prediction of binding sites on proteins. 2010 , 17, 1550-62	68
965	3D-QSAR in drug design--a review. 2010 , 10, 95-115	481
964	The role of water molecules in computational drug design. 2010 , 10, 55-66	138
963	Computer Techniques: Identifying Similarities Between Small Molecules. 2010 , 1	
962	Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. 2010 , 10, 127-41	199
961	FLAP: GRID molecular interaction fields in virtual screening. validation using the DUD data set. 2010 , 50, 1442-50	80
960	Hydration in discrete water. A mean field, cellular automata based approach to calculating hydration free energies. 2010 , 114, 8667-75	16
959	Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors. 2010 , 50, 662-76	52
958	Analyzing the topology of active sites: on the prediction of pockets and subpockets. 2010 , 50, 2041-52	111
957	The Use of Qsar and Computational Methods in Drug Design. 2010 , 261-282	4
956	De novo design: balancing novelty and confined chemical space. 2010 , 5, 789-812	63
955	Modeling and Informatics in Drug Design. 2010 , 1	1
954	Modeling approaches for ligand-based 3D similarity. 2010 , 2, 1547-61	13
953	The scaffold hopping potential of pharmacophores. 2010 , 7, e203-70	39
952	Grid-derived structure-based 3D pharmacophores and their performance compared to docking. 2010 , 7, e203-70	12
951	Fragments: past, present and future. 2010 , 7, e147-202	38

950	Dynamics-Based Discovery of Allosteric Inhibitors: Selection of New Ligands for the C-terminal Domain of Hsp90. 2010 , 6, 2978-89		70
949	Three-dimensional pharmacophore methods in drug discovery. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 539-58	8.3	283
948	Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 2433-42	8.3	45
947	Insolubility classification with accurate prediction probabilities using a MetaClassifier. 2010 , 50, 404-14		22
946	Alignment-free ultra-high-throughput comparison of druggable protein-ligand binding sites. 2010 , 50, 123-35		105
945	Recent Trends in Structure-Based Drug Design and Energetics. 2010 , 685-724		2
944	Docking and Scoring in Drug Discovery. 2010 , 601-684		2
943	High-throughput virtual screening of proteins using GRID molecular interaction fields. 2010 , 50, 155-69		61
942	Pharmacophore screening of the protein data bank for specific binding site chemistry. 2010 , 50, 358-67		22
941	Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan. 2010 , 38, 187-99		6
940	Molecular Descriptors. 2010 , 29-102		37
939	Computational mapping of anchoring spots on protein surfaces. 2010 , 402, 259-77		59
938	On the catalytic role of the active site residue E121 of E. coli L-aspartate oxidase. 2010 , 92, 1335-42		10
937	Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction. 2010 , 50, 1451-65		11
936	Generating inhibitors of P-glycoprotein: where to, now?. 2010 , 596, 405-32		37
935	Predicting polypharmacology by binding site similarity: from kinases to the protein universe. 2010 , 50, 1418-31		86
934	Sesquiterpene lactones from <i>Anthemis melanolepis</i> and their antibacterial and cytotoxic activities. Prediction of their pharmacokinetic profile. 2010 , 73, 242-6		24
933	Computational analysis of structure-activity relationships. 2010 , 49, 113-60		14

932	Recent Advances in QSAR Studies. 2010 ,		82
931	Statistical molecular design of balanced compound libraries for QSAR modeling. 2010 , 17, 2001-16		16
930	The GRID/CPCA approach in drug discovery. 2010 , 5, 333-46		4
929	Different binding modes of structurally diverse ligands for human D3DAR. 2010 , 50, 2162-75		3
928	A novel target-based de novo ligand design by use of pseudomolecular probe. 2010 , 1, 349		
927	Design of O-acetylserine sulphydrylase inhibitors by mimicking nature. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 345-56	8.3	67
926	Self-organizing fuzzy graphs for structure-based comparison of protein pockets. 2010 , 9, 6498-510		25
925	Chloride ions in the pore of glycine and GABA channels shape the time course and voltage dependence of agonist currents. 2011 , 31, 14095-106		32
924	Adhesive water networks facilitate binding of protein interfaces. 2011 , 2, 261		108
923	Functionality mapping on internal surfaces of multidrug transporter AcrB based on molecular theory of solvation: implications for drug efflux pathway. 2011 , 115, 8288-95		39
922	Predicting the binding mode of known NCp7 inhibitors to facilitate the design of novel modulators. 2011 , 51, 446-54		32
921	Structure-based fragment hopping for lead optimization using predocked fragment database. 2011 , 51, 1703-15		11
920	Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 211-21	8.3	52
919	Molecular docking with ligand attached water molecules. 2011 , 51, 909-17		58
918	Druggability assessment of protein-protein interfaces. 2011 , 3, 2021-38		34
917	Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development. 2011 , 3, 1027-55		35
916	Graph-based similarity concepts in virtual screening. 2011 , 3, 485-501		5
915	The Basis for Target-Based Virtual Screening: Protein Structures. 2011 , 87-114		6

914	Pharmacophore Models for Virtual Screening. 2011 , 115-152		5
913	AADS--an automated active site identification, docking, and scoring protocol for protein targets based on physicochemical descriptors. 2011 , 51, 2515-27		95
912	Discovery of novel inhibitors of the NorA multidrug transporter of <i>Staphylococcus aureus</i> . <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 354-65	8.3	58
911	Consideration of Water and Solvation Effects in Virtual Screening. 2011 , 263-289		8
910	Handling Protein Flexibility in Docking and High-Throughput Docking: From Algorithms to Applications. 2011 , 245-262		4
909	Drug Design and Discovery. 2011 ,		7
908	Predicting fragment binding poses using a combined MCSS MM-GBSA approach. 2011 , 51, 1092-105		35
907	Cheminformatics and Computational Chemical Biology. 2011 ,		6
906	Recent advances in the molecular modeling of estrogen receptor-mediated toxicity. 2011 , 85, 217-51		8
905	Full protein flexibility is essential for proper hot-spot mapping. 2011 , 133, 200-2		91
904	Structural chemistry of the histone methyltransferases cofactor binding site. 2011 , 51, 612-23		65
903	A GRID-derived water network stabilizes molecular dynamics computer simulations of a protease. 2011 , 51, 2860-7		13
902	Probing the dynamic nature of water molecules and their influences on ligand binding in a model binding site. 2011 , 51, 2581-94		18
901	Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 8136-47	8.3	44
900	Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza. 2011 , 383-400		1
899	Structure based discovery of small molecule suppressors targeting bacterial lysozyme inhibitors. 2011 , 405, 527-32		17
898	Fragment-based approaches and computer-aided drug discovery. 2012 , 317, 201-22		22
897	Structural basis for the potential antitumour activity of DNA-interacting benzo[<i>kl</i>]xanthene lignans. 2011 , 9, 701-10		28

896	Albumin-directed stereoselective reduction of 1,3-diketones and β -hydroxyketones to anti diols. 2011 , 9, 1987-99		22
895	Inhibitors of human 20 β -hydroxysteroid dehydrogenase (AKR1C1). 2011 , 125, 105-11		29
894	Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 457-71	8.3	47
893	Progress in structure based drug design for G protein-coupled receptors. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 4283-311	8.3	191
892	Structure-based drug discovery and protein targets in the CNS. 2011 , 60, 7-23		21
891	Using computer-aided drug design and medicinal chemistry strategies in the fight against diabetes. 2011 , 28, 787-96		21
890	Cross-kingdom actions of phytohormones: a functional scaffold exploration. 2011 , 111, 2734-60		26
889	Second generation of fucose-based DC-SIGN ligands: affinity improvement and specificity versus Langerin. 2011 , 9, 5778-86		52
888	. 2011 ,		26
887	Theoretical and computational approaches to ligand-based drug discovery. 2011 , 16, 1276-90		13
886	. 2011 ,		6
885	Computational perspectives into plasmepsins structure-function relationship: implications to inhibitors design. 2011 , 2011, 657483		6
884	Novel inhibitor design for hemagglutinin against H1N1 influenza virus by core hopping method. 2011 , 6, e28111		86
883	Improved prediction of protein ligand-binding sites using random forests. 2011 , 18, 1212-8		15
882	Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. 2011 , 18, 1021-7		18
881	An Improved Method for Protein Similarity Searching by Alignment of Fuzzy Energy Signatures. 2011 , 4, 75-88		9
880	Computational Approaches for the Discovery of Natural Lead Structures. 2011 , 97-132		
879	Enzyme kinetic studies of histone demethylases KDM4C and KDM6A: towards understanding selectivity of inhibitors targeting oncogenic histone demethylases. 2011 , 585, 1951-6		14

878	Thiosemicarbazones derived from 1-indanones as new anti-Trypanosoma cruzi agents. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 6818-26	3-4	43
877	Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design. 2011 , 21, 5778-83		22
876	Carbazole-containing arylcarboxamides as BACE1 inhibitors. 2011 , 21, 6657-61		17
875	Snooker: a structure-based pharmacophore generation tool applied to class A GPCRs. 2011 , 51, 2277-92		51
874	Integrating structure-based and ligand-based approaches for computational drug design. 2011 , 3, 735-50		101
873	Target-Based Virtual Screening on Small-Molecule Protein Binding Sites. 2011 , 411-434		
872	Computational systems chemical biology. 2011 , 672, 459-88		18
871	Protein-ligand docking. 2011 , 16, 2289-306		13
870	A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 1740-51	8-3	113
869	Docking glycosaminoglycans to proteins: analysis of solvent inclusion. 2011 , 25, 477-89		61
868	Molecular interaction fields (MIFs) to predict lipophilicity and ADME profile of antitumor Pt(II) complexes. 2011 , 28, 640-6		6
867	Beyond structural genomics: computational approaches for the identification of ligand binding sites in protein structures. 2011 , 12, 109-17		38
866	Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. 2011 , 129, 687-94		72
865	Homology model and docking studies on porcine β -adrenergic receptor: description of two binding sites. 2011 , 17, 2525-38		8
864	Novel GABA-AT inhibitors: QSAR and docking based virtual screening of phenyl substituted β -phenyl ethylidene hydrazine analogues. 2011 , 20, 1482-1489		5
863	Nicotinic acid hydrazones: a novel anticonvulsant pharmacophore. 2011 , 20, 1499-1504		20
862	Antiproliferative activity of aroylacrylic acids. Structure-activity study based on molecular interaction fields. 2011 , 46, 3265-73		17
861	β -Branched acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 2378-91	3-4	19

860	Ligand binding site superposition and comparison based on Atomic Property Fields: identification of distant homologues, convergent evolution and PDB-wide clustering of binding sites. 2011 , 12 Suppl 1, S35		27
859	New insights into the GABA(A) receptor structure and orthosteric ligand binding: receptor modeling guided by experimental data. 2011 , 79, 1458-77		37
858	Structure-Based Pharmacophores for Virtual Screening. 2011 , 30, 398-404		19
857	Conformational Changes of Lipases in Aqueous Media: A Comparative Computational Study and Experimental Implications. 2011 , 353, 2466-2480		39
856	Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ agonists with high potency and in vivo efficacy. 2011 , 6, 633-53		18
855	Applying in silico tools to the discovery of novel CXCR4 inhibitors. 2011 , 72, 95-111		3
854	An estimation method of binding free energy in terms of ABEE/PM and continuum electrostatics fused into LIE method. 2011 , 32, 338-48		12
853	Synthesis and biological assessment of novel 2-thiazolyhydrazones and computational analysis of their recognition by monoamine oxidase B. 2012 , 48, 284-95		29
852	Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach. 2012 , 50, 216-29		55
851	Dynamic water networks in cytochrome cbb3 oxidase. 2012 , 1817, 726-34		16
850	Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β_2 adrenoceptor. <i>Bioorganic and Medicinal Chemistry</i> , 2012 , 20, 933-41	3-4	14
849	Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2012 , 20, 2455-78	3-4	14
848	Synthesis and biological validation of novel pyrazole derivatives with anticancer activity guided by 3D-QSAR analysis. <i>Bioorganic and Medicinal Chemistry</i> , 2012 , 20, 2101-10	3-4	52
847	Recognizing protein-ligand binding sites by global structural alignment and local geometry refinement. 2012 , 20, 987-97		80
846	Direct evaluation of individual hydrogen bond energy in situ in intra- and intermolecular multiple hydrogen bonds system. 2012 , 33, 379-90		12
845	Designing the molecular future. 2012 , 26, 115-20		13
844	Drug design for ever, from hype to hope. 2012 , 26, 137-50		29
843	Virtual screening for potential inhibitors of bacterial MurC and MurD ligases. 2012 , 18, 1063-72		15

842	Fragment informatics and computational fragment-based drug design: an overview and update. 2013 , 33, 554-98		36
841	Grid-based molecular footprint comparison method for docking and de novo design: application to HIVgp41. 2013 , 34, 1226-1240		19
840	Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors. 2013 , 8, 1475-82, 1421		14
839	Efficient microwave-assisted synthetic protocols and in silico behaviour prediction of per-substituted β -cyclodextrins. 2013 , 11, 5521-7		5
838	Protein-Ligand Interactions. 2013 ,		22
837	New linezolid-like 1,2,4-oxadiazoles active against Gram-positive multiresistant pathogens. 2013 , 65, 533-45		33
836	Exploring the orthosteric binding site of the β -aminobutyric acid type A receptor using 4-(Piperidin-4-yl)-1-hydroxypyrazoles 3- or 5-imidazolyl substituted: design, synthesis, and pharmacological evaluation. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 6536-40	8.3	5
835	Perspectives and industrial potential of PGA selectivity and promiscuity. 2013 , 31, 1458-72		25
834	Conformational mobility of active and E-64-inhibited actinidin. 2013 , 1830, 4790-9		6
833	Identification of small-molecule binding pockets in the soluble monomeric form of the A β 2 peptide. 2013 , 139, 035101		60
832	Quantitative Structure-Activity Relationships. 2013 , 371-396		
831	Modelling the possible bioactivity of ellagitannin-derived metabolites. In silico tools to evaluate their potential xenoestrogenic behavior. 2013 , 4, 1442-51		39
830	Structural variations on antitumour agents derived from bisacylimidoselenocarbamate. A proposal for structure-activity relationships based on the analysis of conformational behaviour. 2013 , 66, 489-98		4
829	In Silico Drug Discovery and Design. 2013 ,		3
828	Regulation of the activity of lactate dehydrogenases from four lactic acid bacteria. 2013 , 288, 21295-21306		29
827	Protein Docking Problem as Combinatorial Optimization Using Beta-Complex. 2013 , 2685-2740		0
826	Docking Predictions of Protein-Protein Interactions and Their Assessment: The CAPRI Experiment. 2013 , 87-104		4
825	De Novo Design: From Models to Molecules. 2013 , 1-55		9

824	Coping with Complexity in Molecular Design. 2013 , 57-77	1
823	Structure-Based De Novo Drug Design. 2013 , 97-124	4
822	Hit and Lead Identification from Fragments. 2013 , 143-200	1
821	A pharmacophore-based virtual screening approach for the discovery of Trypanosoma cruzi GAPDH inhibitors. 2013 , 5, 2019-35	19
820	Development of purely structure-based pharmacophores for the topoisomerase I-DNA-ligand binding pocket. 2013 , 27, 1037-49	4
819	Identification of Ligand Binding Site and Protein-Protein Interaction Area. 2013 ,	0
818	Unintended consequences? Water molecules at biological and crystallographic protein-protein interfaces. 2013 , 47, 126-41	11
817	Ligand binding site detection by local structure alignment and its performance complementarity. 2013 , 53, 2462-70	17
816	The Block Relevance (BR) analysis to aid medicinal chemists to determine and interpret lipophilicity. 2013 , 4, 1376	20
815	Thermodynamic analysis of enzyme enantioselectivity: a statistical approach by means of new differential HybridMIF descriptors. 2013 , 31, 272-280	
814	Molecular modeling of the 3D structure of 5-HT(1A)R: discovery of novel 5-HT(1A)R agonists via dynamic pharmacophore-based virtual screening. 2013 , 53, 3202-11	19
813	Fine tuning of the active site modulates specificity in the interaction of O-acetylserine sulfhydrylase isozymes with serine acetyltransferase. 2013 , 1834, 169-81	30
812	Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage. 2013 , 29, 451-60	15
811	S4MPLE--sampler for multiple protein-ligand entities: simultaneous docking of several entities. 2013 , 53, 88-102	20
810	Molecular docking methodologies. 2013 , 924, 339-60	11
809	Large, chemically diverse dataset of logP measurements for benchmarking studies. 2013 , 48, 21-9	32
808	3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues. 2012 , 4, 57-62	21
807	β-Amino butyric acid analogs as novel potent GABA-AT inhibitors: molecular docking, synthesis, and biological evaluation. 2013 , 22, 134-146	7

806	Improving protocols for protein mapping through proper comparison to crystallography data. 2013 , 53, 391-402		29
805	Abstracting knowledge from the Protein Data Bank. 2013 , 99, 183-8		6
804	Butyltin(IV) benzoates: inhibition of thioredoxin reductase, tumor cell growth inhibition, and interactions with proteins. 2013 , 8, 256-64		23
803	Mechanochemical activation of vincamine mediated by linear polymers: assessment of some "critical" steps. 2013 , 50, 56-68		10
802	Three-Dimensional Scaffold Replacement Methods. 2013 , 175-182		
801	Case Study 3: Fragment Hopping to Design Highly Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors. 2013 , 279-296		
800	Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors β/δ agonists. 2013 , 63, 321-32		16
799	Quantum Chemical Methods in the Design of Agrochemicals. 2013 , 43-71		1
798	Quantitative structure-activity relationship of organophosphate compounds based on molecular interaction fields descriptors. 2013 , 35, 228-34		10
797	Synthesis and biological evaluation of enantiomerically pure cyclopropyl analogues of combretastatin A4. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 1357-66	3-4	24
796	A structure-based design of new C2- and C13-substituted taxanes: tubulin binding affinities and extended quantitative structure-activity relationships using comparative binding energy (COMBINE) analysis. 2013 , 11, 3046-56		18
795	Drug Design and Screening by In Silico Approaches. 2013 , 57-79		1
794	Structure-based target druggability assessment. 2013 , 986, 141-64		14
793	Rational design of HIV-1 entry inhibitors. 2013 , 993, 185-204		14
792	Biophysical fragment screening of the β -adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 3446-55 ^{8,3}		129
791	In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE. 2013 , 53, 836-51		28
790	In-Silico ADME Modeling. 2013 , 1005-1052		
789	Molecular interaction fields in drug discovery: recent advances and future perspectives. 2013 , 3, 594-613		25

788	Water network perturbation in ligand binding: adenosine A(2A) antagonists as a case study. 2013 , 53, 1700-13		103
787	Molecular fields in ligand discovery. 2013 , 1008, 479-99		2
786	Biomacromolecular 3D-QSAR to Decipher Molecular Herbicide Resistance in Acetohydroxyacid Synthases. 2013 , 32, 139-44		9
785	Strategy to target the substrate binding site of SET domain protein methyltransferases. 2013 , 53, 681-91		17
784	Molecular interaction fields vs. quantum-mechanical-based descriptors in the modelling of lipophilicity of platinum(IV) complexes. 2013 , 42, 3482-9		34
783	CROSS: an efficient workflow for reaction-driven rescaffolding and side-chain optimization using robust chemical reactions and available reagents. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 4656-70	8.3	7
782	Exploring the potential of protein-based pharmacophore models in ligand pose prediction and ranking. 2013 , 53, 1179-90		21
781	Investigation on the effect of key water molecules on docking performance in CSARdock exercise. 2013 , 53, 1880-92		35
780	Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors. 2013 , 53, 938-47		23
779	Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 9110-21	8.3	18
778	The Movable Type Method Applied to Protein-Ligand Binding. 2013 , 9, 5526-5538		24
777	Addressing selective polypharmacology of antipsychotic drugs targeting the bioaminergic receptors through receptor dynamic conformational ensembles. 2013 , 53, 1761-74		11
776	AutoMap: a tool for analyzing protein-ligand recognition using multiple ligand binding modes. 2013 , 40, 80-90		12
775	SPAM: A Simple Approach for Profiling Bound Water Molecules. 2013 , 9, 5539-49		36
774	Molecular dynamics simulation and linear interaction energy study of D-Glu-based inhibitors of the MurD ligase. 2013 , 27, 723-38		23
773	New strategy for receptor-based pharmacophore query construction: a case study for 5-HT _{1A} receptor ligands. 2013 , 53, 3233-43		22
772	Chemogenomics of pyridoxal 5'-phosphate dependent enzymes. 2013 , 28, 183-94		11
771	Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A2A receptor. 2013 , 4, 52-67		23

770	Pharmacophore modeling. 2013 , 80-93	2
769	Insights into dietary flavonoids as molecular templates for the design of anti-platelet drugs. 2013 , 97, 13-22	34
768	Protein interface pharmacophore mapping tools for small molecule protein: protein interaction inhibitor discovery. 2013 , 13, 989-1001	30
767	Lipases immobilization for effective synthesis of biodiesel starting from coffee waste oils. 2013 , 3, 514-34	17
766	Organism-adapted specificity of the allosteric regulation of pyruvate kinase in lactic acid bacteria. 2013 , 9, e1003159	11
765	Pharmacophore Modeling: 1 [Methods. 2013 ,	
764	Generation of three-dimensional pharmacophore models. 2013 , 3, 449-464	10
763	State-of-the-art and dissemination of computational tools for drug-design purposes: a survey among Italian academics and industrial institutions. 2013 , 5, 907-27	5
762	Detailed analysis of biased histamine H ₁ receptor signalling by JNJ 777120 analogues. 2013 , 170, 78-88	26
761	Computational methods for the design of potent aromatase inhibitors. 2013 , 8, 395-409	26
760	Design, synthesis, and evaluation of indolebutylamines as a novel class of selective dopamine D ₃ receptor ligands. 2013 , 82, 326-35	4
759	. 2013 , 1,	63
758	Histamine Modulates Isoproterenol Efficacy at the β_1 Adrenoceptor: Inferences Regarding Allosteric Modulation by Imidazole-Containing Compounds. 2013 , 02,	
757	In Silico Binding Mode Proposed for Flavonoid Ligands of Tau Protein with Interest in Alzheimer's Disease. 2013 , 9, 21-26	2
756	Drug metabolite generation using a laboratory evolved NADPH independent cytochrome P450: application of in vitro and in silico approaches. 2013 , 7, 68-77	
755	In Silico Prediction of Ionization. 2013 ,	5
754	. 2013 ,	12
753	A unified model of the GABA(A) receptor comprising agonist and benzodiazepine binding sites. 2013 , 8, e52323	85

752	Discovery of Mycobacterium tuberculosis protein tyrosine phosphatase B (PtpB) inhibitors from natural products. 2013 , 8, e77081	37
751	Docking and PLS studies on a set of thiophenes RNA polymerase inhibitors against Staphylococcus aureus. 2014 , 14, 64-80	8
750	Structure and Ligand Based Rational Drug Design for Bace-1 Inhibitors. 2013 , 9, 14-20	2
749	Binding site detection and druggability prediction of protein targets for structure-based drug design. 2013 , 19, 2326-33	106
748	Library Design: Reactant and Product-Based Approaches. 2013 ,	
747	Esterase LpEst1 from Lactobacillus plantarum: a novel and atypical member of the ßHydrolase superfamily of enzymes. 2014 , 9, e92257	17
746	BioGPS descriptors for rational engineering of enzyme promiscuity and structure based bioinformatic analysis. 2014 , 9, e109354	16
745	Target Based Designing of Anthracenone Derivatives as Tubulin Polymerization Inhibiting Agents: 3D QSAR and Docking Approach. 2014 , 2014, 658016	2
744	Pharmacophore-based Drug Design of Novel Potential Tau Ligands for Alzheimer's Disease Treatment. 2014 , 4, 35-44	6
743	PL-PatchSurfer: a novel molecular local surface-based method for exploring protein-ligand interactions. 2014 , 15, 15122-45	16
742	. 2014 ,	11
741	Molecular Dynamics, Density Functional Theory, Pharmacophore Modeling, Molecular Interaction Fields and ADME/Tox Investigation of Novel Bioactive Compounds Interacting with CDK2 Surfaces. 2014 , 4, 94-105	4
740	Quantitative structure-sorption relationships of pesticides used in the sugarcane industry in the northern coastal area of Paraíba State, Brazil. 2014 , 42, 81-90	3
739	3D-QSAR and Docking Studies of a Series of ßCarboline Derivatives as Antitumor Agents of PLK1. 2014 , 2014, 1-10	5
738	Computational studies on sirtuins from Trypanosoma cruzi: structures, conformations and interactions with phytochemicals. 2014 , 8, e2689	22
737	Carbohydrate-protein interactions: molecular modeling insights. 2014 , 71, 9-136	34
736	Molecular simulations with solvent competition quantify water displaceability and provide accurate interaction maps of protein binding sites. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 8530-9	8.3 67
735	5-(Piperidin-4-yl)-3-hydroxypyrazole: A novel scaffold for probing the orthosteric ßaminobutyric acid type A receptor binding site. 2014 , 9, 2475-85	6

734	Accounting for target flexibility and water molecules by docking to ensembles of target structures: the HCV NS5B palm site I inhibitors case study. 2014 , 54, 481-97	12
733	Is it the shape of the cavity, or the shape of the water in the cavity?. 2014 , 223, 853-891	101
732	Structure of Class B GPCRs: new horizons for drug discovery. 2014 , 171, 3132-45	77
731	An integrated platform for automatic design and screening of virtual mutants based on 3D-QSAR analysis. 2014 , 101, 7-15	7
730	Intuitive, but not simple: including explicit water molecules in protein-protein docking simulations improves model quality. 2014 , 82, 916-32	12
729	A brief history of macromolecular crystallography, illustrated by a family tree and its Nobel fruits. 2014 , 281, 3985-4009	61
728	Improved protein-ligand binding affinity prediction by using a curvature-dependent surface-area model. 2014 , 30, 1674-80	62
727	Structural modifications of 4-aryl-4-oxo-2-aminybutanamides and their acetyl- and butyrylcholinesterase inhibitory activity. Investigation of AChE-ligand interactions by docking calculations and molecular dynamics simulations. 2014 , 81, 158-75	17
726	Fragment-based lead discovery and design. 2014 , 54, 693-704	96
725	Computational method to identify druggable binding sites that target protein-protein interactions. 2014 , 54, 1391-400	18
724	Dual RXR Agonists and RAR Antagonists Based on the Stilbene Retinoid Scaffold. 2014 , 5, 533-7	4
723	QSAR modeling: where have you been? Where are you going to?. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 4977-5010	8.3 996
722	A Cavity Corrected 3D-RISM Functional for Accurate Solvation Free Energies. 2014 , 10, 934-941	105
721	Structure-based drug design of chromone antagonists of the adenosine A2A receptor. 2014 , 5, 571-575	22
720	Design and Synthesis of an Inositol Phosphate Analog Based on Computational Docking Studies. 2014 , 70, 984-990	3
719	Binding and molecular dynamics studies of 7-hydroxycoumarin derivatives with human serum albumin and its pharmacological importance. 2014 , 11, 1117-31	90
718	Computational methods in drug discovery. 2014 , 66, 334-95	953
717	Docking to multiple pockets or ligand fields for screening, activity prediction and scaffold hopping. 2014 , 6, 1741-55	13

716	Protein Ligand Docking in Drug Discovery. 2014 , 249-286		5
715	BioGPS: The Music for the Chemo- and Bioinformatics Walzer. 2014 , 33, 446-53		7
714	Inhibitor design strategy based on an enzyme structural flexibility: a case of bacterial MurD ligase. 2014 , 54, 1451-66		17
713	Inhibiting HtrA protease by addressing a computationally predicted allosteric ligand binding site. 2014 , 5, 3583-3590		22
712	Lead Discovery and Lead Modification. 2014 , 19-122		5
711	Extensive consensus docking evaluation for ligand pose prediction and virtual screening studies. 2014 , 54, 2980-6		66
710	DNA Recognition with Polycyclic-Aromatic-Hydrocarbon-Presenting Calixarene Conjugates. 2014 , 2014, 7605-7613		12
709	Docking server for the identification of heparin binding sites on proteins. 2014 , 54, 2068-78		40
708	Quantitative Structure-Activity Relationship (QSAR) Methods for the Prediction of Substrates, Inhibitors, and Inducers of Metabolic Enzymes. 2014 , 319-350		
707	Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 4337-50	8.3	44
706	Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer's disease. 2014 , 32, 1047-63		19
705	Parameter choice matters: validating probe parameters for use in mixed-solvent simulations. 2014 , 54, 2190-9		28
704	Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3). <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 6867-72	8.3	47
703	Applications of Metaheuristics in Process Engineering. 2014 ,		18
702	Applications of Genetic Algorithms in QSAR/QSPR Modeling. 2014 , 315-324		8
701	KVFinder: steered identification of protein cavities as a PyMOL plugin. 2014 , 15, 197		78
700	Long range Debye-Hückel correction for computation of grid-based electrostatic forces between biomacromolecules. 2014 , 7, 4		6
699	Prospective virtual screening in a sparse data scenario: design of small-molecule TLR2 antagonists. 2014 , 9, 813-22		27

698	Site-Identification by Ligand Competitive Saturation (SILCS) assisted pharmacophore modeling. 2014 , 28, 491-507	46
697	Antiproliferative activity of the Michael adducts of aroylacrylic acids and cyclic amines. 2014 , 18, 577-92	2
696	WATsite: hydration site prediction program with PyMOL interface. 2014 , 35, 1255-60	51
695	Iterative weighting of multiblock data in the orthogonal partial least squares framework. 2014 , 813, 25-34	6
694	The use of chlorobenzene as a probe molecule in molecular dynamics simulations. 2014 , 54, 1821-7	28
693	Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies. 2014 , 173, 1907-26	18
692	Analysis of factors influencing hydration site prediction based on molecular dynamics simulations. 2014 , 54, 2987-95	12
691	Perturbation of fluid dynamics properties of water molecules during G protein-coupled receptor-ligand recognition: the human A2A adenosine receptor as a key study. 2014 , 54, 2846-55	23
690	Two isorecticular metal-organic frameworks with CdSO ₄ -like topology: selective gas sorption and drug delivery. 2014 , 43, 17265-73	48
689	Seeking potential anticonvulsant agents that target GABA _A receptors using experimental and theoretical procedures. 2014 , 28, 1217-32	5
688	Synthesis and pharmacological evaluation of 6-aminonicotinic acid analogues as novel GABA(A) receptor agonists. 2014 , 84, 404-16	13
687	PyWATER: a PyMOL plug-in to find conserved water molecules in proteins by clustering. 2014 , 30, 2978-80	28
686	Molecular recognition of epothilones by microtubules and tubulin dimers revealed by biochemical and NMR approaches. 2014 , 9, 1033-43	27
685	Molecular Interaction Fields for Predicting the Sites and Products of Metabolism. 2014 , 221-242	0
684	Targeting cystalysin, a virulence factor of treponema denticola-supported periodontitis. 2014 , 9, 1501-11	21
683	Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery. 2014 , 6, 617-39	30
682	More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. 2014 , 21, 282-288	75
681	Predictive in silico off-target profiling in drug discovery. 2014 , 6, 295-317	20

680	Structure-based design of small-molecule protein-protein interaction modulators: the story so far. 2014 , 6, 343-57	39
679	Applications of structure-based design to antibacterial drug discovery. 2014 , 55, 69-76	16
678	The Block Relevance (BR) analysis supports the dominating effect of solutes hydrogen bond acidity on IbgP(oct-tol). 2014 , 53, 50-4	21
677	3D-QSAR and molecular docking studies of amino-pyrimidine derivatives as PknB inhibitors. 2014 , 45, 354-364	12
676	Pharmacophore modeling: advances, limitations, and current utility in drug discovery. 2014 , 81	22
675	Rational Drug Design. 2014 , 4, 59-85	3
674	Corrigendum. 2014 , 6, 243-244	
673	Virtual Screening. 2015 , 251-280	2
672	- Molecular Mechanics/Coarse-Grained Simulations as a Structural Prediction Tool for GPCRs/Ligand Complexes. 2015 , 354-369	1
671	- Library Design, Chemical Space, and Drug Likeness. 2015 , 96-115	5
670	Investigation of the molecular similarity in closely related protein systems: The PrP case study. 2015 , 83, 1751-65	9
669	Modulation of Retinoic Acid Receptor Subtypes by 5- and 8-Substituted (Naphthalen-2-yl)-based Arotinoids. 2015 , 10, 1378-91	2
668	Computational Chemistry in the Pharmaceutical Industry: From Childhood to Adolescence. 2015 , 10, 1958-62	53
667	Discovery of Novel, Potent, and Specific Cell-Death Inducers in the Jurkat Acute Lymphoblastic Leukemia Cell Line. 2015 , 10, 1700-6	
666	Three-dimensional compound comparison methods and their application in drug discovery. 2015 , 20, 12841-62	35
665	A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets. 2015 , 6, 197	19
664	Provenance of Computers in Pharmacy. 2015 , 05,	1
663	. 2015 ,	5

662	Relating Caco-2 permeability to molecular properties using block relevance analysis. 2015 , 6, 626-629	10
661	An Ab Initio Method for Designing Multi-Target Specific Pharmacophores using Complementary Interaction Field of Aspartic Proteases. 2015 , 34, 380-93	8
660	5-Aryl-1H-pyrazole-3-carboxylic acids as selective inhibitors of human carbonic anhydrases IX and XII. <i>Bioorganic and Medicinal Chemistry</i> , 2015 , 23, 4649-4659	3-4 16
659	Homology Model-Based Virtual Screening for the Identification of Human Helicase DDX3 Inhibitors. 2015 , 55, 2443-54	35
658	Computational development of selective nNOS inhibitors: binding modes and pharmacokinetic considerations. 2015 , 22, 2558-79	1
657	Computational Fragment-Based Drug Design. 2015 , 189-215	
656	Understanding Water and Its Many Roles in Biological Structure: Ways to Exploit a Resource for Drug Discovery. 2015 , 85-110	
655	BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity. 2015 , 83, 517-32	52
654	A Collective Variable for the Rapid Exploration of Protein Druggability. 2015 , 11, 1292-307	16
653	Fragmentbasierte Wirkstoffentwicklung. 2015 , 63, 116-121	1
652	NF023 binding to XIAP-BIR1: searching drugs for regulation of the NF- κ B pathway. 2015 , 83, 612-20	6
651	Structural analysis of selective agonists of thyroid hormone receptor β using 3D-QSAR and molecular docking. 2015 , 49, 1-18	12
650	Structural basis for complementary and alternative medicine: Phytochemical interaction with non-structural protein 2 protease-a reverse engineering strategy. 2015 , 21, 445-52	8
649	Methoxyflavones from <i>Stachys glutinosa</i> with binding affinity to opioid receptors: in silico, in vitro, and in vivo studies. 2015 , 78, 69-76	17
648	Role of water in ligand binding to maltose-binding protein: insight from a new docking protocol based on the 3D-RISM-KH molecular theory of solvation. 2015 , 55, 317-28	20
647	G Protein-Coupled Receptor Screening Assays. 2015 ,	
646	Prediction and interpretation of the lipophilicity of small peptides. 2015 , 29, 361-70	3
645	GRID/BIOCUBE4mf to rank the influence of mutations on biological processes to design ad hoc mutants. 2015 , 24, 2612-2620	

644	Predicting sites of cytochrome P450-mediated hydroxylation applied to CYP3A4 and hexabromocyclododecane. 2015 , 41, 538-546	1
643	New perspectives on proton pumping in cellular respiration. 2015 , 115, 2196-221	175
642	Scoring functions for AutoDock. 2015 , 1273, 467-74	11
641	Glycoinformatics. 2015 ,	6
640	Molecular descriptors calculation as a tool in the analysis of the antileishmanial activity achieved by two series of diselenide derivatives. An insight into its potential action mechanism. 2015 , 60, 63-78	6
639	Protein Crystallography and Drug Discovery. 2015 , 511-537	3
638	Chemometrics tools in QSAR/QSPR studies: A historical perspective. 2015 , 149, 177-204	85
637	Challenging AQP4 druggability for NMO-IgG antibody binding using molecular dynamics and molecular interaction fields. 2015 , 1848, 1462-71	25
636	The Application of Ligand-Mapping Molecular Dynamics Simulations to the Rational Design of Peptidic Modulators of Protein-Protein Interactions. 2015 , 11, 3199-210	25
635	Evaluating Free Energies of Binding and Conservation of Crystallographic Waters Using SZMAP. 2015 , 55, 1552-65	51
634	Detection of Binding Site Molecular Interaction Field Similarities. 2015 , 55, 1600-15	29
633	DOCK 6: Impact of new features and current docking performance. 2015 , 36, 1132-56	405
632	GRID and docking analyses reveal a molecular basis for flavonoid inhibition of Src family kinase activity. 2015 , 26, 1156-65	19
631	The Discovery of in Vivo Active Mitochondrial Branched-Chain Aminotransferase (BCATm) Inhibitors by Hybridizing Fragment and HTS Hits. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 7140-63	8.3 22
630	Biochemical characterization and molecular dynamic simulation of β -sitosterol as a tubulin-binding anticancer agent. 2015 , 760, 154-62	20
629	Predicting drug metabolism: experiment and/or computation?. 2015 , 14, 387-404	255
628	Synthesis and biological evaluations of a series of thaxtomin analogues. 2015 , 63, 3734-41	17
627	Identification of binding sites and favorable ligand binding moieties by virtual screening and self-organizing map analysis. 2015 , 16, 93	11

626	A novel inhibitor of Plasmodium falciparum spermidine synthase: a twist in the tail. 2015 , 14, 54	8
625	Molecular modelling approach to evaluate poisoning of topoisomerase I by alternariol derivatives. 2015 , 189, 93-101	21
624	Evidence of water molecules--a statistical evaluation of water molecules based on electron density. 2015 , 55, 771-83	40
623	Introduction to 3D-QSAR. 2015 , 291-317	5
622	Background of QSAR and Historical Developments. 2015 , 1-46	15
621	The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. 2015 , 10, 733-55	318
620	Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery. 2015 , 36, 724-736	42
619	Prediction of Water Binding to Protein Hydration Sites with a Discrete, Semiexplicit Solvent Model. 2015 , 11, 5961-72	13
618	Antagonistic effects of indoloquinazoline alkaloids on antimycobacterial activity of evocarpine. 2015 , 118, 864-72	18
617	Accurate Binding Free Energy Predictions in Fragment Optimization. 2015 , 55, 2411-20	83
616	Structures of G protein-coupled receptors reveal new opportunities for drug discovery. 2015 , 20, 1355-64	111
615	Open challenges in structure-based virtual screening: Receptor modeling, target flexibility consideration and active site water molecules description. 2015 , 583, 105-19	78
614	Combined molecular dynamics and continuum solvent approaches (MM-PBSA/GBSA) to predict nospapinoid binding to β -tubulin dimer. 2015 , 26, 507-19	11
613	A Pipeline To Enhance Ligand Virtual Screening: Integrating Molecular Dynamics and Fingerprints for Ligand and Proteins. 2015 , 55, 2256-74	52
612	An β 1-adrenergic receptor ligand repurposed as a potent antiproliferative agent for head and neck squamous cell carcinoma. 2015 , 5, 6536-6542	4
611	Computational solvent mapping in structure-based drug design. 2015 , 7, 337-53	10
610	Expanding the chemical space of human serine racemase inhibitors. 2015 , 25, 4297-303	19
609	Ergot alkaloids: From witchcraft till analysis. Multi-receptor analysis of ergotamine metabolites. 2015 , 2, 535-545	18

608	Malonate-based inhibitors of mammalian serine racemase: kinetic characterization and structure-based computational study. 2015 , 89, 189-97	41
607	3D-QSAR, molecular docking and molecular dynamics studies of a series of ROR β inhibitors. 2015 , 33, 1929-40	19
606	Continuous indicator fields: a novel universal type of molecular fields. 2015 , 29, 233-47	3
605	How good are ensembles in improving QSAR models? The case with eCoRIA. 2015 , 33, 749-69	7
604	Decorated 6,6,7,7-tetrahydro-1H,1H-2,3-biindole scaffold as promising candidate for recognition of the CDK2 allosteric site. 2015 , 6, 311-318	7
603	Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation. 2015 , 33, 1756-79	16
602	Molecular dynamics in drug design. 2015 , 91, 4-14	130
601	Solvatochromism of symmetrical 2,6-distyrylpyridines. An experimental and theoretical study. 2015 , 135, 435-46	6
600	Virtual screening: an in silico tool for interlacing the chemical universe with the proteome. 2015 , 71, 44-57	34
599	Pharmaceutical Preformulation and Formulation. 2016 ,	12
598	2. Drug designing in novel drug discovery: Trends, scope and relevance. 2016 ,	
597	Computational methods for studying G protein-coupled receptors (GPCRs). 2016 , 132, 359-99	24
596	Anticonvulsant and Toxicological Evaluation of Parafluorinated/Chlorinated Derivatives of 3-Hydroxy-3-ethyl-3-phenylpropionamide. 2016 , 2016, 3978010	
595	Identification of Protein-Excipient Interaction Hotspots Using Computational Approaches. 2016 , 17,	16
594	Virtual Screening Approaches towards the Discovery of Toll-Like Receptor Modulators. 2016 , 17,	22
593	Human Aquaporin-4 and Molecular Modeling: Historical Perspective and View to the Future. 2016 , 17,	10
592	Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies. 2016 , 10, 265	49
591	AutoDock-GIST: Incorporating Thermodynamics of Active-Site Water into Scoring Function for Accurate Protein-Ligand Docking. 2016 , 21,	31

590	The use of conformationally thermostabilised GPCRs in drug discovery: application to fragment, structure and biophysical techniques. 2016 , 30, 8-13		12
589	Computational functional group mapping for drug discovery. 2016 , 21, 1928-1931		10
588	AutoSite: an automated approach for pseudo-ligands prediction-from ligand-binding sites identification to predicting key ligand atoms. 2016 , 32, 3142-3149		31
587	Protein-Ligand Informatics Force Field (PLIFF): Toward a Fully Knowledge Driven "Force Field" for Biomolecular Interactions. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 6891-902	8.3	18
586	Rational Hit Generation. 2016 , 159-182		
585	ProtLID, a Residue-Based Pharmacophore Approach to Identify Cognate Protein Ligands in the Immunoglobulin Superfamily. 2016 , 24, 2217-2226		8
584	A functional BH3 domain in an aquaporin from <i>Leishmania infantum</i> . 2016 , 2, 16043		11
583	Mapping the 3D structures of small molecule binding sites. 2016 , 8,		10
582	Assessment of the interacting mechanism between <i>Candida rugosa</i> lipases and hydroxyapatite and identification of the hydroxyapatite-binding sequence through proteomics and molecular modelling. 2016 , 6, 34818-34824		7
581	ILP-assisted de novo drug design. 2016 , 103, 309-341		8
580	Conformational flexibility of DENV NS2B/NS3pro: from the inhibitor effect to the serotype influence. 2016 , 30, 251-70		6
579	Water, water, everywhere—it's time to stop and think. 2016 , 21, 1139-46		54
578	Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 4121-51	8.3	74
577	Identifying Interactions that Determine Fragment Binding at Protein Hotspots. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 4314-25	8.3	64
576	Emerging Computational Methods for the Rational Discovery of Allosteric Drugs. 2016 , 116, 6370-90		140
575	Computational analysis of EBNA1 "druggability" suggests novel insights for Epstein-Barr virus inhibitor design. 2016 , 30, 285-303		24
574	A QSPR approach to the ecotoxicity of ionic liquids () using VolSurf principal properties. 2016 , 5, 1090-1096		11
573	Polarity study of ionic liquids with the solvatochromic dye Nile Red: a QSPR approach using in silico VolSurf+ descriptors. 2016 , 72, 3282-3287		5

572	Prediction of ionic liquid's heat capacity by means of their in silico principal properties. 2016 , 6, 36085-36089		7
571	Structure and Function of Human CYP2D6. 2016 , 341-414		
570	Understanding PPAR- α affinity and selectivity using hologram quantitative structure-activity modeling, molecular docking and GRID calculations. 2016 , 8, 1913-1926		2
569	Active site cavities identification of amyloid beta precursor protein: Alzheimer disease study. 2016 ,		1
568	In silico identification and computational analysis of the nucleotide binding site in the C-terminal domain of Hsp90. 2016 , 70, 253-274		10
567	Aiding Candidate Drug Selection: Introduction and Objectives. 2016 , 23-28		
566	Driving Structure-Based Drug Discovery through Cosolvent Molecular Dynamics. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 10383-10399	8.3	48
565	Molecular dynamics techniques for modeling G protein-coupled receptors. 2016 , 30, 69-75		24
564	Correlating Drug-Target Kinetics and Pharmacodynamics: Long Residence Time Inhibitors of the FabI Enoyl-ACP Reductase. 2016 , 7, 5945-5954		19
563	Selecting the Right Targets for Fragment-Based Drug Discovery. 2016 , 37-56		2
562	Computational Methods to Support Fragment-based Drug Discovery. 2016 , 197-222		4
561	Identifying binding hot spots on protein surfaces by mixed-solvent molecular dynamics: HIV-1 protease as a test case. 2016 , 105, 21-34		29
560	Development, synthesis and structure-activity-relationships of inhibitors of the macrophage infectivity potentiator (Mip) proteins of <i>Legionella pneumophila</i> and <i>Burkholderia pseudomallei</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 5134-5147	3.4	8
559	An alignment-independent 3D-QSAR study on series of hydroxamic acid-based tumor necrosis factor- α converting enzyme inhibitors. 2016 , 30, 537-547		5
558	Identification of Ligand Binding Hot Spots of the Histamine H Receptor following Structure-Based Fragment Optimization. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 9047-9061	8.3	24
557	DESIGN AND SYNTHESIS OF CARBOHYDRATES AND CARBOHYDRATE MIMETICS AS ANTI-INFLUENZA AGENTS. 2016 , 455-481		1
556	Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case. 2016 , 11, 1653-66		12
555	Development of a protein-ligand-binding site prediction method based on interaction energy and sequence conservation. 2016 , 17, 39-49		7

554	The Role of Fragment-based Discovery in Lead Finding. 2016 , 1-36		3
553	In silico investigation into the interactions between murine 5-HT receptor and the principle active compounds of ginger (<i>Zingiber officinale</i>). 2016 , 70, 315-327		5
552	Molecular descriptors for polarity: the need for going beyond polar surface area. 2016 , 8, 2013-2016		32
551	Two-Dimensional Theta Functions and Crystallization among Bravais Lattices. 2016 , 48, 3236-3269		21
550	Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4'-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 6729-38	8.3	17
549	GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain. 2016 , 7, 552-7		38
548	Role of Tunnels and Gates in Enzymatic Catalysis. 2016 , 445-488		
547	Geomfinder: a multi-feature identifier of similar three-dimensional protein patterns: a ligand-independent approach. 2016 , 8, 19		3
546	Development and validation of hydrophobic molecular fields derived from the quantum mechanical IEF/PCM-MST solvation models in 3D-QSAR. 2016 , 37, 1147-62		6
545	Development of Influenza Virus Sialidase Inhibitors. 2016 , 651-686		1
544	The effect of various atomic partial charge schemes to elucidate consensus activity-correlating molecular regions: a test case of diverse QSAR models. 2016 , 34, 540-59		13
543	In silico study on β -aminoketone derivatives as thyroid hormone receptor inhibitors: a combined 3D-QSAR and molecular docking study. 2016 , 34, 2619-2631		3
542	Prediction of retention time in reversed-phase liquid chromatography as a tool for steroid identification. 2016 , 916, 8-16		44
541	Cyto- and enzyme toxicities of ionic liquids modelled on the basis of VolSurf+ descriptors and their principal properties. 2016 , 27, 221-244		15
540	Modelling the aquatic toxicity of ionic liquids by means of VolSurf in silico descriptors. 2016 , 27, 1-15		15
539	Fluorescence properties and sequestration of peripheral anionic site specific ligands in bile acid hosts: Effect on acetylcholinesterase inhibition activity. 2016 , 158, 192-201		2
538	GPCR-Bench: A Benchmarking Set and Practitioners' Guide for G Protein-Coupled Receptor Docking. 2016 , 56, 642-51		21
537	Quantitative Correlation of Conformational Binding Enthalpy with Substrate Specificity of Serine Proteases. 2016 , 120, 299-308		4

536	Drug design, synthesis, in vitro and in silico evaluation of selective monoaminoxidase B inhibitors based on 3-acetyl-2-dichlorophenyl-5-aryl-2,3-dihydro-1,3,4-oxadiazole chemical scaffold. 2016 , 108, 542-552		26
535	Identification and Visualization of Kinase-Specific Subpockets. 2016 , 56, 335-46		14
534	Structure-based approach for the study of thyroid hormone receptor binding affinity and subtype selectivity. 2016 , 34, 2251-67		6
533	Beyond spectral tuning: human cone visual pigments adopt different transient conformations for chromophore regeneration. 2016 , 73, 1253-63		6
532	Antiproliferative and antibacterial activity of some glutarimide derivatives. 2016 , 31, 915-23		8
531	Alignment independent 3D-QSAR, quantum calculations and molecular docking of Mer specific tyrosine kinase inhibitors as anticancer drugs. 2016 , 24, 197-212		8
530	Corrigendum. 2017 , 9, 706-707		
529	Software for molecular docking: a review. 2017 , 9, 91-102		523
528	Recent Developments in 3D QSAR and Molecular Docking Studies of Organic and Nanostructures. 2017 , 2133-2161		3
527	Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses. 2017 , 9, 135-151		16
526	Ligand binding to telomeric G-quadruplex DNA investigated by funnel-metadynamics simulations. 2017 , 114, E2136-E2145		74
525	Discovery and Preclinical Characterization of 3-((4-(4-Chlorophenyl)-7-fluoroquinoline-3-yl)sulfonyl)benzotrile, a Novel Non-acetylenic Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator for Psychiatric Indications. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 2170-2181	8.3	18
524	Modeling from Theory and Modeling from Data: Complementary or Alternative Approaches? The Case of Ionic Liquids. 2017 , 6, 90-101		3
523	Topological and quantum molecular descriptors as effective tools for analyzing cytotoxic activity achieved by a series of (diselanediyl)benzene-4,1-diyl(nide)biscarbamate derivatives. 2017 , 73, 62-73		3
522	Translational Bioinformatics and Drug Discovery. 2017 , 29-53		
521	Ligand Selectivity between the ADP-Ribosylating Toxins: An Inverse-Docking Study for Multitarget Drug Discovery. 2017 , 2, 1710-1719		6
520	The Roles of Water in the Protein Matrix: A Largely Untapped Resource for Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 6781-6827	8.3	77
519	Indirect quantitative structure-retention relationship for steroid identification: A chemometric challenge at Chimieométrie 2016 2017 , 160, 52-58		1

518	Mitochondria-dependent benzothiadiazole-based molecule probe for quantitatively intracellular pH imaging. 2017 , 145, 576-583	26
517	Three-Component Aminoalkylations Yielding Dihydronaphthoxazine-Based Sirtuin Inhibitors: Scaffold Modification and Exploration of Space for Polar Side-Chains. 2017 , 350, e1700097	14
516	Deciphering Cryptic Binding Sites on Proteins by Mixed-Solvent Molecular Dynamics. 2017 , 57, 1388-1401	41
515	Crystal structure of the GLP-1 receptor bound to a peptide agonist. 2017 , 546, 254-258	126
514	Geometric Detection Algorithms for Cavities on Protein Surfaces in Molecular Graphics: A Survey. 2017 , 36, 643-683	19
513	Statistical Analysis, Investigation, and Prediction of the Water Positions in the Binding Sites of Proteins. 2017 , 57, 1517-1528	6
512	Staphylococcus aureus Exonin in aqueous solution: Behavior in monomeric and multimeric states. 2017 , 227, 21-28	2
511	Drug Discovery. 2017 , 3-28	
510	Predicting "Hot" and "Warm" Spots for Fragment Binding. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 4036-4046	23
509	Surface area, volume and shape descriptors as a novel tool for polymer lead design and discovery. 2017 , 102, 188-195	6
508	Comparative mapping of on-targets and off-targets for the discovery of anti-trypanosomatid folate pathway inhibitors. 2017 , 1861, 3215-3230	8
507	Comparing structural and transcriptional drug networks reveals signatures of drug activity and toxicity in transcriptional responses. 2017 , 3, 23	10
506	Tailoring Hit Identification and Qualification Methods for Targeting Protein-Protein Interactions. 2017 , 29-59	
505	Allosteric Communication Networks in Proteins Revealed through Pocket Crosstalk Analysis. 2017 , 3, 949-960	37
504	Relative Binding Free Energy Calculations in Drug Discovery: Recent Advances and Practical Considerations. 2017 , 57, 2911-2937	254
503	Pharmacophore Generation for Multiple Ligands. 2017 , 275-312	3
502	Synthesis meets theory: Past, present and future of rational chemistry. 2017 , 2,	2
501	3D descriptors calculation and conformational search to investigate potential bioactive conformations, with application in 3D-QSAR and virtual screening in drug design. 2017 , 35, 2966-2974	9

500	Structural exploration of PPAR γ modulators through pharmacophore mapping, fragment-based design, docking, and molecular dynamics simulation analyses. 2017 , 26, 52-63	2
499	Effects of dietary oxidized tyrosine products on insulin secretion via the thyroid hormone T3-regulated TR β /Akt/mTOR pathway in the pancreas. 2017 , 7, 54610-54625	7
498	Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo- β -lactamases. 2017 , 7, 17716	23
497	Molecular property diagnostic suite (MPDS): Development of disease-specific open source web portals for drug discovery. 2017 , 28, 913-926	4
496	Fragment-Based Lead Discovery. 2017 , 371-439	9
495	3D-QSAR and molecular docking analysis of (4-piperidiny)-piperazines as acetyl-CoA carboxylases inhibitors. 2017 , 10, S617-S626	11
494	Computer-Aided Drug Discovery in Plant Pathology. 2017 , 33, 529-542	9
493	. 2017 ,	2
492	Recent Advances and Applications of Molecular Docking to G Protein-Coupled Receptors. 2017 , 22,	32
491	Dynamic Docking: A Paradigm Shift in Computational Drug Discovery. 2017 , 22,	71
490	Identification, In Vitro Testing and Molecular Docking Studies of Microginins' Mechanism of Angiotensin-Converting Enzyme Inhibition. 2017 , 22,	6
489	Degradation of Aflatoxins by Means of Laccases from <i>Trametes versicolor</i> : An In Silico Insight. 2017 , 9,	29
488	Computational Methods in Multitarget Drug Discovery. 2017 , 239-258	1
487	Using Force-Field Grids for Sampling Translation/Rotation of Partially Rigid Macromolecules. 2017 , 10, 6	
486	Mechanistic Insights into the Binding of Class IIa HDAC Inhibitors toward Spinocerebellar Ataxia Type-2: A 3D-QSAR and Pharmacophore Modeling Approach. 2016 , 10, 606	10
485	Kinase-Centric Computational Drug Development. 2017 , 197-236	5
484	Modeling and Design for Membrane Protein Targets. 2017 , 145-188	2
483	Detecting similar binding pockets to enable systems polypharmacology. 2017 , 13, e100522	24

482	Determinants of Macromolecular Specificity from Proteomics-Derived Peptide Substrate Data. 2017 , 18, 905-913	0
481	Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry. 2017 , 4, 308-321	48
480	Structure-based drug design: aiming for a perfect fit. 2017 , 61, 431-437	53
479	Quantitative Structure-Activity Relationships. 2017 , 379-392	7
478	Current perspectives in fragment-based lead discovery (FBLD). 2017 , 61, 453-464	89
477	Lessons and Successes in the Use of Molecular Fields. 2017 , 253-296	2
476	Molecular modeling study of the thymidine phosphorylase inhibitor by SBDD and classical QSAR analysis. 2017 , 17, 19-29	
475	Mapping ligand binding pockets in chloride CLC-1 channels through an integrated in silico and experimental approach using anthracene-9-carboxylic acid and niflumic acid. 2018 , 175, 1770-1780	9
474	3D-QSAR with R: A new 3D-QSAR methodology applied to a set of DGAT1 inhibitors [corrected]. 2018 , 74, 123-131	8
473	QSAR/QSPR. 2018 , 9-52	1
472	Pharmacophore Perception and Applications. 2018 , 259-282	1
471	Computational Analysis of Solvent Inclusion in Docking Studies of Protein-Glycosaminoglycan Systems. 2018 , 1762, 445-454	2
470	Molecular Dynamics Simulation and Prediction of Druggable Binding Sites. 2018 , 1762, 87-103	6
469	Large-Scale Validation of Mixed-Solvent Simulations to Assess Hotspots at Protein-Protein Interaction Interfaces. 2018 , 58, 784-793	16
468	Detailed solvent, structural, quantum chemical study and antimicrobial activity of isatin Schiff base. 2018 , 196, 16-30	6
467	Active Search for Computer-aided Drug Design. 2018 , 37, 1700130	12
466	Retention prediction in reversed phase high performance liquid chromatography using quantitative structure-retention relationships applied to the Hydrophobic Subtraction Model. 2018 , 1541, 1-11	33
465	Predicting Binding Affinity Based on Docking Measures for Spinocerebellar Ataxia: A Study. 2018 , 33-43	

464	Locating Large, Flexible Ligands on Proteins. 2018 , 58, 315-327		2
463	So you think computational approaches to understanding glycosaminoglycan-protein interactions are too dry and too rigid? Think again!. 2018 , 50, 91-100		53
462	Computational chemical biology and drug design: Facilitating protein structure, function, and modulation studies. 2018 , 38, 914-950		23
461	The Role of Interfacial Water in Protein-Ligand Binding: Insights from the Indirect Solvent Mediated Potential of Mean Force. 2018 , 14, 512-526		18
460	Toward the identification of a reliable 3D-QSAR model for the protein tyrosine phosphatase 1B inhibitors. <i>Journal of Molecular Structure</i> , 2018 , 1158, 75-87	3-4	5
459	When fragments link: a bibliometric perspective on the development of fragment-based drug discovery. 2018 , 23, 1596-1609		24
458	Crius: A novel fragment-based algorithm of de novo substrate prediction for enzymes. 2018 , 27, 1526-1534		
457	New insights in the in vitro characterisation and molecular modelling of the P-glycoprotein inhibitory promiscuity. 2018 , 121, 85-94		10
456	Fragment-Based Ligand Designing. 2018 , 1762, 123-144		4
455	Incorporation of Hydrogen Bond Angle Dependency into the Generalized Solvation Free Energy Density Model. 2018 , 58, 761-772		2
454	High-affinity ligands of the colchicine domain in tubulin based on a structure-guided design. 2018 , 8, 4242		20
453	Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents. 2018 , 143, 1543-1552		27
452	Computational Modeling of Gamma-Secretase Inhibitors as Anti-Alzheimer Agents. 2018 , 283-303		
451	xMaP-An Interpretable Alignment-Free Four-Dimensional Quantitative Structure-Activity Relationship Technique Based on Molecular Surface Properties and Conformer Ensembles. 2018 , 58, 165-181		11
450	AquaMMapS: An Alternative Tool to Monitor the Role of Water Molecules During Protein-Ligand Association. 2018 , 13, 522-531		17
449	Methodologies for the Examination of Water in GPCRs. 2018 , 1705, 207-232		5
448	Methods for Virtual Screening of GPCR Targets: Approaches and Challenges. 2018 , 1705, 233-264		2
447	Methods of Exploring Protein-Ligand Interactions to Guide Medicinal Chemistry Efforts. 2018 , 1705, 159-177		1

446	Quantitative structure-property relationship modeling of small organic molecules for solar cells applications. 2018 , 32, e2957		5
445	Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains. 2018 , 143, 1474-1488		5
444	An Improved Receptor-Based Pharmacophore Generation Algorithm Guided by Atomic Chemical Characteristics and Hybridization Types. 2018 , 9, 1463		5
443	. 2018 ,		1
442	Molecular Dynamics Applications to GPCR Ligand Design. 2018 , 225-246		
441	From Computers to Bedside: Computational Chemistry Contributing to FDA Approval. 2018 , 163-203		2
440	Solvents to Fragments to Drugs: MD Applications in Drug Design. 2018 , 23,		14
439	Protein structure and computational drug discovery. 2018 , 46, 1367-1379		17
438	Truly Target-Focused Pharmacophore Modeling: A Novel Tool for Mapping Intermolecular Surfaces. 2018 , 23,		19
437	Impact of Molecular Descriptors on Computational Models. 2018 , 1825, 171-209		16
436	Receptor pharmacophore ensemble (REPHARMBLE): a probabilistic pharmacophore modeling approach using multiple protein-ligand complexes. 2018 , 24, 282		7
435	In silico fragment-mapping method: a new tool for fragment-based/structure-based drug discovery. 2018 , 32, 1229-1245		8
434	Genetically-encoded fragment-based discovery of glycopeptide ligands for DC-SIGN. <i>Bioorganic and Medicinal Chemistry</i> , 2018 , 26, 5368-5377	3-4	13
433	Electrostatic recognition in substrate binding to serine proteases. 2018 , 31, e2727		8
432	Computational Methods Applicable to the Discovery of Small-Molecule Inhibitors of Protein-Protein Interactions. 2018 , 73-94		
431	Computational explorations to gain insight into the structural features of TNF- β receptor I inhibitors. 2018 , 15, 2519-2531		1
430	GRAIL: GRids of phArmacophore Interaction fieLds. 2018 , 14, 4958-4970		12
429	A Computational Study on the Blocking Ability of Selected Commercially Available Anticancer Drugs and Their Hypothetic Derivatives on the CCR5. 2018 , 16, 266-277		2

428	Placement of Water Molecules in Protein Structures: From Large-Scale Evaluations to Single-Case Examples. 2018 , 58, 1625-1637	22
427	Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57. 2018 , 8, 10425	35
426	In silico fragment-based drug design with SEED. 2018 , 156, 907-917	10
425	Predicting how drug molecules bind to their protein targets. 2018 , 42, 34-39	12
424	Machine learning in chemoinformatics and drug discovery. 2018 , 23, 1538-1546	382
423	Methylselenol release as a cytotoxic tool: a study of the mechanism of the activity achieved by two series of methylselenocarbamate derivatives. 2018 , 10, 1128-1140	2
422	Identification of Antifungal Targets Based on Computer Modeling. 2018 , 4,	10
421	Molecular Docking for Detoxifying Enzyme Studies. 2018 ,	
420	Drug Repurposing and Multi-Target Therapies. 2019 , 780-791	
419	WebMetabase: cleavage sites analysis tool for natural and unnatural substrates from diverse data source. 2019 , 35, 650-655	2
418	Binding Site Comparison Software and Applications. 2019 , 650-660	
417	Combating influenza: natural products as neuraminidase inhibitors. 2019 , 18, 69-107	4
416	110th Anniversary: Selective Recognition of 5-Fluorouracil with Molecular Imprinting Membranes: Molecular Details. 2019 , 58, 15497-15505	2
415	New Trypanosoma cruzi Trypanothione Reductase Inhibitors Identification using the Virtual Screening in Database of Nucleus Bioassay, Biosynthesis and Ecophysiology (NuBBE). 2019 , 17, 138-149	1
414	www.3d-qsar.com: a web portal that brings 3-D QSAR to all electronic devices-the Py-CoMFA web application as tool to build models from pre-aligned datasets. 2019 , 33, 855-864	17
413	Solvation Free Energy as a Measure of Hydrophobicity: Application to Serine Protease Binding Interfaces. 2019 , 15, 5872-5882	20
412	The role of hydration effects in 5-fluorouridine binding to SOD1: insight from a new 3D-RISM-KH based protocol for including structural water in docking simulations. 2019 , 33, 913-926	4
411	In silico prediction of estrogen receptor subtype binding affinity and selectivity using 3D-QSAR and molecular docking. 2019 , 28, 1974-1994	1

410	FRSite: Protein drug binding site prediction based on faster R-CNN. 2019 , 93, 107454	7
409	Molecular Docking of Isolated Alkaloids for Possible β -Glucosidase Inhibition. 2019 , 9,	20
408	The role of water and protein flexibility in the structure-based virtual screening of allosteric GPCR modulators: an mGlu receptor case study. 2019 , 33, 787-797	4
407	A novel protein descriptor for the prediction of drug binding sites. 2019 , 20, 478	9
406	Software-aided workflow for predicting protease-specific cleavage sites using physicochemical properties of the natural and unnatural amino acids in peptide-based drug discovery. 2019 , 14, e0199270	3
405	Computer-based techniques for lead identification and optimization I: Basics. 2019 , 4,	10
404	Understanding Ligand Binding Selectivity in a Prototypical GPCR Family. 2019 , 59, 2830-2836	16
403	High resolution crystal structure of the FAK FERM domain reveals new insights on the Druggability of tyrosine 397 and the Src SH3 binding site. 2019 , 20, 10	5
402	Approaching Target Selectivity by De Novo Drug Design. 2019 , 14, 791-803	15
401	Characterization of Hydration Properties in Structural Ensembles of Biomolecules. 2019 , 59, 3316-3329	3
400	Ligity: A Non-Superpositional, Knowledge-Based Approach to Virtual Screening. 2019 , 59, 2600-2616	8
399	Design of pyrimidine-based scaffolds as potential anticancer agents for human DHFR: three-dimensional quantitative structure-activity relationship by docking derived grid-independent descriptors. 2019 , 16, 2365-2378	1
398	Navigating within thiamine diphosphate-dependent decarboxylases: Sequences, structures, functional positions, and binding sites. 2019 , 87, 774-785	1
397	Synthesis and biological evaluation of flavone-8-acrylamide derivatives as potential multi-target-directed anti Alzheimer agents and investigation of binding mechanism with acetylcholinesterase. 2019 , 88, 102960	11
396	Analysis of tractable allosteric sites in G protein-coupled receptors. 2019 , 9, 6180	21
395	Application of In Silico Drug Repurposing in Infectious Diseases. 2019 , 427-462	
394	In Silico Repurposing of Cell Cycle Modulators for Cancer Treatment. 2019 , 255-279	
393	In Silico Target Druggability Assessment: From Structural to Systemic Approaches. 2019 , 1953, 63-88	4

392	Diphenyl ether derivatives occupy the expanded binding site of cyclohexanedione compounds at the colchicine site in tubulin by movement of the H5 loop. 2019 , 171, 195-208		4
391	Analysis of hydrophobic and hydrophilic moments of short penetrating peptides for enhancing mitochondrial localization: prediction and validation. 2019 , 33, 7970-7984		2
390	C-6H- vs C-7H-Substituted Steroidal Aromatase Inhibitors: Which Is Better? Synthesis, Biochemical Evaluation, Docking Studies, and Structure-Activity Relationships. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 3636-3657	8.3	21
389	Crystallographic screening using ultra-low-molecular-weight ligands to guide drug design. 2019 , 24, 1081-1086		37
388	Identification of novel imidazole flavonoids as potent and selective inhibitors of protein tyrosine phosphatase. 2019 , 88, 102900		4
387	The impact of binding site waters on the activity/selectivity trade-off of Janus kinase 2 (JAK2) inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019 , 27, 1497-1508	3-4	2
386	MLR, PLSR-BR Analysis and MBPLSR to Interpret Multivariate QSPR Models. The Case of a Micellar Liquid Chromatography Descriptor (log K). 2019 , 38, e1800144		3
385	A model of the three-dimensional structure of human interferon responsive factor 1 and its modifications upon phosphorylation or phosphorylation-mimicking mutations. 2019 , 37, 4632-4643		
384	All in One: Cavity Detection, Druggability Estimate, Cavity-Based Pharmacophore Perception, and Virtual Screening. 2019 , 59, 573-585		13
383	Cell-based assays and molecular dynamics analysis of a boron-containing agonist with different profiles of binding to human and guinea pig beta2 adrenoceptors. 2019 , 48, 83-97		5
382	Ligand design for somatostatin receptor isoforms 4 and 5. 2019 , 163, 148-159		7
381	Protein-protein binding supersites. 2019 , 15, e1006704		9
380	Structure-Based Drug Design with a Special Emphasis on Herbal Extracts. 2019 , 271-305		
379	High-Throughput Virtual Screening (HTVS) of Natural Compounds and Exploration of Their Biomolecular Mechanisms. 2019 , 523-548		5
378	An insight of early PrP-E200K aggregation by combined molecular dynamics/fragment molecular orbital approaches. 2019 , 87, 51-61		5
377	Structure-based exploration and pharmacological evaluation of N-substituted piperidin-4-yl-methanamine CXCR4 chemokine receptor antagonists. 2019 , 162, 631-649		8
376	In silico approaches for screening molecular targets in <i>Candida albicans</i> : A proteomic insight into drug discovery and development. 2019 , 842, 64-69		16
375	Duffy binding-like 1H adhesin from <i>Plasmodium falciparum</i> recognizes ABH histo-blood group saccharide in a type specific manner. 2019 , 207, 266-275		

374	Molecular docking, synthesis and anticonvulsant activity of some novel 3-(2-substituted)-4-oxothiazolidine-3-yl)-2-phenylquinazoline-4(3H)-ones. 2019 , 45, 471-486		9
373	Structure-Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu) X-ray Structures. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 207-222	8.3	48
372	Human dopamine transporter: the first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities. 2019 , 37, 291-306		7
371	Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist. 2020 , 38, 32-47		16
370	Plant natural fragments, an innovative approach for drug discovery. 2020 , 19, 1141-1156		4
369	Alignment independent 3D-QSAR studies and molecular dynamics simulations for the identification of potent and selective S1P receptor agonists. 2020 , 94, 107459		3
368	Structure-based design of selective histone deacetylase 6 zinc binding groups. 2020 , 38, 3166-3177		5
367	Allosteric activation of metabotropic glutamate receptor 5. 2020 , 38, 2624-2632		4
366	Molecular modelling of epitopes recognized by neoplastic B lymphocytes in Chronic Lymphocytic Leukemia. 2020 , 185, 111838		12
365	Pharmaker: Pharmacophore modeling and hit identification based on druggability simulations. 2020 , 29, 76-86		14
364	Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 1528-1543	8.3	23
363	Thermodynamic profiling for fragment-based lead discovery and optimization. 2020 , 15, 117-129		2
362	Discovery of 1,2,4-oxadiazole derivatives as a novel class of noncompetitive inhibitors of 3-hydroxykynurenine transaminase (HKT) from <i>Aedes aegypti</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2020 , 28, 115252	3.4	6
361	Inhibition of the transcriptional repressor LexA: Withstanding drug resistance by inhibiting the bacterial mechanisms of adaptation to antimicrobials. 2020 , 241, 117116		10
360	Chemometrics for QSAR Modeling. 2020 , 599-634		5
359	A molecular interaction field describing nonconventional intermolecular interactions and its application to protein-ligand interaction prediction. 2020 , 96, 107515		6
358	Symmetrical arrangement of positively charged residues around the 5-fold axes of SAT type foot-and-mouth disease virus enhances cell culture of field viruses. 2020 , 16, e1008828		2
357	Screening of Bacterial Quorum Sensing Inhibitors in a LuxR-Based Synthetic Fluorescent Biosensor. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	4

356	Current advances on the development of BET inhibitors: insights from computational methods. 2020 , 122, 127-180	2
355	Virtual and Antiviral Screening Revive Therapeutic Drugs for COVID-19. 2020 , 3, 1278-1292	22
354	Polyphenols bind to low density lipoprotein at biologically relevant concentrations that are protective for heart disease. 2020 , 694, 108589	8
353	Effect of Vitamin K Inhibiting the Function of NorA Efflux Pump and Its Gene Expression on. 2020 , 10,	14
352	Artificial Intelligence-Based Drug Design and Discovery. 2020 ,	5
351	aquaPELE: A Monte Carlo-Based Algorithm to Sample the Effects of Buried Water Molecules in Proteins. 2020 , 16, 7655-7670	5
350	Batch and column adsorption of cations, oxyanions and dyes on a magnetite modified cellulose-based membrane. 2020 , 27, 8215-8235	6
349	Micellization Behavior of Conventional Cationic Surfactants within Glycerol-Based Deep Eutectic Solvent. 2020 , 5, 19350-19362	8
348	GridSolvate: A Web Server for the Prediction of Biomolecular Hydration Properties. 2020 , 60, 5907-5911	1
347	In-silico analysis of the strigolactone ligand-receptor system. 2020 , 4, e00263	5
346	A Benzene-Mapping Approach for Uncovering Cryptic Pockets in Membrane-Bound Proteins. 2020 , 16, 5948-5959	3
345	A Personal History of Using Crystals and Crystallography to Understand Biology and Advanced Drug Discovery. 2020 , 10, 676	1
344	Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to. 2020 , 25,	4
343	Refining the model to design β -chymotrypsin superactivators: the role of the binding mode of quaternary ammonium salts. 2020 , 44, 20823-20833	1
342	Benchmark Sets for Binding Hot Spot Identification in Fragment-Based Ligand Discovery. 2020 , 60, 6612-6623	3
341	Instantaneous generation of protein hydration properties from static structures. 2020 , 3,	2
340	Advances in Docking. 2019 , 26, 7555-7580	36
339	Using the Semiempirical Quantum Mechanics in Improving the Molecular Docking: A Case Study with CDK2. 2020 , 39, e2000036	4

338	Dityrosine suppresses the cytoprotective action of thyroid hormone T3 inhibiting thyroid hormone receptor-mediated transcriptional activation.. 2020 , 10, 21057-21070		1
337	Oseltamivir analogs with potent anti-influenza virus activity. 2020 , 25, 1389-1402		4
336	A Computer Vision Approach to Align and Compare Protein Cavities: Application to Fragment-Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 7127-7142	8.3	4
335	Accurate Prediction of GPCR Ligand Binding Affinity with Free Energy Perturbation. 2020 , 60, 5563-5579		16
334	Structure-Based Drug Discovery of -((()-3-(7-Methyl-1-indazol-5-yl)-1-oxo-1-(((()-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propyl)amino)propyl)amino)propanoic acid (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 7906-7920		4
333	Identification of Small-Molecule Positive Modulators of Calcitonin-like Receptor-Based Receptors. 2020 , 3, 305-320		9
332	Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach. 2020 , 34, 897-914		3
331	Advances in therapeutic peptides targeting G protein-coupled receptors. 2020 , 19, 389-413		70
330	Hotspots API: A Python Package for the Detection of Small Molecule Binding Hotspots and Application to Structure-Based Drug Design. 2020 , 60, 1911-1916		8
329	A Grid Map Based Approach to Identify Nonobvious Ligand Design Opportunities in 3D Protein Structure Ensembles. 2020 , 60, 2178-2188		2
328	12. Computer-based techniques for lead identification and optimization I: Basics. 2020 , 311-332		1
327	AutoPH4: An Automated Method for Generating Pharmacophore Models from Protein Binding Pockets. 2020 , 60, 4326-4338		7
326	Applications of the Pharmacophore Concept in Natural Product inspired Drug Design. 2020 , 39, e2000059		13
325	The rise of molecular simulations in fragment-based drug design (FBDD): an overview. 2020 , 25, 1693-1701		10
324	Navigating the intricacies of molecular docking. 2020 , 12, 469-471		4
323	Biocatalysis and Strategies for Enzyme Improvement. 2020 ,		6
322	Next generation 3D pharmacophore modeling. 2020 , 10, e1468		49
321	Applications of water molecules for analysis of macromolecule properties. 2020 , 18, 355-365		10

320	Exploring the computational methods for protein-ligand binding site prediction. 2020 , 18, 417-426	33
319	Protein-Ligand Complex Solvation Thermodynamics: Development, Parameterization, and Testing of GIST-Based Solvent Functionals. 2020 , 60, 1409-1423	8
318	Automated in Silico Design of Homogeneous Catalysts. 2020 , 10, 2354-2377	66
317	Impact of Recently Determined Crystallographic Structures of GPCRs on Drug Discovery. 2020 , 449-477	1
316	Targeting Protein-Protein Interactions Perspective. 2020 , 479-502	2
315	An Innovative Sequence-to-Structure-Based Approach to Drug Resistance Interpretation and Prediction: The Use of Molecular Interaction Fields to Detect HIV-1 Protease Binding-Site Dissimilarities. 2020 , 8, 243	2
314	Structural Characterization of Carbonic Anhydrase VIII and Effects of Missense Single Nucleotide Variations to Protein Structure and Function. 2020 , 21,	8
313	Energetic contributions of amino acid residues and its cross-talk to delineate ligand-binding mechanism. 2020 , 88, 1207-1225	11
312	Candidate Binding Sites for Allosteric Inhibition of the SARS-CoV-2 Main Protease from the Analysis of Large-Scale Molecular Dynamics Simulations. 2021 , 12, 65-72	6
311	A second generation of 1,2,4-oxadiazole derivatives with enhanced solubility for inhibition of 3-hydroxykynurenine transaminase (HKT) from. 2021 , 12, 222-236	2
310	The AutoDock suite at 30. 2021 , 30, 31-43	21
309	A survey on adverse drug reaction studies: data, tasks and machine learning methods. 2021 , 22, 164-177	7
308	Modeling Protein-Ligand Interactions: Are We Ready for Deep Learning?. 2021 , 163-173	
307	Fragment dissolved molecular dynamics: a systematic and efficient method to locate binding sites. 2021 , 23, 3123-3134	2
306	Structure-Based Virtual Screening: Theory, Challenges and Guidelines. 2021 ,	
305	Ligand-based pharmacophore modeling: A technique utilized for virtual screening of commercial databases. 2021 , 203-234	
304	Structure-Activity relationships and drug design. 2021 , 129-153	0
303	Anticancer Lead Compounds that Prevent DNA Binding to hnRNP K. 2021 , 677-694	

302	Water molecules at protein-drug interfaces: computational prediction and analysis methods. 2021 , 50, 9104-9120	4
301	Design and Discovery of Kinase Inhibitors Using Docking Studies. 2021 , 337-365	
300	Aspects of Protein Structure, Function, and Dynamics in Rational Drug Designing. 2021 , 35-57	0
299	Computational Drug Target Tractability Analysis. 2021 , 145-153	0
298	Computer-Aided Drug Design. 2021 , 137-210	7
297	Structural genetics of circulating variants affecting the SARS-CoV-2 spike/human ACE2 complex. 2021 , 1-11	21
296	REDIAL-2020: A Suite of Machine Learning Models to Estimate Anti-SARS-CoV-2 Activities. 2020 ,	1
295	Polymer-matrix stabilized metal nanoparticles: Synthesis, characterizations and insight into molecular interactions between metal ions, atoms and polymer moieties. 2021 , 325, 115135	3
294	Outliers in SAR and QSAR: 3. Importance of considering the role of water molecules in protein-ligand interactions and quantitative structure-activity relationship studies. 2021 , 35, 371-396	2
293	Molecular docking and density functional theory studies of potent 1,3-disubstituted-9H-pyrido[3,4-b]indoles antifilarial compounds. 2021 , 32, 1925-1947	1
292	Structure-Based Drug Design for G Protein-Coupled Receptors. 1-59	
291	Application of Nonaqueous Media in Biocatalysis. 2021 , 245-274	1
290	Artificial Intelligence in Medicinal Chemistry. 1-19	
289	Residue-based pharmacophore approaches to study protein-protein interactions. 2021 , 67, 205-211	2
288	Docking, Scoring, and Virtual Screening in Drug Discovery. 1-102	1
287	Allosterism and Drug Discovery. 1-78	
286	Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors. 2021 , 189, 105055	13
285	Simultaneous Identification of Multiple Binding Sites in Proteins: A Statistical Mechanics Approach. 2021 , 125, 5052-5067	

284	CAVIAR: a method for automatic cavity detection, description and decomposition into subcavities. 2021 , 35, 737-750	0
283	Virtual Screening for Chemists. 2021 ,	
282	A machine learning platform to estimate anti-SARS-CoV-2 activities. 2021 , 3, 527-535	13
281	Criteria for Engineering Cutinases: Bioinformatics Analysis of Catalophores. 2021 , 11, 784	
280	Revisiting the Proposition of Binding Pockets and Bioactive Poses for GSK-3 β Allosteric Modulators Addressed to Neurodegenerative Diseases. 2021 , 22,	4
279	De Novo Molecule Design Through the Molecular Generative Model Conditioned by 3D Information of Protein Binding Sites. 2021 , 61, 3240-3254	6
278	An Overview of Computer-aided Drug Design Tools and Recent Applications in Designing of Anti-diabetic Agents. 2021 , 22, 1158-1182	2
277	Permeability prediction in the beyond-Rule-of 5 chemical space: Focus on cyclic hexapeptides. 2021 , 165, 259-270	3
276	ePharmer: An integrated and graphical software for pharmacophore-based virtual screening. 2021 , 42, 2181-2195	
275	Combining machine learning and quantum mechanics yields more chemically aware molecular descriptors for medicinal chemistry applications. 2021 , 42, 2068-2078	2
274	Preliminary modelling as the first stage of targeted organic synthesis. 2021 , 90, 831-867	1
273	Accurate Prediction of Hydration Sites of Proteins Using Energy Model With Atom Embedding. 2021 , 8, 756075	0
272	Treasuring the computational approach in medicinal plant research. 2021 , 164, 19-32	7
271	Comprehensive strategies of machine-learning-based quantitative structure-activity relationship models. 2021 , 24, 103052	10
270	Homology modelling, molecular dynamics simulation and docking evaluation of β -tubulin of <i>Schistosoma mansoni</i> . 2021 , 278, 106660	
269	A novel multi-objective metaheuristic algorithm for protein-peptide docking and benchmarking on the LEADS-PEP dataset. 2021 , 138, 104896	3
268	Indomethacin-based PROTACs as pan-coronavirus antiviral agents. 2021 , 226, 113814	7
267	Water mapping: Analysis of binding site spaces to enhance binding. 2021 , 179-201	

266	Use of molecular docking computational tools in drug discovery. 2021 , 60, 273-343	22
265	Molecular Multi-target Approach on COVID-19 for Designing Novel Chemicals. 2021 , 179	1
264	Molecular docking analysis: Basic technique to predict drug-receptor interactions. 2021 , 131-155	3
263	Recent Trends in Quantitative Structure-Activity Relationships. 2003 , 49-76	22
262	Virtual Screening. 2003 , 243-279	3
261	Docking and Scoring Functions/Virtual Screening. 2003 , 281-331	11
260	Structure-Based Drug Design. 2003 , 417-469	4
259	Computer Graphics and Molecular Modeling in the Analysis of Synthetic Targets. 1-85	4
258	Searching Techniques for Databases of Three-Dimensional Chemical Structures. 467-511	9
257	Cheminformatics Taking Biology into Account: Proteochemometrics. 57-92	2
256	DEVELOPMENT AND APPLICATIONS OF GLOBAL ADMET MODELS. 245-265	3
255	Structure-Based Design: From Renin to HIV-1 Protease. 37-71	1
254	Inhibition of Sialidase. 105-119	1
253	New Computational Approaches to Predict Protein-Ligand Interactions. 129-142	1
252	Cheminformatics and the Quest for Leads in Drug Discovery. 1508-1531	4
251	Progress in Force-Field Calculations of Molecular Interaction Fields and Intermolecular Interactions. 2002 , 3-17	1
250	Rapid Estimation of Relative Binding Affinities of Enzyme Inhibitors. 2002 , 85-98	2
249	3D QSAR of Flexible Molecules Using Tensor Representation. 1998 , 167-182	4

248	Pseudoreceptor Modelling in Drug Design: Applications of Yak and PrGen. 1998 , 135-157	1
247	Molecular Diversity in Site-focused Libraries. 2002 , 141-174	2
246	Protein-Ligand Interactions. 2002 , 363-374	1
245	Defining Drug Interactions with the Viral Membrane Protein Vpu from HIV-1. 2005 , 187-205	1
244	Molecular Similarity Searching Using COSMO Screening Charges (COSMO/3PP). 2005 , 175-185	1
243	Computer Modelling and Information Technology. 1991 , 253-289	3
242	A Discussion of Various Computational Methods for Drug Design. 1994 , 170-210	1
241	The Calculation, Representation and Analysis of Molecular Fields. 1994 , 266-304	1
240	Molecular Similarity Calculations for the Rational Design of Bioactive Molecules. 1994 , 305-332	2
239	Predicting Protein Function from Surface Properties. 2009 , 167-186	3
238	Structure-Guided Discovery of New Antimicrobial Agents. 2012 , 969-984	1
237	Complications of RNA heterogeneity for the engineering of virus vaccines and antiviral agents. 1992 , 14, 13-31	38
236	Multivariate Design and Modelling in QSAR, Combinatorial Chemistry, and Bioinformatics. 2000 , 27-45	4
235	Chemometric Detection of Binding Sites of 7TM Receptors. 2000 , 207-212	2
234	Handling Information from 3D Grid Maps for QSAR Studies. 2000 , 73-81	7
233	Inhibitor binding induces structural changes in porcine pepsin. 1991 , 306, 9-21	11
232	Multiple-Start Monte Carlo Docking of Flexible Ligands. 1994 , 71-108	10
231	Similarity Analysis of Molecular Interaction Potential Distributions. The MIPSIM Software. 2001 , 333-338	0

230	Protein Docking in the Absence of Detailed Molecular Structures. 1995 , 505-514	3
229	Computer-aided design of GPCR ligands. 2015 , 1272, 271-91	8
228	Protocol for fragment hopping. 2015 , 1289, 57-73	3
227	A computational fragment-based de novo design protocol guided by ligand efficiency indices (LEI). 2015 , 1289, 89-100	3
226	The role and application of in silico docking in chemical genomics research. 2005 , 310, 63-91	1
225	Structure-based functional design of drugs: from target to lead compound. 2012 , 823, 359-66	23
224	Targeting the purinome. 2009 , 575, 47-92	13
223	Using active site mapping and receptor-based pharmacophore tools: prelude to docking and de novo/fragment-based ligand design. 2011 , 716, 39-54	6
222	The Pharmacophore Concept and Its Applications in Computer-Aided Drug Design. 2019 , 110, 99-141	17
221	QSAR/QSPR Modeling in the Design of Drug Candidates with Balanced Pharmacodynamic and Pharmacokinetic Properties. 2017 , 339-384	2
220	Molecular Dynamics and Related Computational Methods with Applications to Drug Discovery. 2018 , 267-285	1
219	From Molecular Modeling to Drug Design. 2008 , 35-71	2
218	Energy Properties of Protein Structures in the Analysis of the Human RAB5A Cellular Activity. 2009 , 121-131	4
217	Disrupting Protein-Protein Interfaces Using GRID Molecular Interaction Fields. 2013 , 61-82	1
216	Structure-Activity Relationships of Diphenyl Ethers and Other Oxygen-Bridged Protoporphyrinogen Oxidase Inhibitors. 1999 , 141-161	5
215	Current Problems in Quantitative Structure Activity Relationships. 1988 , 235-247	2
214	The Advantages of Using Rational Drug Design in Modern Drug Discovery: How to Integrate Computer-Aided Drug Design and Modern Biotechnology. 1995 , 99-109	2
213	Computer modelling and drug design. 1992 , 133-162	1

212	Experiences with searching for molecular similarity in conformationally flexible 3D databases. 1995 , 138-162	5
211	New strategies that improve the efficiency of the 3D design of bioactive molecules. 1993 , 20-26	9
210	GOLPE: An advanced chemometric tool for 3D QSAR problems. 1993 , 256-259	0
209	LUDI: A computer program for de novo ligand design. 1993 , 27-34	1
208	Grid-assisted similarity perception (GRASP): A new method of overlapping molecular structures. 1993 , 394-395	1
207	Drug Discovery, Design, and Development. 1992 , 4-51	3
206	The Cambridge Structural Database (CSD). 2019 ,	2
205	THREE-DIMENSIONAL QUANTITATIVE STRUCTURE-PROPERTY RELATIONSHIPS. 2003 , 405-416	3
204	Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design. 1993 , 268, 15343-15346	113
203	The role of computer-aided and structure-based design techniques in the discovery and optimization of cyclic urea inhibitors of hiv protease. 1997 , 1-40	7
202	Comparative molecular field analysis: CoMFA. 1996 , 1-52	23
201	Chapter 4 The binding of ions to proteins. 1999 , 99-152	2
200	CHAPTER 4:Current Status and Future Direction of Fragment-Based Drug Discovery: A Computational Chemistry Perspective. 2015 , 73-100	2
199	Chapter 8:Three-Dimensional Molecular Modelling of Receptor-Based Mechanisms in Toxicology. 2010 , 210-227	1
198	Fragments: where are we now?. 2020 , 48, 271-280	16
197	Structural Genetics of circulating variants affecting the SARS-CoV-2 Spike / human ACE2 complex.	3
196	Combined in silico docking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and HCoV-OC43 inhibitors.	2
195	Deciphering colchicine like actions of clerodin in terms of microtubule destabilization based mitotic abnormalities, G2/M-phase arrest, and plant polyploidy.	1

194	Macrocyclic MR contrast agents: evaluation of multiple-organ gadolinium retention in healthy rats. 2020 , 11, 11	15
193	Docking and Scoring. 2003 ,	1
192	Normal Modes Expose Active Sites in Enzymes. 2016 , 12, e1005293	6
191	Bound water at protein-protein interfaces: partners, roles and hydrophobic bubbles as a conserved motif. 2011 , 6, e24712	48
190	The cysteine-rich protein thimet oligopeptidase as a model of the structural requirements for S-glutathiolation and oxidative oligomerization. 2012 , 7, e39408	12
189	HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. 2012 , 7, e39652	74
188	Structure prediction and validation of the ERK8 kinase domain. 2013 , 8, e52011	8
187	Fully Flexible Docking of Medium Sized Ligand Libraries with RosettaLigand. 2015 , 10, e0132508	59
186	Rational Structure-Based Rescaffolding Approach to De Novo Design of Interleukin 10 (IL-10) Receptor-1 Mimetics. 2016 , 11, e0154046	2
185	The Effects of Ca ²⁺ Concentration and E200K Mutation on the Aggregation Propensity of PrPC: A Computational Study. 2016 , 11, e0168039	7
184	Hot-spot identification on a broad class of proteins and RNA suggest unifying principles of molecular recognition. 2017 , 12, e0183327	4
183	A computer-based approach for developing linamarase inhibitory agents. 2020 , 5,	1
182	An Alignment-Independent 3D-QSAR Study of FGFR2 Tyrosine Kinase Inhibitors. 2017 , 7, 409-418	4
181	Rational Drug Design of Antineoplastic Agents Using 3D-QSAR, Cheminformatic, and Virtual Screening Approaches. 2019 , 26, 3874-3889	8
180	In Silico Chemogenomics Drug Repositioning Strategies for Neglected Tropical Diseases. 2019 , 26, 4355-4379	15
179	Advances in the Treatment of Explicit Water Molecules in Docking and Binding Free Energy Calculations. 2019 , 26, 7598-7622	5
178	Computational Modeling Approach in Probing the Effects of Cytosine Methylation on the Transcription Factor Binding to DNA. 2017 , 17, 1778-1787	2
177	Targeting Kinase Interaction Networks: A New Paradigm in PPI Based Design of Kinase Inhibitors. 2019 , 19, 467-485	8

176	Antimytotoxic Activity of Synthetic Peptides Derived from Bothrops atrox Snake Gamma Phospholipase A2 Inhibitor Selected by Virtual Screening. 2019 , 19, 1952-1961	3
175	Computer-aided Drug Design Applied to Parkinson Targets. 2018 , 16, 865-880	6
174	In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease. 2018 , 16, 786-848	10
173	Molecular Docking in Formulation and Development. 2019 , 16, 30-39	22
172	Design and Biological Evaluation of Novel Imidazolyl Flavonoids as Potent and Selective Protein Tyrosine Phosphatase Inhibitors. 2020 , 16, 563-574	2
171	Relevance of Molecular Docking Studies in Drug Designing. 2020 , 15, 270-278	19
170	An Introduction to the Basic Concepts in QSAR-Aided Drug Design. 2015 , 1-47	4
169	Application of Docking Methodologies in QSAR-Based Studies. 2016 , 29-55	2
168	Protein-Ligand Docking Methodologies and Its Application in Drug Discovery. 2017 , 891-914	1
167	Virtual Screening and Its Applications in Drug Discovery Process. 2019 , 101-126	0
166	Virtual Screening. 2011 , 28-60	6
165	Structure Activity Relationships by Autocorrelation Descriptors and Genetic Algorithms. 2011 , 60-94	4
164	Development of a Novel Pharmacophore Model Guided by the Ensemble of Waters and Small Molecule Fragments Bound to SARS-CoV-2 Main Protease. 2021 , e2100178	0
163	In Silico Protein Design and Virtual Screening. 2021 , 85-99	
162	A View on Affinity and Selectivity of Nonpeptidic Matrix Metalloproteinase Inhibitors from the Perspective of Ligands and Target. 2000 , 123-128	
161	Atypical Antipsychotics: Modelling and QSAR. 2000 , 448-449	1
160	Structural Requirements for Binding to Cannabinoid Receptors. 2000 , 369-370	
159	Computer Aided Drug Design. 2001 ,	1

- 158 Protein Interactions. **2001**, 87-108
- 157 Molecular Dynamics Simulations: A Tool for Drug Design. **2002**, 181-209
- 156 De Novo Ligand Design.
- 155 Molecular Docking and Structure-based Design.
- 154 De Novo Design Systems.
- 153 High-throughput Virtual Chemistry.
- 152 Structure Databases.
- 151 Three-dimensional Structure Searching.
- 150 ELECTRONIC SCREENING: LEAD FINDING FROM DATABASE MINING. **2003**, 131-145
- 149 Combinatorial Library Design, Molecular Similarity, and Diversity Applications. **2003**, 187-242 3
- 148 De novo design methods. **2003**, 153-66
- 147 Use of Pharmacophores in Structure-Based Drug Design. **2003**, 453-481
- 146 Sialidases. **2003**,
- 145 Computational Studies of Ligand-Receptor Interactions in Ionotropic Glutamate Receptors. **2004**, 3-25
- 144 Protein-Ligand Interactions: Knowledge-Based Methods.
- 143 Description and Representation of Chemicals. **2005**, 11-35 1
- 142 In-Silico ADME Modeling. **2006**, 409-436 1
- 141 Virtual Ligand Screening: A Method to Discover New Drug Leads. **2007**, 251-272

- 140 In Silico Prediction Models for Blood-Brain Barrier Permeation. 403-428
- 139 Protein Interactions. 87-108
- 138 De-Novo Design Systems. 1712-1731
- 137 Pharmacophore and Drug Discovery. 1687-1711 0
- 136 Quantitative Struktur-Wirkungsbeziehungen. **2009**, 265-282
- 135 Integrating Crystallography into Early Metabolism Studies. **2009**, 63-77
- 134 Chapter 8:Computational Approaches to Ionotropic Glutamate Receptors. **2010**, 203-224
- 133 Nitrogen Acids. **2013**, 77-92
- 132 An Approach to the Design of Anti-Influenza Agents. **1990**, 61-74 1
- 131 Aladdin: A Real Tool for Structure-Based Drug Design. **1990**, 254-263
- 130 The Use of Supercomputers in Medicinal Chemistry Examples from Peptide and Protein Projects. **1990**, 99-113
- 129 Using 3-D Similarity Searching to Develop Synthetic Targets. **1993**, 303-314 1
- 128 Multidimensional NMR Studies of Immunosuppressant/Immunophilin Complexes. **1993**, 92-133
- 127 Use of the GRID program in the 3D QSAR of a series of calcium channel agonists. **1993**, 517-518
- 126 Molecular modeling of viral peptides bound to class I MHC proteins. **1993**, 186-192
- 125 Potent transition state renin inhibitors containing a diacyl hydrazine group. **1993**, 944-946
- 124 Similarity Searching in Databases of Three-Dimensional Chemical Structures. **1994**, 280-293
- 123 3D QSAR The Integration of QSAR with Molecular Modeling. **1994**, 9-88

- 122 Drug Design Methods in Real-Life Situations: Recent Examples and Future Opportunities. **1995**, 207-224
- 121 Reflections on Collaborations of a Computational Chemist with Medicinal Chemists and Other Scientists. **1995**, 39-60
- 120 Applications of Empirical Amino Acid Potential Functions. **1995**, 151-166
- 119 Generation of new-lead structures in computer-aided drug design. **1995**, 45, 205-43 3
- 118 From Structure to Therapy?. **1996**, 97-108 1
- 117 Substrate Binding and Catalytic Mechanism in Phospholipase C from *Bacillus cereus*. **1997**, 93-96
- 116 Computational tools for structure-based design. **1997**, 433-450
- 115 Diagnosis and Therapy. **1997**, 227-236
- 114 Drugs Targeting Influenza Virus Neuraminidase. **1998**, 87-93
- 113 The Development and Application of Knowledge-Based Approaches to Molecular Design. **1999**, 243-260
- 112 Using Structural Information for the Creative Design of Molecules. **1999**, 93-101
- 111 Molecular Docking at a Glance. **2016**, 1-38 1
- 110 Recent Developments in 3D QSAR and Molecular Docking Studies of Organic and Nanostructures. **2016**, 1-29 1
- 109 Protein-Ligand Docking Methodologies and Its Application in Drug Discovery. **2016**, 196-219
- 108 Combined Action of Resveratrol and Carnosol on Down Regulation of NF- κ B: A Computational Study. **2016**, 2, 1-9
- 107 Role of Molecular Docking in Computer-Aided Drug Design and Development. **2016**, 1-28 1
- 106 Applying Computational Scoring Functions to Assess Biomolecular Interactions in Food Science: Applications to the Estrogen Receptors. **2016**, 3,
- 105 Molecular Fields to Assess Recognition Forces and Property Spaces?. **2016**, 0

- 104 Recent Advancements in Docking Methodologies. **2016**, 267-294
- 103 Application of Docking Methodologies in QSAR-Based Studies. **2017**, 850-876
- 102 Rational Drug Design Rational Drug Design. **2017**, 1144-1174
- 101 An Introduction to the Basic Concepts in QSAR-Aided Drug Design. **2017**, 20-66
- 100 Recent Advancements in Docking Methodologies. **2017**, 848-875
- 99 Role of Molecular Docking in Computer-Aided Drug Design and Development. **2017**, 683-710
- 98 Molecular Docking at a Glance. **2017**, 764-803
- 97 Competitive fragment assay for the selective inhibitor of WNKs kinase. **2017**, 17, 34-37
- 96 Integrated Structure-Transcription analysis of small molecules reveals widespread noise in drug-induced transcriptional responses and a transcriptional signature for drug-induced phospholipidosis.
- 95 The HYBOT 3D MF Application and its Integration with CoMFA. **2018**, 1, e00073
- 94 Calculation of Structure Descriptors. 349-396
- 93 Software-aided workflow for predicting protease-specific cleavage sites using physicochemical properties of the natural and unnatural amino acids in peptide-based drug discovery: Peptide cleavage sites prediction workflow.
- 92 Computational and Metabolic Studies on a Set of N-Myristoyltransferase Inhibitors Against Trypanosoma Brucei. **2018**, 3, 80-94
- 91 Partitioned Least Squares. **2019**, 180-192
- 90 Ecotoxicological QSAR Modeling of Nanomaterials: Methods in 3D-QSARs and Combined Docking Studies for Carbon Nanostructures. **2020**, 215-233
- 89 Nitric Oxide Synthases and Their Inhibitors: A Review. **2020**, 17, 228-252 1
- 88 Combiphore (Structure and Ligand Based Pharmacophore) - Approach for the Design of GPR40 Modulators in the Management of Diabetes. **2020**, 17, 233-247 1
- 87 Using diverse potentials and scoring functions for the development of improved machine-learned models for protein-ligand affinity and docking pose prediction. **2021**, 35, 1095-1123 1

86	The Bark Beetle (Curculionidae: Scolytinae) Has Digestive Capacity to Degrade Complex Substrates: Functional Characterization and Heterologous Expression of an β -Amylase. 2020 , 22,	0
85	A benzene-mapping approach for uncovering cryptic pockets in membrane-bound proteins.	0
84	Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints. 2022 , 2390, 61-101	1
83	Deep Learning Applied to Ligand-Based De Novo Drug Design. 2022 , 2390, 273-299	3
82	Supercomputers in Modeling of Biological Systems. 201-222	
81	Design of Small Libraries for Lead Exploration. 2002 , 197-220	
80	Clues from Three-Dimensional Structure Analysis and Molecular Modelling. 2006 , 30-38	
79	On Using Energy Signatures in Protein Structure Similarity Searching. 2008 , 939-950	4
78	Proceedings of the British Pharmacological Society. London, 19th-21st December. Abstracts. 1989 , 96 Suppl, 1P-368P	
77	Transcription factor-based drug design in anticancer drug development. 1997 , 3, 799-810	
76	Computer applications for prediction of protein-protein interactions and rational drug design. 2009 , 2, 101-23	9
75	Ion binding to biological macromolecules. 2014 , 23, 735-744	7
74	Molecular Modeling Techniques Applied to the Design of Multitarget Drugs: Methods and Applications. 2021 ,	0
73	Application of Site-Identification by Ligand Competitive Saturation in Computer-Aided Drug Design.. 2022 , 46, 919-932	1
72	Insulin Complexation with Cyclodextrins-A Molecular Modeling Approach.. 2022 , 27,	0
71	Fragment Hotspot Mapping to Identify Selectivity-Determining Regions between Related Proteins.. 2022 , 62, 284-294	0
70	Design, synthesis, in vitro and in silico characterization of new 2-quinolone- L-alaninate-1,2,3-triazoles as novel antimicrobial agents.. 2022 ,	1
69	GLUT3 inhibitor discovery through in silico ligand screening and in vivo validation in eukaryotic expression systems.. 2022 , 12, 1429	1

- 68 Computational Medicinal Chemistry to Target GPCRs. **2022,**
- 67 Structural Insights into the Substrate Binding Site of Main Protease for the Structure-Based COVID-19 Drug Discovery.. **2022,** 1
- 66 FragExplorer: GRID-Based Fragment Growing and Replacement.. **2022,** 0
- 65 Getting Insights into Structural and Energetic Properties of Reciprocal Peptide-Protein Interactions.. **2022,** 2
- 64 Prediction on the Resistance of Acetohydroxyacid Synthase Mutants to Herbicide Flumetsulam. **2022,** 80, 141
- 63 Using Surface Hydrophobicity Together with Empirical Potentials to Identify Protein-Protein Binding Sites: Application to the Interactions of E-cadherins.. **2022,** 2340, 41-50
- 62 Effect of Binding Modules Fused to Cutinase on the Enzymatic Synthesis of Polyesters. **2022,** 12, 303 0
- 61 Novel Macrocyclic Antagonists of the Calcitonin Gene-Related Peptide Receptor: Design, Realization, and Structural Characterization of Protein-Ligand Complexes.. **2022,** 0
- 60 Discovery of HTL26119. **2022,** 179-200
- 59 The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs.. **2022,** 13, 847788 2
- 58 Crystal structure and metal binding properties of the periplasmic iron component EfeM from *Pseudomonas syringae* EfeUOB/M iron-transport system.. **2022,** 1 0
- 57 ELIXIR-A: An Interactive Visualization Tool for Multi-Target Pharmacophore Refinement.. **2022,** 7, 12707-12715
- 56 In vitro activity of novel cinnamic acids hydrazides against clinically important pathogens. *Journal of Molecular Structure,* **2022,** 133016 3-4
- 55 Data_Sheet_1.xlsx. **2020,**
- 54 Data_Sheet_2.xlsx. **2020,**
- 53 Table_1.DOCX. **2020,**
- 52 Table_1.DOCX. **2018,**
- 51 Table_2.XLSX. **2018,**

50	In silico approaches to develop herbal acaricides against R. (Boophilus) Microplus and In vitro Anti-Tick activities of selected medicinal plants. <i>Saudi Journal of Biological Sciences</i> , 2022 , 29, 103302	4	1
49	Drug Design by Pharmacophore and Virtual Screening Approach. <i>Pharmaceuticals</i> , 2022 , 15, 646	5.2	3
48	Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes. <i>Pharmaceuticals</i> , 2022 , 15, 668	5.2	0
47	Fragment hopping protocol for the design of small-molecule protein-protein interaction inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2022 , 69, 116879	3.4	0
46	Introduction to drug design and discovery. 2022 , 1-15		
45	Quantitative structure-activity relationships (QSARs). 2022 , 101-123		
44	Molecular docking and antibacterial activity of some natural products against cariogenic Staphylococcus aureus. <i>Materials Today: Proceedings</i> , 2022 ,	1.4	1
43	Fundamentals of Molecular Docking and Comparative Analysis of Protein-Small-Molecule Docking Approaches.		
42	An alignment-independent three-dimensional quantitative structure-activity relationship study on α 1-adrenoreceptor tyrosine kinase inhibitors. 2022 , 20,		
41	Structure-based in silico design and in vitro acaricidal activity assessment of Acacia nilotica and Psidium guajava extracts against Sarcoptes scabiei var. cuniculi.		1
40	Effective Protein-Ligand Docking Strategy via Fragment Reuse and a Proof-of-Concept Implementation.		
39	A Review of Computational Methods in Predicting hERG Channel Blockers. 2022 , 7,		0
38	Critical Assessment of State-of-the-Art Ligand-Based Virtual Screening Methods. 2200103		1
37	General Strategies for Rational Design and Discovery of Multitarget Drugs. 2022 , 677-736		0
36	In silico approaches in drug discovery for SARS-CoV-2. 2022 , 235-251		0
35	Computational approaches for drug-metabolizing enzymes: Concepts and challenges. 2022 , 29-72		0
34	New Drug Design Avenues Targeting Alzheimer's Disease by Pharmacoinformatics-Aided Tools. 2022 , 14, 1914		1
33	Informed Use of 3D-QSAR for the Rational Design of Coumarin Derivatives as Potent and Selective MAO B Inhibitors. 2023 , 197-205		0

32	Predicting Conserved Water Molecules in Binding Sites of Proteins Using Machine Learning Methods and Combining Features. 2022 , 2022, 1-11	0
31	Machine Learning Approaches to Improve Prediction of Target-Drug Interactions. 2022 , 21-96	0
30	Small molecule superposition: A comprehensive overview on pose scoring of the latest methods.	0
29	Estimating the Similarity between Protein Pockets. 2022 , 23, 12462	0
28	Synthesizing, Studying Molecular Docking, Characterizing, and Preliminary Evaluating Anti-Bacterial Effects of Derivatives of Serotonin Contain Imidazolidine Ring. 2022 , 22, 1-16	0
27	An open-source molecular builder and free energy preparation workflow. 2022 , 5,	0
26	Novel Macrocyclic Antagonists of the CGRP Receptor Part 2: Stereochemical Inversion Induces an Unprecedented Binding Mode.	0
25	An Integrated Machine Learning Model To Spot Peptide Binding Pockets in 3D Protein Screening.	1
24	An In-Silico Identification of Potential Flavonoids against Kidney Fibrosis Targeting TGF β -1. 2022 , 12, 1764	2
23	Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach. 2022 , 27, 7522	0
22	Interactions of Proteins with Small Molecules, Allosteric Effects. 2022 , 315-332	0
21	Exploiting ELIOT for Scaffold-Repurposing Opportunities: TRIM33 a Possible Novel E3 Ligase to Expand the Toolbox for PROTAC Design. 2022 , 23, 14218	0
20	Uncovering water effects in protein-ligand recognition: importance in the second hydration shell and binding kinetics.	0
19	New bioisosteric sulphur-containing choline kinase inhibitors with a tracked mode of action. 2023 , 246, 115003	0
18	Machine learning and molecular simulation ascertain antimicrobial peptide against <i>Klebsiella pneumoniae</i> from public database. 2023 , 102, 107800	0
17	Design and synthesis of new thiazolidinone/uracil derivatives as antiproliferative agents targeting EGFR and/or BRAFV600E. 10,	2
16	Water Networks in Complexes between Proteins and FDA-Approved Drugs.	0
15	Synthesis and in vitro assessment of anticholinesterase and antioxidant properties of triazineamide derivatives.	0

- 14 Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth. 11,
- 13 Inhibitors of ABCG2-mediated multidrug resistance: Lead generation through computer-aided drug design. **2023**, 248, 115070
- 12 A Guide to In Silico Drug Design. **2023**, 15, 49
- 11 Mapping interaction between big spaces; active space from protein structure and available chemical space. **2023**, 299-332
- 10 Molecular dynamics simulations suggest Thiosemicarbazones can bind p53 cancer mutant R175H. **2023**, 1871, 140903
- 9 Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease.
- 8 Synthesis and anti-Alzheimer potential of novel β -amino phosphonate derivatives and probing their molecular interaction mechanism with acetylcholinesterase. **2023**, 253, 115288
- 7 Prediction of co-amorphous formation using non-bonded interaction energy: Molecular dynamic simulation and experimental validation. **2023**, 272, 118618
- 6 Application of computational methods for class A GPCR Ligand discovery. **2023**, 121, 108434
- 5 Polymerized stimuli-responsive microgels for the removal of organic dye from water. **2023**, 375, 121267
- 4 Assessing the functional impact of protein binding site definition.
- 3 REVERSIBLE INHIBITORS. **2023**, 317-355
- 2 Alternative biological screening methods. **2023**, 95-137
- 1 Study of MDM2 as Prognostic Biomarker in Brain-LGG Cancer and Bioactive Phytochemicals Inhibit the p53-MDM2 Pathway: A Computational Drug Development Approach. **2023**, 28, 2977